DANMAP 2013:Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark by Agersø, Yvonne et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
DANMAP 2013
Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food
animals, food and humans in Denmark
Agersø, Yvonne; Bager, Flemming; Boel, Jeppe; Helwigh, Birgitte; Borck Høg, Birgitte; Jensen, Lars
Bogø; de Knegt, Leonardo; Korsgaard, Helle Bisgaard; Larsen, Lars Stehr; Sørensen, Anna Irene Vedel;
Dalby, Tine; Hammerum, Anette M.; Hoffmann, Steen; Gaardbo Kuhn, Katrin; Rhod Larsen, Anders;
Laursen, Maja; Nielsen, Eva Møller; Olsen, Stefan S.; Petersen, Andreas; Bagger-Skjøt, Line; Skov,
Robert L.; Slotved, Hans-Christian; Torpdahl, Mia
Publication date:
2014
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Agersø, Y., Bager, F., Boel, J., Helwigh, B., Borck Høg, B., Jensen, L. B., ... Torpdahl, M. (2014). DANMAP
2013: Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food
and humans in Denmark. Statens Serum Institut.
DANMAP
 2013
D
A
N
M
A
P
 2
0
1
3
DANMAP 2013 - Use of antimicrobial agents and occurrence 
of antimicrobial resistance in bacteria from food animals, 
food and humans in Denmark
Statens Serum Institut
National Veterinary Institute, Technical University of Denmark
National Food Institute, Technical University of Denmark
This report is issued by DANMAP - The Danish Integrated Antimicrobial Resistance Monitoring and Research 
Programme. It presents the results of monitoring the antimicrobial use and antimicrobial resistance in food 
animals, food and humans in 2013. The report is produced in collaboration between the National Food Institute, 
Technical University of Denmark and Statens Serum Institut. The DANMAP programme is funded jointly by 
the Ministry of Health, the Ministry of Science, Innovation and Higher Education and the Ministry of Food, 
Agriculture and Fisheries. 
DANMAP 2013
Editors: 
Birgitte Borck Høg (bibo@food.dtu.dk)
Helle Korsgaard (hkor@food.dtu.dk) 
Yvonne Agersø (yvoa@food.dtu.dk) 
National Food Institute,
Technical University of Denmark
Mørkhøj Bygade 19, DK - 2860 Søborg
Line Skjøt-Rasmussen (lbs@ssi.dk) 
Anette M. Hammerum (ama@ssi.dk)
Microbiology and Infection Control, 
Statens Serum Institut 
Artillerivej 5, DK - 2300 Copenhagen
Authors:
National Food Institute
Yvonne Agersø, Flemming Bager, Jeppe Boel, Birgitte Helwigh, Birgitte Borck Høg, Lars Bogø Jensen, 
Leonardo de Knegt, Helle Korsgaard, Lars Stehr Larsen, Anna Vedel Sørensen
Statens Serum Institut
Tine Dalby, Anette M. Hammerum, Steen Hoffmann, Katrin Gaardbo Kuhn, 
Anders Rhod Larsen, Maja Laursen, Eva Møller Nielsen, Stefan S. Olsen, Andreas Petersen, 
Line Skjøt-Rasmussen, Robert L. Skov, Hans-Christian Slotved,  Mia Torpdahl
DANMAP board:
National Food Institute
Yvonne Agersø, Flemming Bager 
National Veterinary Institute
Svend Erik Jorsal
Statens Serum Institut
Anette M. Hammerum, Robert L. Skov
Layout:
National Food Institute
Susanne Carlsson
Photos: Colourbox and Mikkel Adsbøl
Printing: Rosendahls-Schultz Grafisk A/S
DANMAP 2013 - September 2014
ISSN 1600-2032
Text and tables may be cited and reprinted only with reference to this report: DANMAP 2013. Use of 
antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and 
humans in Denmark. ISSN 1600-2032
The report is available from www.danmap.org
DANMAP 
2013
DANMAP 2013 - Use of antimicrobial agents and occurrence 
of antimicrobial resistance in bacteria from food animals, 
food and humans in Denmark
                                                                           
       4 DANMAP 2013  
TABLE OF CONTENTS
1. Introduction            6 
 1.1.  About DANMAP            6
 1.2. Acknowledgements           7  
 1.3.  DANRES              8
2.  Summary              9
 2.1  Sammendrag           10
 2.2   Summary           14
3.  Background  information                                 19
 3.1  Populations           20
 3.2   Marketed antimicrobial agents         20
4.  Antimicrobial consumption in animals                                         23
 4.1.  Introduction           24
 4.2.  Total antimicrobial consumption        25
 4.3.  Antimicrobial consumption by animal species       27
 
5.  Antimicrobial consumption in humans                                          31
 5.1.  Introduction          32
 5.2.   Total consumption in both primary healthcare and hospitalcare      32
            Textbox 1:       Consumption of antimicrobial agents and incidence of multi-resistant bacteria in Greenland 35
            Textbox 2:        Maintained focus on the use of antimicrobial agents in the Faroe Islands   37
            Textbox 3:        The Danish Council of Ethics’ statement on the use of antibiotics                         39
 5.3.  Primary healthcare                        41
 Textbox 4:       Temporal and geographical variation in tetracycline prescription patterns in Denmark                 46
 5.4.  Hospital care          47
            
   
6.  Resistance in zoonotic bacteria                                          53
 6.1.  Salmonella           54
            Textbox 5:        Surveillance of Salmonella and Campylobacter in Denmark     59
 6.2.   Campylobacter          61
 
7.  Resistance in indicator bacteria                                          65  
 7.1.  Enterococci           66
 7.2.  Escherichia coli         70
            Textbox 6:       Occurrence of extended spectrum beta-lactamase (ESBL)-producing Escherichia coli 
                      in meat and slaughter pigs, but no sign of carbapenemase producing E. coli  74
8.  Resistance in human clinical bacteria                                         77  
 8.1  Escherichia coli             78 
 8.2.                   Klebsiella pneumoniae         80
            Textbox 7:       Carbapenemase producing bacteria in Denmark                     82
            8.3.        Pseudomonas aeruginosa         84
 8.4.   Streptococci          84 
 8.5.  Enterococci           85
            Textbox 8:       Increased occurrence of vancomycin resistant enterocooci in Danish hospitals   86
            Textbox 9:       Neisseria gonorrhoeae 2013        87
 8.6.   Staphylococcus aureus          89
            Textbox 10:      Livestock associated methicillin-resistant Staphylococcus aureus (LA-MRSA)
                                       among humans 2013         92
                                                                           
       5DANMAP 2013  
TABLE OF CONTENTS
9. Materials and Methods                                            93
 9.1.  General information            94
 9.2.  Data on antimicrobial consumption          94
 9.3.  Collection of bacterial isolates          97 
             9.4.  Isolation and identification of bacteria         98
 9.5.   Susceptibility testing           99
 9.6.  Data handling          100
 
10.    Terminology                                           103
 10.1.  List of abbreviations                       104
 10.2.  Glossary                        105
DANMAP 2013  
                                                                           
       6
INTRODUCTION1.
1. Introduction
1.1   About DANMAP
Antimicrobial resistance is considered a major threat to 
human health. While antimicrobial agents are essential for 
treating disease in humans and in animals, they are also the 
main contributors to the selection and spread of antimicrobial 
resistance. It is, therefore, essential to monitor trends in 
antimicrobial resistance and consumption of antimicrobial 
agents in order to identify the risk factors that contribute to 
the dissemination of resistance and the interaction between the 
risk factors.
Humans and animals constitute overlapping reservoirs of 
resistance and an integrated approach that takes this into account 
is therefore needed. The Danish Integrated Antimicrobial 
Resistance Monitoring and Research Programme, DANMAP, 
has implemented the One Health approach, comprising the 
entire chain from farm to fork to sickbed since 1995. The 
organisation and collection of DANMAP data are presented in 
Figure 1.1.
DANMAP was established at the initiative of the Danish 
Ministry of Health and the Danish Ministry of Food, 
Agriculture and Fisheries. The programme participants are the 
National Food Institute and the National Veterinary Institute, 
both at the Technical University of Denmark (DTU), as well 
as Statens Serum Institut (SSI). The DANMAP programme 
is funded jointly by the Ministry of Health, the Ministry of 
Science, Innovation and Higher Education, and the Ministry of 
Food, Agriculture and Fisheries.
 
The objectives of DANMAP are:
•	 to monitor the consumption  of antimicrobial  agents in 
food animals and humans;
•	 to monitor the occurrence of antimicrobial resistance in 
bacteria isolated from food animals, food of animal origin 
(e.g. meat) and humans;
•	 to study associations between antimicrobial consumption 
and antimicrobial resistance; and
•	 to identify routes  of transmission and areas for further 
research studies.
 
The monitoring of antimicrobial resistance is based on three 
categories of bacteria:
•	 human and animal pathogens that cause infections and 
are thought to reflect resistance caused by the use of 
antimicrobial agents in the respective reservoirs;
•	 zoonotic bacteria that can develop resistance in the animal 
reservoir, which may subsequently compromise treatment 
effect when causing infection in humans;
•	 indicator bacteria (enterococci and E. coli) due to their 
ubiquitous nature in animals, food and humans, and their 
ability to readily develop or transfer antimicrobial resistance 
in response to selective pressure in both reservoirs. 
All pathogens may be considered reservoirs of resistance 
determinants – genes – that may be disseminated independently 
of the bacterial hosts.
A web annex presenting minimum inhibitory concentration 
(MIC) distributions, detailed tables of antimicrobial 
consumption and other additional data are available for 
download at www.danmap.org. Current and previous 
DANMAP reports are also available at the website (PDF 
versions).
Public health risks
Bacteria become resistant either by spontaneous mutation or by transfer of resistance genes from other bacteria. Resistant 
strains are favoured when use of antimicrobial agents provide a selective pressure. This occurs in humans as well as in 
animals undergoing antimicrobial treatment. Resistant bacteria can spread between humans in the community, at healthcare 
centres and at hospitals. Furthermore, resistant bacteria from animals can be transmitted to humans either through direct 
contact with animals and their environment or through ingestion of contaminated food or other contaminated vehicles.
Antimicrobial treatment failure may occur if the ingested resistant bacteria are a direct cause of disease, or if resistance 
determinants are transferred to pathogenic bacteria causing the disease. Bacteria may be resistant to several – sometimes 
all – antimicrobial agents available for treatment, leading to life-threatening illness.
Currently, there is only a limited number of antimicrobial agents, with novel modes of actions, under development by 
the pharmaceutical industry. Therefore, it is vital for public health organisations to ensure the continued effectiveness of 
compounds considered critically important to human treatment by ensuring prudent use for both humans and animals. 
Prudent use should include the restriction of critical antimicrobial agents for use in humans only, as well as the elimination 
of overuse, i.e. only humans and animals suffering from an infection responsive to antimicrobial treatment should be 
exposed to antimicrobial agents.
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Figure 1.1. Organisation of DANMAP
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2. Summary
2.1 Sammendrag
DANMAP (Danish Antimicrobial Resistance Monitoring and 
Research Program) har siden 1995 beskrevet det årlige forbrug 
af antibiotika og forekomsten af antibiotikaresistens hos dyr og 
mennesker i Danmark. Denne udgave beskriver udviklingen i 
2013. 
Antibiotikaforbrug til dyr
Siden 2001 er al anvendelse af receptordineret medicin til dyr 
registreret i det offentlige register VetStat.
I 2013 blev der brugt 116,3 tons antibiotika (aktivt stof) til 
dyr i Danmark. Fordelt på dyrearter står svin for ca. 78 % af 
antibiotikaforbruget i 2013, kvæg for 10%, akvakultur for 3 %, 
fjerkræ for 1 %, pelsdyr for 4 % og kæledyr, heste og andre dyr 
for de resterende 3 %.
De overordnede ændringer i antibiotikaforbruget til dyr 
er primært styret af ændringer i forbrugsmønstret til 
svin. Svineproduktionen står for ca. 84 % af den danske 
kødproduktion, men kun ca. 40 % af den totale levende 
biomasse. 
Svin: Det totale antibiotikaforbrug til svin i 2012 var på ca. 
91 tons aktivt stof. I forhold til forbruget i 2012, er der sket 
en stigning på 5 % stigning når forbruget udregnes i DAPD 
og der justeres for eksport. Antibiotikaforbruget til svin faldt 
drastisk i perioden umiddelbart efter ”Gult kort-ordningen” 
blev bekendtgjort den 1. juli 2010. Ordningen, som har til 
hensigt at reducere forbruget, er rettet specifikt mod de 
svinebesætninger, som har det højeste antibiotikaforbrug pr 
svin. Selvom stigninger blev observeret også i 2013 er forbruget 
12 % lavere end i 2009 og på niveau med forbruget i 2008.
Stigningen i antibiotikaforbrug (DAPD) skyldtes især et 
øget forbrug af pleuromutiliner og tetracykliner, men også 
stigninger i forbruget af sulfonamid/trimethroprim og 
penicilliner. Pleuromutiliner og tetracykliner tilsættes primært 
til foder eller vand i forbindelse med mave-tarm lidelser. Visse 
typer antibiotika – især fluorkinoloner og 3. og 4. generations 
cefalosporiner – er kritisk vigtige i behandling af sygdom 
hos mennesker. I svin var forbruget af 3. og 4. generations 
cefalosporiner meget lavt (3 kg), hvilket er et resultat af, at 
svinebranchen i 2010 frivilligt indførte stop for brugen af disse 
stoffer. Brugen af fluorkinoloner var på det samme lave niveau, 
som det har været siden 2003, hvor lovgivning om begrænsning 
af fluorkinolonforbruget trådte i kraft.
Kvæg: Det totale antibiotikaforbrug til kvæg har ligget relativt 
stabilt på ca. 14 tons aktivt stof om året siden 2005, men i 2013 
faldt forbruget til ca. 12 tons. Målt i standard doser (DADD) 
steg forbruget til golddyrsbehandling med 7 %, hvorimod 
antallet af DADDer til behandling af klinisk mastitis faldt med 
9 % i forhold til 2012. Forbruget af beta-laktamase følsomme 
penicilliner udgjorde som tidligere år størstedelen af forbruget. 
I relation til antibiotika kritisk vigtige i human behandling 
har forbruget af fluorkinoloner siden 2003 været stort set nul. 
Sammenlignet med 2012 faldt forbruget af 3. og 4. generations 
cefalosporiner til systemisk behandling med 14 %. 
Fjerkræ: Antibiotikaforbruget til fjerkræ var cirka 1.270 kg 
aktivt stof i 2013, hvilket er 57 % højere end i 2012. Den primære 
årsag til denne stigning var en høj forekomst af luftvejssygdom 
i kalkunflokke i starten af 2013, samt en øget forekomst af 
diarre i slagtekyllingeflokke i 2013. Forbruget af fluorkinoloner 
i den danske fjerkræproduktion, inklusiv avl og opdræt, har 
været meget lavt siden 2006, og der er ikke rapporteret brug af 
cefalosporiner til fjerkræ i mere end 10 år.
Fisk: Det totale antibiotikaforbrug til fisk i akvakultur var på 
3.582 kg aktivt stof i 2013, en generel stigning på 23 % i forhold 
til 2012. Antibiotikaforbruget til fisk er meget afhængig af 
vandtemperaturen, og de ekstraordinære høje temperaturer 
i juli og august måned i 2013 medførte øget forekomst af 
bakterielle infektioner i forhold til de foregående år. Industrien 
har fortsat fokus på brug af vaccine for at begrænse brugen af 
antibiotika.
Kæledyr og heste: Oplysningerne i VetStat vedrørende 
antibiotikaforbrug til kæledyr og heste er mindre detaljerede 
end oplysningerne vedrørende produktionsdyr. Forbrug til 
kæledyr steg fra 1,449 kg aktivt stof i 2012 til 1,989 kg aktivt stof 
i 2013. Stigninger forekom for adskillige grupper af antibiotika: 
aminoglycosider, makrolider, penicilliner (beta-laktamase 
følsomme), sulfonamider, trimethoprim og tetracykliner. 
Forbruget af kritisk vigtige antibiotika som cefalosporiner og 
fluorkinoloner faldt i 2013. Men, forbruget af kritisk vigtige 
antibiotika til behandling af alvorlige infektionssygdomme 
hos mennesker er stadig højt i kæledyr sammenlignet med 
forbruget i produktionsdyr og giver stadig anledning til øget 
bevågenhed.
Antibiotikaforbruget til dyr fortsatte med at stige i 2013. 
Det totale forbrug til svin målt i kg aktivt stof steg med 
6 % i 2013,svarende til en 5 % stigning i beregnet i 
DAPD. Brugen af kritisk vigtige antibiotika i den danske 
svineproduktion er fortsat lav. Derimod er brugen af især 
kritisk vigtige antibiotika til kæledyr høj sammenlignet 
med forbruget til produktionsdyr, men forbruget af disse 
stoffer til kæledyr var lavere i 2013 end 2012.
Antibiotikaforbrug til mennesker 
Forbruget af receptordineret medicin på patientniveau er 
blevet overvåget siden begyndelsen af 1990erne.
Totalforbrug: I 2013 steg det totale forbrug af antibiotika 
til systemisk brug (primærsektoren og hospitalssektoren 
sammenlagt) til mennesker med 1,2 %. Forbruget i 
primærsektoren udgjorde 90 % af det totale forbrug. Forbruget 
af bredspektrede antibiotika var 5 % højere i 2013 sammenlignet 
med 2012. Fra 2004 til 2013 er det totale forbrug af antibiotika 
i Danmark steget med 20 %. For bredspektrede antibiotika var 
stigningen 72 %.
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2.SUMMARY
Resistens i zoonotiske bakterier
Zoonotiske bakterier som Salmonella og Campylobacter 
er sygdomsfremkaldende bakterier, som kan overføres fra 
dyr til mennesker. Udvikles der resistens i disse bakterier i 
husdyrproduktionen, kan resistens overføres til mennesker via 
fødevarer, og kan i visse tilfælde medføre behandlingssvigt ved 
sygdom. 
Forekomsten af monofasiske S. Typhimurium, som ofte 
er multiresistent, er steget i svin, svinekød og blandt 
humane infektioner de seneste fem år. Blandt de humane 
infektioner, var resistensforekomsten i 2013 generelt 
højere, for 4 ud af 16 stoffer i testpanelet (herunder 
fluorkinoloner), blandt de rejserelaterede humane 
tilfælde end blandt de hjemligt erhvervede infektioner. 
Selvom resistens var hyppigst forekommende blandt 
isolater fra patienter med rejserelaterede infektioner, 
faldt andelen af multiresistente isolater i 2013 blandt 
disse, og niveauet af multiresistens var sammenligneligt 
med niveauet i isolater fra sporadiske infektioner 
erhvervet i Danmark.
Primærsektor: Det totale antibiotikaforbrug i primærsektoren 
steg med 1,2 % sammenlignet med 2012. De  mest udtaltestig-
ninger blev observeret for tetracykliner, ’kombinations-
penicilliner’, beta-laktamase resistente penicilliner og peni-
cilliner med udvidet spektrum. Forbruget af makrolider faldt 
med 12 % i forhold til 2012 og forsatte således det fald, der 
er blevet observeret siden 2011. Forbruget af bredspektrede 
antibiotika steg 5,7 % fra 2012 til 2013.
I det seneste årti er forbruget af antibiotika i primærsektoren 
steget med 19 %. Denne stigning skyldes sandsynligvis en 
stigning i dosis (DDD) per behandlet patient samt en øget dosis 
per udskrevet medicinpakning. Årsagen til denne ændring 
kendes ikke. 
I Textbox 4 er forbruget af tetracykliner beskrevet nærmere. 
Fra 2005 til 2013 er forbruget af tetracykliner (DDD pr. 1.000 
indbygger-dage) steget med 54 %. Den største stigning sås for 
de 10–14 årige (86 %) samt for de 15–19 årige (58 %). Dette 
betød, at 5.400 flere unge blev behandlet med tetracyklin i 2013 
sammenlignet med 2005 (justeret for populationsændringer). 
Størstedelen af udskrivningerne var sandsynligvis til behandling 
af akne. Det var oftere praktiserende læger end dermatologer, 
der udskrev tetracykliner.
Hospitaler: På somatiske hospitaler steg det totale 
antibiotikaforbrug opgjort i DDD pr. 100 sengedage (DBD) 
med 1,4 % fra 2012 til 2013. 
Fra 2012 til 2013 steg forbruget af ‘kombinationspenicilliner’, 
kombinationer af sulfonamid og trimethoprim, beta-laktamase 
resistente penicilliner, penicilliner med udvidet spektrum og 
carbapenemer. Der blev observeret et fald for anden generations 
cefalosporiner, fluorkinoloner, makrolider og tetracykliner.
Fra 2004–2013 steg det totale antibiotikaforbrug med 66 %. 
Denne stigning skyldtes primært en kombination af stigning i 
DDD og et fald i antallet af sengedage. I løbet af det seneste årti 
er forbruget af bredspektret antibiotika på somatiske hospitaler 
steget med 114 %.
Salmonella???
I 2013 steg det totale forbrug af antibiotika til systemisk 
behandling af mennesker (primær- og hospitalssektoren 
sammenlagt) med 1,2 % sammenholdt med 2012. 
Forbruget i primærsektoren udgjorde 90 % af det totale 
forbrug, mens forbruget på hospitalerne udgjorde de 
resterende 10 %. Over en 10-årig periode fra 2004 til 
2013 steg det totale forbrug af antibiotika til mennesker i 
Danmark med 20 %.
Salmonella Typhimurium er en af de mest almindelig 
forekommende serotyper i danske svin, dansk svinekød og i 
humane Salmonella infektioner. Blandt S. Typhimurium fra 
svin var 61-70 % af isolaterne resistente overfor ampicillin, 
streptomycin, sulfonamid, og tetracyklin, og forekomsten 
af resistens overfor disse fire antibiotika (ASSuT resistens) 
er steget over de sidste fem år. Dette kan primært tilskrives 
den stigende forekomst af monofasiske varianter, som ofte 
er multiresistente, og i 2013 var 52 % af de undersøgte S. 
Typhimurium isolater fra svin var monofasiske. Der blev 
også fundet høj forekomst af resistens blandt S. Typhimurium 
isolater fra dansk svinekød. Generelt var forekomsten af 
multiresistens blandt S. Typhimurium isolater fra danske svin 
(64 %) og svinekød (71 %), højere end i Salmonella generelt 
(Salmonella spp.), hvor hhv. 37 % og 36 % var multiresistente. 
Når resultaterne fra Salmonella overvågningsprogrammerne 
sammenholdes med disse forekomster, estimeres det at 9 % 
af svinene og 0,5 % af slagtekroppene havde multiresistent 
Salmonella. Som i de foregående år blev der ikke påvist resistens 
overfor cefalosporiner (ceftiofur og cefotaxim) eller kinoloner 
(ciprofloxacin og nalidixansyre) blandt Salmonella isolater fra 
svin eller dansk svinekød. 
Ligesom for svin og svinekød, er der de seneste fem år sket 
en stigning i den relative forekomst af de monofasiske S. 
Typhimurium varianter blandt isolater fra patienter, som 
havde erhvervet infektionen i Danmark (både sporadiske 
og udbrudstilfælde). I 2013 blev der påvist multiresistens 
i 54 % af S. Typhimurium isolater fra sporadiske tilfælde 
erhvervet i Danmark, og resistens niveauet var generelt på 
niveau med 2012. Resistensforekomsten var højere for fire 
ud af de 16 testede stoffer, når forekomsten i isolater fra 
patienter med rejse-relaterede infektioner sammenlignes med 
forekomsten i isolater fra sporadiske infektioner erhvervet i 
Danmark. Det gælder også for fluorkinoloner, som bruges til 
behandling af patienter med alvorlige mave-tarm infektioner 
forårsaget af både Salmonella og Campylobacter. Andelen af 
multiresistente isolater faldt i 2013 blandt patienter med rejse-
relaterede infektioner, og i 2013 var niveauet af multiresistens 
sammenligneligt med niveauet i isolater fra sporadiske 
infektioner erhvervet i Danmark.
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Fluorkinolon resistens i C. jejuni er fortsat højere blandt 
isolater fra importeret kyllingekød sammenlignet med 
dansk kyllingekød, og blandt C. jejuni fra patienter med 
rejse-relaterede infektioner i forhold til patienter, hvor 
infektionen var erhvervet i Danmark og denne forskel er 
mere udtalt i 2013 end i 2012.
Resistens i indikatorbakterier
Indikatorbakterier er inkluderet i DANMAP overvågningen for 
at kunne give et indblik i den generelle forekomst af resistens i 
raske husdyr og i kød.
I E. faecalis fra danske slagtekyllinger var forekomsten af 
tetracyklin resistens størst (38 %) efterfulgt af resistens overfor 
erythromycin og salinomycin.
Højeste forekomster af resistens blev fundet blandt E. faecalis 
isoleret fra svin sammenlignet med isolater fra slagtekyllinger, 
hvilket følger forbrugsmønsteret i Danmark til disse dyrearter. 
Blandt E. faecalis isoleret fra svin var forekomsten af tetracyklin 
højest (91 %). Tetracykliner er og har været de mest anvendte 
antimikrobielle stoffer til danske svin i en årrække og har 
primært været brugt til behandling af E. coli infektioner. 
Forekomst af erythromycin resistens blandt E. faecalis isoleret 
fra svin var 45 % og faldt i forhold til forekomsten i 2012. 
Forekomst af resistens var højere i importeret end i dansk 
produceret svinekød.
Blandt isolater fra kyllingekød, blev den højeste forekomst 
af resistens overfor flere stofgrupper fundet i importeret 
kyllingekød. Ligeledes blev der fundet højere forekomst af 
multiresistens blandt isolater fra importeret kyllingekød 
(39 % og 24 % for henholdsvis E. faecalis og E. faecium) ved 
sammenligning med forekomster i dansk produceret kød. I alt 
72 % af de multiresistente E. faecalis fra importeret kyllingekød 
havde samme resistensprofil (erythromycin, kanamycin, 
streptomycin og tetracyklin).  
Generelt er forekomsten af resistens overfor kritisk vigtige 
antibiotika lav, men et dansk E. faecalis isolat var resistent 
overfor fluorkinoloner (ciprofloxacin).
Set i et  ’One Health’ perspektiv er  der en  direkte sammen-
hæng mellem antibiotikaforbruget i kyllingeproduktionen 
og forekomsten af antibiotikaresistente E. faecalis i dansk 
kyllingekød. Denne kobling findes ikke mellem danske 
svin og dansk svinekød. I dansk svinekød er forekomsten 
af resistens blandt E. faecalis generelt lavere end blandt 
isolater fra svin. Foruden dette, er resistens forekomsten i 
svinekød faldende, en tendens som ikke observeres i svin.
Indikator Escherichia coli fra slagtekyllinger var ofte 
resistente overfor sulfonamid og ampicillin (begge 26 %), som 
typisk bruges til slagtekyllinger. Der blev påvist fluorkinolon 
(ciprofloxacin) resistens i 6 % af isolaterne, og resistens 
overfor 3. generations cefalosporiner (ceftiofur) blev påvist 
i to isolater fra slagtekyllinger. Resistensforekomsten i E. coli 
fra slagtekyllinger og dansk kyllingekød var sammenlignelig. 
Resistensforekomsten i isolater fra kvæg og dansk oksekød var 
som foregåede år ganske lav. Resistens i E. coli fra svin var den 
højeste blandt produktionsdyrene og forblev på samme høje 
niveau som i 2012.
Blandt isolaterne fra kød havde isolaterne fra importeret 
kyllingekød generelt de højeste resistensforekomster – også 
når det gjaldt de kritisk vigtige antibiotika. Sammenlignet 
med dansk kyllingekød havde E. coli isolater fra importeret 
kyllingekød højere resistens overfor 14 af de 16 testede 
antibiotika. For svinekød havde E. coli isolater fra dansk kød 
en lavere resistensforekomst overfor kinoloner (ciprofloxacin 
og nalidixin syre) end isolaterne fra importeret svinekød.
ESBL-producerende bakterier er et af de hurtigst voksende 
resistensproblemer verden over. Flere nyere studier finder 
de samme ESBL gener, plasmider og kloner af E. coli isolater 
i både dyr og i mennesker med infektioner, hvilket tyder 
på et zoonotisk link. Forekomsten af Enterobacteriaceae 
bakterier, der er resistente overfor carbapenemer, er også en 
voksende trussel, idet carbapenemer er sidste mulighed for 
antibiotikabehandling af mennesker med infektioner, der 
skyldes multiresistente Gram-negative bakterier.
Seks procent af slagtesvinene havde ESBL-producerende E. coli, 
hvilket var lavere end i 2012 og signifikant lavere end i 2010 og 
2009 før landbrugets frivillige stop for brug af cefalosporiner 
trådte i kraft. Den højeste prævalens of ESBL-producerende E. 
coli i kødprøver blev fundet i importeret kyllingekød (52 %), 
hvilket er på samme niveau som i 2012 og 2010. Forekomsten 
af ESBL-producerende E. coli i prøver af dansk kyllingekød var 
signifikant lavere i 2013 sammenlignet med 2012. Desuden 
var andelen af prøver positive for ESBL producerende E. 
coli i dansk kyllingekød signifikant lavere end forekomsten i 
det importerede kyllingekød. Dette skyldes sandsynligvis et 
frivilligt stop af brug af 3. generations cefalosporiner i toppen 
af avlspyramiden i udlandet, hvilket resulterer i der overføres 
færre ESBL producerende E. coli fra importerede forældredyr 
til de danske slagtekyllinger. I lighed med sidste år er der stadig 
ingen fund af carbapenemase producerende E. coli.
I 2013 var resistensforekomsten i Campylobacter jejuni isolater 
fra kyllinger og kvæg på samme niveau som i 2011, men en 
anelse højere end i 2012. Selv om disse ændringer ikke var 
statistisk signifikante, har det fulgt forbrugsmønstret for 
tetracyklin i fjerkræ.
Set i en europæisk sammenhæng er resistensforekomsten i C. 
jejuni fra danske slagtekyllinger og kyllingekød samt C. coli fra 
svin blandt Europas laveste. 
Fluorkinolon resistens i C. jejuni var også højere blandt isolater 
fra importeret kyllingekød (53 %) end fra dansk kyllingekød 
(20 %).
Som i de foregående år var forekomsten af fluorkinolon resistens 
i C. jejuni isolater fra patienter med rejse-relaterede infektioner 
(92 %) højere end i isolater fra patienter, hvor infektionen var 
erhvervet i Danmark (24 %).
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Det frivillige stop i brugen af cefalosporiner i 
svineproduktionen resulterer fortsat i en lav forekomst 
af ESBL producerende E. coli i slagtesvin. Ligeledes ses 
et signifikant fald i ESBL producerende E. coli i dansk 
kyllingekød, hvilket sandsynligvis skyldes et frivilligt 
stop i brug af cefalosporiner i toppen af avlspyramiden 
i udlandet.
Resistens i bakterier fra diagnostiske 
indsendelser fra mennesker
Rapporteringen af antibiotikaresistens i bakterier fra 
diagnostiske indsendelser fra mennesker er baseret på frivillig 
indsendelse af data fra DANRES-gruppen, som dækker de 
Klinisk Mikrobiologiske Afdelinger (KMA) i Danmark. 
Undtagelser omfatter methicillin-resistente Staphylococcus 
aureus (MRSA) og invasive Streptococcus pneumoniae, som 
er anmeldepligtige. Data vedr. disse bakterier kommer fra 
referencelaboratorierne på SSI.
Blandt Escherichia coli isolater fra blod var forekomsten af 
3. generations cefalosporin resistens 8 % i 2013, hvilket er det 
samme niveau som i 2012, men højere end i de andre nordiske 
lande i 2012. Ciprofloxacin resistensen faldt til 12 % i 2013 
sammenlignet med 14 % i 2012. Aminoglykosid resistensen 
(gentamicin) var 7 % i 2013, hvilket er samme niveau som i 2012. 
Resistensdata for piperacillin/tazobactam blev rapporteret 
for første gang i denne DANMAP rapport. Data omfatter de 
sidste fem år (2009–2013); i denne periode var forekomsten af 
resistens på omkring 4 %.
Blandt E. coli isolater fra urin fra patienter på hospitalerne 
var forekomsten af 3. generations cefalosporin resistens 6 % i 
2013, hvilket er det samme niveau som i 2012. Forekomsten af 
fluorkinolon (ciprofloxacin) resistens var 12 % i 2013, hvilket 
er samme niveau som i 2012, men der har været en stigende 
forekomst fra 3 % i 2004. Aminoglykosid (gentamicin) resistens 
var 5 % i 2013 og sulfonamid resistens var 33 %, begge var på 
samme niveau som i 2012.
Blandt E. coli isolater fra urin fra patienter i almen praksis 
er forekomsten af fluorkinolon (ciprofloxacin) resistens steget 
støt fra 3 % i 2004 til 10 % i 2013. Forekomsten af 3. generations 
cefalosporin resistente E. coli var 4 %, sulfonamid resistens var 
33 % og ampicillin resistens var 40 % i 2013, hvilket for alle tre 
antibiotika var på samme niveau som i 2012.
Blandt Klebsiella pneumoniae isolater fra blod var forekomsten 
af resistens den samme i 2013 som i 2012. Forekomsten af 
3. generations cefalosporin resistens var 9 %, aminoglykosid 
(gentamicin) resistens var 4 %, og fluorkinolon (ciprofloxacin) 
resistens var 9 %.
Blandt K. pneumoniae isolater fra urin fra patienter på 
hospitalerne faldt forekomsten af resistens for mecillinam 
(10 %), sulfonamid (20 %), gentamicin (4 %), 2. generations 
cefalosporiner (cefuroxim) (9 %) og 3. generations cefalosporiner 
(7 %) fra 2012 til 2013. Fluorkinolon (ciprofloxacin) resistens 
var på samme niveau i 2013 som i 2012.
Blandt K. pneumoniae isolater fra urin fra patienter i almen 
praksis var forekomsten af 3. generations cefalosporin resistens 
6 %, hvilket er samme niveau som i 2012. Fluorkinolon 
(ciprofloxacin) resistens var 7 %, og mecillinam resistens var 
10 %, hvilket også er på samme niveau som i 2012. Sulfonamid 
resistens faldt fra 26 % i 2012 til 22 % i 2013.
Blandt Pseudomonas aeruginosa isolater fra blod var 
niveauet af resistens for alle testede antibiotika ikke signifikant 
forskelligt fra niveauet i 2012, men der sås en stigende tendens 
for aminoglykosid (gentamicin) resistens i perioden 2007–
2013. 
Forekomsten af carbapenemase producerende bakterier 
i Danmark er beskrevet i Textbox 7. I 2013 blev der fundet 
18 carbapenemase producerende Enterobacteriaceae (CPE) 
sammenlignet med 19 CPE i hele perioden 2008–2012. I 
2013 var der spredning af NDM-1 producerende Citrobacter 
freundii imellem fire patienter på en hospitalsafdeling i Region 
Nordjylland. Ingen af patienterne havde været ude at rejse 
for nylig, og kilden til den NDM-1 producerende C. freundii 
var ukendt. To af de fire patienter med C. freundii havde også 
NDM-1 producerende K. pneumoniae. Der blev detekteret 
syv OXA-23 producerende Acinetobacter baumannii isolater i 
2013. 
Der blev i to tilfælde set spredning af OXA-23 producerende 
A. baumannii mellem to patienter. I 2013 blev der fundet tre 
OXA-40-like producerende A. baumannii. Her var der også 
sket smittespredning fra en patient til en anden. Derudover 
blev der detekteret to NDM-1 producerende A. baumannii. 
I 2013 blev der fundet tre VIM producerende P. aeruginosa, 
og en NDM og VIM producerende P. aeruginosa. For første 
gang blev der detekteret en IMP producerende P. aeruginosa 
i Danmark. Patienterne med de to sidstnævnte P. aeruginosa 
havde begge forinden været indlagt på udenlandske hospitaler.
I 2013 var forekomsten af resistens for penicillin og makrolider 
(erythromycin) stadig lav blandt Streptococcus pneumoniae 
og gruppe A, B, C og G streptokokker.
Forekomsten af ampicillin resistens i Enterococcus faecium 
isolater fra blod var 93 % i 2013. Vancomycin resistens var 3,4 % 
i E. faecium og 0,2 % i Enterococcus faecalis isolater fra blod. I 
2013 modtog Reference laboratoriet for Antibiotikaresistens et 
øget antal vancomycin resistente enterokokker (VRE) (Textbox 
8); 258 isolater fra infektioner og 168 fra fækale screeninger. 
Næsten alle VRE var vanA E. faecium isolater. VRE isolaterne 
var primært fra hospitaler i Region Hovedstaden, men der 
var også isolater fra hospitaler i Region Sjælland samt Region 
Midtjylland. Der blev tillige fundet VRE i de to andre regioner, 
men i meget lavere antal. Pulsfelt gelelektroforese typning viste, 
at der var sket spredning af flere forskellige typer vanA VRE 
både inden for hospitalerne samt imellem hospitalerne.
Forekomsten af fluorkinolon (ciprofloxacin) resistens i 
Neisseria gonorrhoeae steg støt fra 30 % i 2003 til 75 % i 2009, 
efterfulgt af et fald til 56 % i 2013. Penicillinase produktion 
blandt gonokok isolater svingede imellem 24 % i 2003 og 11 % 
i 2013. Der blev ikke rapporteret hverken ceftriaxon resistente 
isolater eller tilfælde af ceftriaxon behandlingssvigt i denne 
periode. I 2013 var forekomsten af makrolid (azithromycin) 
resistens 45 %, cefixim resistens var 9 %, og der var ingen 
spectinomycin resistente isolater (Textbox 9).
I 2013 blev der indrapporteret 1.769 tilfælde af Staphylococcus 
aureus bakteriæmier svarende til en incidens på 32,9 tilfælde 
per 100.000 indbyggere. Antallet af methicillin-resistente S. 
aureus (MRSA) fra bakteriæmier var 30 (1,7 %), hvilket er på 
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I 2013 blev der fundet 18 carbapenemase producerende 
Enterobacteriaceae (CPE) sammenlignet med 19 CPE i hele 
perioden 2008–2012. I 2013 var der spredning af NDM-1 
producerende Citrobacter freundii imellem fire patienter 
på en hospitalsafdeling i Region Nordjylland. Ingen af 
patienterne havde været ude at rejse for nylig, og kilden til 
NDM-1 producerende C. freundii var ukendt.
Et stigende antal vancomycin resistente enterokokker blev 
modtaget på SSI i 2013; 258 isolater fra infektioner og 168 
fra fækale screeninger. Næsten alle VRE isolater var vanA 
E. faecium. VRE isolaterne var primært fra hospitaler 
i Region Hovedstaden, men der var også isolater fra 
hospitaler i Region Sjælland samt Region Midtjylland.
Antallet af nye MRSA tilfælde (både koloniserede og 
inficerede personer) steg i 2013 til 2.094 sammenlignet 
med 1.556 i 2012 Stigningen blev primært set for MRSA 
tilhørende klonal kompleks CC398 (LA-MRSA), hvor der 
blev observeret 643 tilfælde i 2013 sammenlignet med 232 
tilfælde i 2012. CC398 udgjorde 31 % af alle nye MRSA 
tilfælde i 2013. Antallet af hospitals-erhvervede MRSA 
tilfælde var fortsat lavt og udgjorde kun 2 % i 2013.
2.2  Summary
DANMAP (Danish Antimicrobial Resistance Monitoring and 
Research Program) has monitored antimicrobial resistance and 
consumption of antimicrobial agents in food animals and in 
humans in Denmark since 1995. This report describes changes 
and trends in 2013.
Antimicrobial consumption in animals
Data on all medicines prescribed by veterinarians have been 
registered at the farm and species level by the official VetStat 
programme since 2001.
The total consumption of antimicrobial agents in 2013 
amounted to 116.3 tonnes of active compounds, an increase 
of 4% increase compared with 2013. Pigs accounted for 
approximately 78%, cattle for approximately 10%, fur animals 
for 4%, aquaculture for 3%, and poultry for 1% of the total 
veterinary consumption of antimicrobials measured in kg 
active compounds. The remaining 3% was used in pets, horses 
and others.
The overall changes in veterinary consumption are generally 
driven by changes in consumption in pig production. Pigs 
account for approximately 84% of the meat production in 
Denmark, but only about 40% of the total live biomass.
Pigs: The total consumption of veterinary antimicrobial 
agents in Danish pig production was approximately 91 tonnes. 
Measured in DAPD, we observed a 5% increase from 2012 
to 2013. This follows a decrease in 2010–2011, which was 
probably the result of the introduction of legislation to reduce 
overuse of antimicrobials in the pig production. Even though 
the antimicrobial consumption increased in 2013, it remained 
approximately 12% lower than in 2009 and was at the same 
level as in 2008.
In 2013, the increase in consumption (measured in DAPD) 
was attributed mainly to an increase in pleuromutilins and 
tetracyclines and to a lesser extent, to the use of penicillins 
and sulfonamides/trimethroprim. Pleuromutilins and 
tetracyclinesare mainly used in feed or water medication for 
gastrointestinal disease. Some types of antimicrobials including 
fluoroquinolones and 3rd and 4th generation cephalosporins 
are considered critically important for treatment of severe 
infections in humans. The use of 3rd and 4th generation 
cephalosporins in pigs remained very low (3 kg), as a result of 
a voluntary ban on cephalosporins introduced by the Danish 
pig industry in 2010. The use of fluoroquinolones remained at 
the same low level as has been observed since legal restrictions 
were enforced in 2003.
Cattle: Overall, the antimicrobial consumption in cattle has 
remained stable at around 14 tonnes since 2005, but in 2013 
it declined to about 12 tonnes. Measured in standard doses 
(DADD) the consumption for drying-off treatment increased 
by 7% whereas, the number of DADDs for treatment of 
clinical mastitis decreased by 9% compared to 2012. The beta- 
lactamase sensitive penicillins account for the majority of the 
consumption. For critically important antimicrobials, the use 
of fluoroquinolones has been close to zero since 2003. The 
use of 3rd and 4th generation cephalosporins for systemic 
treatment decreased by 14% compared with 2012.
samme niveau som tidligere år og blandt de laveste incidenser 
observeret i Europa. Den højeste forekomst af resistens ud 
over penicillin resistens var resistens for fusidinsyre (15 %), 
erythromycin (7 %), clindamycin (6 %) og norfloxacin (5 %). 
Niveauet af resistens for de testede antibiotika var det samme 
som i 2012.
Antallet af nye MRSA tilfælde (både koloniserede og inficerede 
personer) steg i 2013 til 2.094 sammenlignet med 1,556 i 2012. 
Stigningen blev primært set for MRSA tilhørende klonal 
kompleks CC398 (LA-MRSA), hvor der blev observeret 643 
tilfælde i 2013 sammenlignet med 232 tilfælde i 2012. CC398 
udgjorde 31 % af alle nye MRSA tilfælde i 2013. En stor del af 
stigningen skyldes formentlig inklusionen af kontakt til svin 
som en risikofaktor medførende screening ved indlæggelse på 
hospitalerne. Størstedelen (87 %) af de personer, som havde 
CC398 (både infektion og kolonisation), havde haft kontakt 
med svin eller boede sammen med personer, der havde kontakt 
med svin. Der var dog ingen tegn på betydelig spredning af 
CC398 til byområder, hvilket indikerer, at fødevarer ikke udgør 
en væsentlig smittekilde. 
Blandt alle MRSA tilfælde var forekomsten af infektioner lavere 
i 2013 end i 2012 (45 % versus 57 %). Antallet af hospitals-
erhvervede tilfælde var fortsat lavt i 2013 og udgjorde kun 2 
%. I 2013 er der ikke foretaget undersøgelser for MRSA i dyr 
og fødevarer.
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Poultry: In 2013, the overall consumption of antimicrobial 
agents in poultry was approximately 1,270 kg active compound, 
which represents a 57% increase compared with 2012. The 
main reason for this appears to be widespread problems with 
respiratory disease in turkey flocks produced in early 2013 
and an increased occurrence of diarrhea in broiler flocks. The 
reported use of fluoroquinolones in poultry has been low since 
2006, and they were not used in the poultry production in 2013. 
Furthermore, use of cephalosporins has not been reported in 
Danish poultry production for more than a decade.
Aquaculture: The overall antimicrobial consumption in 
aquaculture was 3,582 kg in 2013, an overall increase of 23%. 
The relatively large increase in consumption in 2013 is explained 
mainly by extraordinary high temperatures in July and August 
2013, leading to higher water temperatures and an increase in 
the occurrence of bacteriological infections. There is, however, 
in the aquaculture industry, still focus on vaccination to reduce 
the risk of diseases that may require antibiotic treatment.
Pets and horses: The information available on antimicrobial 
consumption in pet animals and horses is less detailed 
as for production animals. The overall antimicrobial 
consumption for pets increased from 1,449 kg in 2012 to 
1,989 kg active compound in 2013. The increase was seen for 
several antimicrobial classes; aminoglycosides, macrolides 
and penicillin’s (b-lactamase sensitive), sulfonamides and 
trimethoprim, as well as for tetracyclines. The consumption 
of antimicrobials critical for human treatment such as 
cephalosporins and flouroquinolones decreased in 2013. 
Nonetheless, consumption of broad-spectrum antimicrobials 
in pet animals and the use of antimicrobial agents critical for 
treatment of human infections remains high compared with 
both production animals and is a matter of concern.
The antimicrobial consumption in animals continued 
to increase in 2013. The total consumption (measured 
in kg active compound) in pigs increased by 6% in 
2013, corresponding to a 5% increase in DAPD. Use of 
critically important antimicrobials in the pig production 
remains low. However, the use of critically important 
antimicrobials in pets remains high compared with 
other species, but decreased from 2012 to 2013.
Antimicrobial consumption in humans 
In Denmark, the Department of Data Delivery and Medicinal 
Product Statistics at Statens Serum Institut register the 
consumption of antimicrobial agents to humans. 
Total consumption: In 2013, the total consumption of 
antimicrobial agents for systemic use (primary healthcare and 
hospital care) was 1.2% higher than in 2012. The consumption in 
primary healthcare accounts for 90% of the total antimicrobial 
consumption. The proportion of broad-spectrum agents was 
5% higher in 2013 compared with 2012. Since 2004, the overall 
consumption of antimicrobial agents in humans has increased 
by 20%. For broad-spectrum agents, the increase has been 72%. 
Primary healthcare: In 2013, the total consumption of 
antimicrobial agents for systemic use in the primary sector 
was 1.2% higher than observed in 2012. Particular increases 
were observed for tetracyclines, ‘combination penicillins’, beta-
lactamase resistant penicillins and penicillins with extended 
spectrum. The consumption of macrolides was 12% lower in 
2013 compared with 2012, continuing the decrease observed 
since 2011. The consumption of broad-spectrum agents 
increased by 5.7% from 2012 to 2013. 
During the past decade, the consumption of antimicrobial 
agents in the Danish primary sector has increased by 19%. This 
seems to be caused by the fact that the dosage prescribed for 
each patient and in each package has increased significantly 
over the years, however, the underlying medical reasons for 
this (if any) are unclear. 
The increased consumption of tetracyclines has been further 
described in Textbox 4. From 2005 to 2013, the consumption 
(DDDs per 1,000 inhabitant-days) of tetracyclines for all ages 
increased by 54% with large increases observed for the 10–14 
year olds (86%) and 15–19 year olds (58%). When adjusted for 
population increases, approximately 5,400 more persons in 
these age groups were treated with tetracyclines in 2013 than 
in 2005. General Practioners (GPs) rather than dermatologists 
prescribed the majority of the prescriptions, presumably for 
acne.
Hospitals: In 2013, the consumption of antimicrobial agents 
in somatic hospitals (expressed as DBDs, i.e. DDDs per 100 
occupied bed-days) was 1.4% higher than in 2012.
From 2012 to 2013, a higher consumption was observed for 
‘combination penicillins’, combinations of sulfonamide and 
trimethoprim, beta-lactamase resistant penicillins, penicillins 
with extended spectrum and carbapenems, while decreased 
consumption was seen for 2nd generation cephalosporins, 
fluoroquinolones, macrolides and tetracyclines.  
The consumption in hospitals has steadily increased by 66% 
in the past decade, primarily caused by an increase in DDDs 
and a decrease in the number of hospital bed-days. This has 
especially been seen in the consumption of broad-spectrum 
antimicrobial agents which increased by 114%.
In humans, the overall consumption of antimicrobial 
agents for systemic use increased slightly (1.2 %) 
from 2012 to 2013. Antimicrobial consumption in the 
primary healthcare sector represented 90% of the total 
consumption and the hospital sector accounted for the 
remaining 10%. From 2004 to 2013, the total consumption 
of antimicrobial agents by humans in Denmark increased 
by 20%.
Resistance in zoonotic bacteria 
Zoonotic bacteria such as Salmonella and Campylobacter can 
develop resistance in the animal reservoir. The resistant bacteria 
may be transferred to humans via food and may subsequently 
compromise treatment effect when causing infection in 
humans.
Resistance in zoonotic bacteria 
Zoonotic bacteria such as Salmonella and Campylobacter 
can develop resistance in the animal reservoir. The resistant 
bacteria may be transferred to humans via food and may 
subsequently compromise treatment effect when they cause 
disease in humans.
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Salmonella Typhimurium is one of the most common serovars 
in Danish pigs and pork as well as in human infections. 
Among S. Typhimurium from pigs, 61–70% of the isolates 
were resistant to ampicillin, streptomycin, sulfonamide, and 
tetracycline; and the occurrence of resistance to these four 
antimicrobial agents have increased over the last five years. 
This can mainly be attributed to an increasing prevalence of 
monophasic S. Typhimurium that has a strong tendency to be 
multi-resistant. In 2013, 52% of the S. Typhimurium isolates 
from pigs were of the monophasic variants. High levels of 
resistance in S. Typhimurium were also found among isolates 
from Danish pork. In general, we found higher levels of multi-
resistance among S. Typhimurium (including the monophasic 
variants) isolates from Danish pigs (64%) and pork (71%) 
compared to other Salmonella spp. isolates from pigs and pork 
(37% and 36%, respectively). Based on the relative occurrence 
of resistance from DANMAP samples and the Salmonella 
prevalence from the national control programmes, it was 
estimated that 9% of Danish pigs and 0.5% of the pig carcasses 
were positive with multi-resistant Salmonella. As in previous 
years, resistance to cephalosporins (ceftiofur or cefotaxim) or 
quinolones (ciprofloxacin or nalidixic acid) was not detected 
among Salmonella from Danish pigs or pork.
As in isolates from pigs and pork, the occurrence of monophasic 
variants of S. Typhimurium in humans increased in prevalence 
among both domestic sporadic cases and outbreaks over the 
last five years. In 2013, multi-resistant isolates were recovered 
from 54% of the domestic sporadic cases, however, generally 
the levels of resistance was comparable to 2012. Resistance to 4 
of the 16 tested compounds was higher among travel-associated 
cases than domestic human cases, including resistance to 
fluoroquinolones, which are used for empiric treatment of 
adults with severe bacterial gastroenteritis caused by both 
Salmonella and Campylobacter. Among the travel-associated 
cases, the occurrence of multi-resistance decreased in 2013 
to a level comparable to the occurrence among the sporadic 
domestic cases.
The occurrence of monophasic S. Typhimurium, which 
are often multi-resistant, has increased in pigs, pork and 
among isolates from human infections the past five years. 
Among isolates from human infections, the resistance 
levels were higher for four out of 16 compounds tested 
(including fluoroquinolones) among the travel related 
human cases compared to the domestically acquired 
cases. Although resistance was most common among 
isolates from travel related human cases the amount 
of multi-resistance isolates decreased in 2013 to a level 
comparable to isolates from domestically sporadic 
cases.
In 2013, Campylobacter jejuni isolates from Danish broilers 
and cattle were similar to the observed levels in 2011, and 
slightly higher than in 2012. The observed changes in 
resistance to tetracycline were not statistically significant; 
nonetheless they correspond well to changes in consumption 
of tetracycline in the broiler production.
The level of fluoroquinolone(ciprofloxacin) resistance 
in C. jejuni remains higher among isolates from 
imported broiler meat compared with isolates from 
Danish broiler meat, and among C. jejuni from travel-
associated cases compared with domestic cases and 
this difference became more pronounced from 2012 
to 2013.
Resistance in indicator bacteria
Indicator bacteria, enterococci and Escherichia coli, are 
included in the DANMAP programme to provide information 
about the general levels of resistance in healthy production 
animals and in meat.
In Enterococcus faecalis from Danish broilers, resistance 
to tetracycline (38%) was the most dominant, followed by 
resistance to erythromycin and salinomycin.
Higher prevalence of resistance to antimicrobials was observed 
among E. faecalis isolated from pigs compared to poultry, which 
reflects the usage pattern of antimicrobials in these animal 
species. Among E. faecalis from pigs, the highest occurrence 
of resistance was to tetracycline (91%). Tetracycline has been 
the most widely used antimicrobial agent in the Danish pig 
production for more than a decade and has primary been used 
for treatment of E. coli infections. Erythromycin resistance in 
E. faecalis from pigs was 45% a decline since 2012. Occurrences 
of resistance were higher in imported pork when compared to 
Danish produced pork.
Among isolates from broiler meat, the highest level of 
resistance to several compounds was observed in imported 
broiler meat, similar to previous years. Moreover, higher 
prevalences of multi-resistance was observed in isolates from 
imported broiler meat (39% and 34% for E. faecalis and E. 
faecium, respectively) compared to broiler meat produced in 
Denmark. Among the multi-resistant E. faecalis isolates from 
imported broiler meat, 72% had an identical resistance profile 
(erythromycin, kanamycin, streptomycin and tetracycline).
In general, resistance to antimicrobial agents of critical 
importance for human treatment was low, but fluoroquinolone 
(ciprofloxacin) resistance was observed in one E. faecalis 
isolate from a Danish pig.
In a European context, Denmark reports the lowest levels of 
antimicrobial resistance among C. jejuni from broilers and 
broiler meat and for C. coli isolates obtained from pigs.
For several years, the level of fluoroquinolone resistance in C. 
jejuni has been higher among isolates from imported broiler 
meat (53%), compared with isolates from Danish broiler meat 
(20%).
As observed in previous years, the C. jejuni isolates from the 
travel-associated cases continued to have a significantly higher 
level of fluoroquinolone resistance (92%) compared with 
domestic cases (24%).
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In a One Health perspective, there appears to be a direct 
link between the antimicrobial consumption in the 
broiler production and the level of resistance in E. faecalis 
isolates from Danish broilers. A similar link between 
Danish pork and pigs has not been observed. E. faecalis 
isolates from pork were generally more susceptible 
when compared with isolates from pigs. Furthermore, 
resistance in Danish pork has been declining, a trend not 
seen in Danish pigs.
Indicator Escherichia coli from broilers were most often 
resistant to sulfonamide and ampicillin (both 26%), 
which can be explained by the usage pattern. Resistance to 
fluoroquinolones was observed in 6% of the isolates and 
ceftiofur (3rd generation cephalosporin) resistance was 
observed in two E. coli isolates from broilers. Resistance in 
isolates from Danish broiler meat was similar to the findings 
in broilers. Resistance in isolates from cattle and beef was 
generally low. The highest occurrence among production 
animals was observed in pigs, and resistance was at the same 
high level as in 2012.
In isolates from meat, the highest occurrence of resistance, 
including resistance to critically important antimicrobials, 
was found in imported broiler meat. Compared with Danish 
broiler meat, we found higher levels of resistance for 14 of 16 
tested antimicrobial agents from imported broiler meat. For 
E. coli from pork of domestic origin, resistance to quinolones 
(ciprofloxacin and nalidixic acid) was significantly lower than 
in imported pork.
Extended spectrum beta-lactamase (ESBL)-producing 
bacteria is one of the fastest emerging resistance problems 
worldwide. Lately, several studies have found the same ESBL 
genes, plasmids and clones of E. coli isolates originating from 
animals and isolates involved in human infections, suggesting 
a zoonotic link. The occurrence of Enterobacteriaceae resistant 
to carbapenems is a growing threat in human medicine 
because carbapenems are the last resort for treatment of 
infections caused by multidrug resistant Gram-negative 
bacteria in humans.
In 2013, six percent of pigs at slaughter had ESBL-producing 
E. coli, which was lower than in 2012 and 2010 and 2009. From 
meat samples, the highest prevalence of ESBL producing E. 
coli was found among imported broiler meat (52%), similar 
level as in 2010 to 2012. The occurrence of meat samples 
positive for ESBL producing E. coli from Danish broiler 
meat was significantly lower (25%) than in 2012 (36%). The 
occurrence of ESBL producing E. coli in meat samples was 
significantly higher in imported broiler meat when compared 
to Danish broiler meat. This is most likely due to a voluntary 
stop in the usage of 3rd generation cephalosporins in the 
top of the breeding pyramid abroad resulting in a reduced 
transmission of ESBL producing E. coli from imported parent 
animals to the Danish broilers. As in 2012 no carbapenemase 
producing E. coli were found.
The voluntary stop in usage of cephalosporins in the 
Danish pig production continuously results in a low 
occurrence of ESBL producing E. coli in pigs at slaughter. 
Also a significant decrease in the occurrence of ESBL 
producing E. coli in Danish produced broiler meat was 
observed, which is most likely due to a voluntary stop 
in usage in cephalosporins in the top of the breeding 
pyramid abroad.
Resistance in human clinical bacteria 
Data on antimicrobial resistance in bacteria from diagnostic 
submissions from human patients were gathered by voluntary 
reporting from the DANRES group, which covers the 
Departments of Clinical Microbiology (DCM) in Denmark. 
Exceptions were methicillin-resistant Staphylococcus aureus 
(MRSA) and invasive Streptococcus pneumoniae that are 
notifiable. Data on these bacteria were obtained from the 
reference laboratories at SSI.
In Escherichia coli blood isolates, resistance to 3rd generation 
cephalosporins was 8% in 2013, the same level as reported in 
2012, but above the 2012 level reported in the other Nordic 
countries. The occurrence of ciprofloxacin resistance decreased 
from 14% in 2012 to 12% in 2013. Aminoglycoside (gentamicin) 
resistance was 7% and at the same level as reported in 2012. 
Resistance data on piperacillin/tazobactam was reported for the 
first time in the present DANMAP report. Data were obtained 
for five years (2009–2013). For all five years, the resistance was 
at the same level (around 4%). 
In E. coli urine isolates from hospital patients, 3rd generation 
cephalosporin resistance was 6% - the same level as in 2012. 
The occurrence of ciprofloxacin resistance (12%) was at the 
same level as in 2012, but a steady increase has been seen in 
ciprofloxacin resistance from 3% in 2004. Aminoglycoside 
(gentamicin) resistance was 5% and sulfonamide resistance was 
33%, which are at the same levels as in 2012.
In E. coli urine isolates from primary healthcare, ciprofloxacin 
resistance has increased steadily from 3% in 2004 to 10% in 2013. 
The occurrence of 3rd generation cephalosporin resistance was 
4%, sulfonamide resistance was 33% and ampicillin resistance 
was 40% in 2013, all at same levels as reported in 2012.
In Klebsiella pneumoniae blood isolates, the resistance levels 
were the same as reported in 2012. Resistance to 3rd generation 
cephalosporins was 9%, aminoglycoside (gentamicin) resistance 
was 4%, and ciprofloxacin resistance was 9%.
In K. pneumoniae urine isolates from hospital patients, 
resistance to mecillinam (10%), sulfonamide (20%), gentamicin 
(4%), 2nd generation cephalosporins (cefuroxime) (9%) and to 
3rd generation cephalosporins (7%) decreased from 2012 to 
2013. Ciprofloxacin resistance was at the same level as reported 
in 2012.
DANMAP 2013  
                                                                           
       18
SUMMARY2.
In K. pneumoniae urine isolates from primary healthcare, 
resistance to 3rd generation cephalosporins was 6%, which is 
similar to the level reported in 2012. Resistance to ciprofloxacin 
was 7% and resistance to mecillinam was 10%, which were 
similar to the levels reported in 2012. Sulfonamide resistance 
decreased from 26% in 2012 to 22% in 2013.
In Pseudomonas aeruginosa blood isolates, resistance to all 
the tested antimicrobial agents was not significantly different 
from the levels reported in 2012, but an increasing trend has 
been observed for gentamicin resistance during 2007–2013. 
The occurrence of carbapenemase producing bacteria in 
Denmark is described in Textbox 7. In 2013, 18 carbapenemase 
producing Enterobacteriaceae (CPE) were detected compared 
to 19 during 2008–2012. In 2013, spread of NDM-1 producing 
Citrobacter freundii was detected between four patients at 
a hospital ward in the North Denmark Region. None of the 
four patients had been travelling recently and the origin of 
the NDM-1 producing C. freundii was unknown. Besides the 
NDM-1 producing C. freundii, two of the four patients had 
NDM-1 producing K. pneumoniae. During 2013, seven OXA-
23 producing A. baumannii isolates were detected. Spread of 
OXA-23 producing A. baumannii was detected twice between 
patients. Furthermore, OXA-40-like producing A. baumannii 
(n = 3) was detected, two of these isolates were part of the same 
transmission chain. Two NDM-1 producing A. baumannii 
isolates were detected. In 2013, three VIM producing P. 
aeruginosa isolates were detected. Furthermore, an NDM 
and VIM producing P. aeruginosa was detected. For the first 
time, an IMP producing P. aeruginosa isolate was detected in 
Denmark. Both patients had been hospitalized abroad prior to 
detection of these isolates.    
Resistance to penicillin and erythromycin in Streptococcus 
pneumoniae and in group A, B, C and G streptococci 
remained low in 2013.
In 2013, resistance to ampicillin was 93% in Enterococcus 
faecium isolates from blood. Vancomycin resistance was 3.4% 
in E. faecium and 0.2% in Enterococcus faecalis blood isolates. 
During 2013, an increasing number of vancomycin resistant 
enterococci were referred to the Antimicrobial Resistance 
Reference Laboratory at SSI (Textbox 8). Of the VRE isolates, 
248 were from clinical infections and 168 were faecal screening 
isolates. Nearly all VRE isolates were vanA E. faecium isolates. 
The VRE isolates were primarily from hospitals in the Capital 
Region, but also from the Zealand Region and the Central 
Denmark Region. VRE was detected in the two other regions 
of Denmark too, but to a much lower extent. Pulsed-field 
gel electrophoresis typing showed spread of several vanA E. 
faecium types both within hospitals and between hospitals.
Ciprofloxacin resistance in Neisseria gonorrhoeae increased 
steadily from 30% in 2003 to 75% in 2009, followed by a 
decrease to 56% in 2013. Penicillinase production among 
gonococcus isolates fluctuated between 24% in 2003 and 
11% in 2013, and no ceftriaxone resistant isolates or cases of 
ceftriaxone treatment failure, were reported in this period. In 
2013, azithromycin resistance was 45%, cefixime resistance 
was 9%, and no spectinomycin resistant isolates were detected 
(Textbox 9).
In 2013, 1,769 cases of Staphylococcus aureus bacteraemia were 
reported, corresponding to 32.9 cases per 100,000 inhabitants. 
The number of methicillin-resistant S. aureus (MRSA) from 
bacteraemia was 30 (1.7%), a level similar to previous years and 
among the lowest incidences recorded in Europe. The highest 
frequency of resistance in addition to penicillin was observed 
for fusidic acid (15%), erythromycin (7%), clindamycin (6%) 
and norfloxacin (5%). Susceptibility to the tested antimicrobial 
agents was at the same level as in 2012.
The number of new cases of MRSA (both infected and colonized 
persons) increased in 2013 to 2,094 compared to 1,556 in 2012.
The increase was primarily seen in livestock associated MRSA, 
belonging to clonal complex 398 (CC398), with 643 cases in 
2013 vs 232 in 2012. In 2013, CC398 constituted 31% of all 
new MRSA cases in Denmark. A significant part of the increase 
was associated with inclusion of contact to pigs as a risk factor 
requiring screening for MRSA when being admitted to hospitals. 
The majority (87%) of persons infected or colonized with 
CC398 had close contact to pigs or were household members 
to persons who had pig contact. There were, however, no signs 
of significant spread of CC398 to urban areas, which indicates 
that food does not constitute an important transmission route.
Among all MRSA cases, the proportion of cases presenting 
with infection was lower in 2013 compared to 2012 (45% vs. 
57%, respectively). The number of hospital-acquired (HA) 
cases continued to be low and constituted only 2% of the total 
number of MRSA cases in 2013. In 2013, no monitoring of 
MRSA in animals and meat was performed.
In 2013, 18 carbapenemase producing Enterobacteriaceae 
(CPE) were detected compared to 19 CPE during 2008–
2012. Spread of NDM-1 producing C. freundii was 
detected between four patients at a hospital ward in the 
North Denmark Region. None of the four patients had 
been travelling recently and the origin of the NDM-1 
producing C. freundii was unknown.
An increasing number of vancomycin resistant 
enterococci were received at SSI during 2013. Two-
hundred-four-eight of the VRE isolates were from 
clinical infections and 168 were faecal screening isolates. 
Nearly all VRE isolates were vanA E. faecium. They were 
primarily detected at hospitals in the Capital Region, but 
also from the Zealand Region and the Central Denmark 
Region.
The number of new cases of MRSA (both infected 
and colonized persons) increased in 2013 to 2,094 
compared to 1,556 in 2012. The increase was primarily 
seen in livestock associated MRSA, belonging to clonal 
complex 398 (CC398), with 643 cases in 2013 vs 232 in 
2012. CC398 constituted 31% of all new MRSA cases 
in Denmark in 2013. The number of hospital-acquired 
MRSA cases continued to be low and constituted only 
2% of the total number of MRSA cases in 2013.
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3. Background information
The following section presents general information about the 
human population in Denmark in 2013, and the production 
of food animals in Denmark, over the past decade. It also 
provides an overview of the antimicrobial agents for systemic 
and intramammary therapeutic use in humans and animals in 
2013.
3.1  Populations
The distribution of the Danish human population, which could 
potentially have received antimicrobial treatment in 2013, is 
displayed in Figure 3.1, together with the 5 healthcare regions 
and the 11 Departments 
The production of food animals and the production of meat 
and milk is presented in Table 3.1. While the number pigs was 
approximately 1% lower than in 2012, the number of fattening 
pigs (15–50 kg) exported increased by 5%, and the export has 
increased by more than five-fold since 2004. As in the previous 
years, the amount of milk produced increased (2%). 
There was a 6% increase in the Danish broiler production 
from 2012 to 2013 (Table 3.1). Approximately 8% of the 
broilers produced in 2013 were exported for slaughter, a slight 
decrease compared to 2012, but a marked increase from 0.1% 
of the production in 2003. The annual production of turkeys 
has fluctuated considerably over the last decade. Since 2006, 
more than 99% of the turkeys produced have been exported for 
slaughter, thus all turkey meat available in Denmark is listed as 
imported.
3.2  Marketed antimicrobial agents
Table 3.2 shows the antimicrobial agents that are registered 
to treat bacterial infections in humans and animals. Some of 
these antimicrobial agents are considered critically important 
for humans by WHO. An antimicrobial agent is considered 
critically important if it is the only compound, or one of limited 
available therapy, to treat serious human disease. Critically 
important antimicrobial agents are also used in food animals 
and pets to treat veterinary diseases, and bacteria that are 
resistant to these critically important agents may be transmitted 
to humans.
Figure 3.1 The five healthcare regions and 11 Departments of Clinical Microbiology (DCM) in Denmark
DANMAP 2013
Source: Statistics Denmark (www.dst.dk) and the 
Danish Medical Association (www.laeger.dk) 
GP=general practitioner
North Denmark Region
No. of inhabitants 580,272 No. 
of inhabitants/km2 73        
No. of inhabitants/GP 1707
Central Denmark Region
No. of inhabitants 1,272,510 
No. of inhabitants/km2 97       
No. of inhabitants/GP 1517
Capital Region of Denmark
No. of inhabitants 1,732,068 
No. of inhabitants/km2 676         
No. of inhabitants/GP 1573
Region Zealand
No. of inhabitants 816,359 No. 
of inhabitants/km2 112        
No. of inhabitants/GP 1623
Region of Southern Denmark
No. of inhabitants 1,201,419 
No. of inhabitants/km2 98        
No. of inhabitants/GP 1489
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3. Background information Bacteria that cause human disease may acquire resistance genes 
from bacteria of animal origin. Fluoroquinolones, 3rd and 4th 
generation cephalosporins, macrolides and glycopeptides are 
among the antimicrobial agents considered critically important 
for humans [AGISAR, WHO 2009].
Source: Statistics Denmark (www.dst.dk) and The Danish AgriFish Agency. Production data for farmed fish was not available for 2013. Live animals 
exported prior to slaughter are included in number of animals and amount of meat produced. Export data for poultry from Statistics Denmark 
(personal communication) and export of 15-50 kg live pigs from Danish Agriculture and Food
a) The numbers for 2013 are not final. The production of farmed fish includes fish transferred from one production facility to another. 
b) Assume a final slaughtered weight of 1.51 kg per broiler produced (Danish Agriculture and Food, 2013)
c) Export of 15-50 kg live pigs. These are included in total number of heads, but antimicrobial use after export until slaughter is not registered as it 
takes place outside of Denmark
d) Increase from 2012 to 2013
Table 3.1. Production of food animals and the production of meat and milk, Denmark
DANMAP 2013
Year Broilers Turkeys Cattle(slaughtered) Dairy cows Pigs
 Farmed fish(a) 
Fresh 
water Marine
1,000 
heads mill. kg
(b) 1,000 
heads mill. kg
1,000 
heads mill. kg
1,000 
heads
mill. kg
milk
1,000 
heads
Export
1,000
heads(c)
mill. kg mill. kg mill. kg
1990 94560 116 571 2.5 789 219 753 4542 16425 - 1260 - -
1992 107188 137 761 5.4 862 236 712 4405 18442 - 1442 35 7
1994 116036 152 1091 8.6 813 210 700 4442 20651 - 1604 35 7
1996 107895 149 961 9.3 789 198 701 4494 20424 - 1592 32 8
1998 126063 168 1124 11.6 732 179 669 4468 22738 - 1770 32 7
2000 133987 181 1042 10.3 691 171 636 4520 22414 - 1748 32 7
2001 136603 192 1086 13.2 653 169 623 4418 23199 - 1836 31 8
2002 136350 190 1073 12.8 668 169 611 4455 24203 - 1892 32 8
2003 129861 197 777 11.2 625 161 596 4540 24434 - 1898 34 8
2004 130674 198 1086 19.6 632 165 569 4434 25141 1712 1967 34 9
2005 122179 183 1237 17.4 549 145 559 4449 25758 2720 1988 31 8
2006 106182 161 785 11.3 509 140 556 4492 25763 3204 1957 29 8
2007 107952 163 1009 14.4 512 141 545 4515 26311 3522 2046 31 10
2008 107595 163 1068 12.3 509 138 559 4585 27078 4943 1985 30 10
2009 108851 165 1175 11.1 507 137 569 4734 27603 6642 1898 29 11
2010 117653 178 1184 14 519 142 574 4830 28505 7074 1974 28 10
2011 115454 175 960 9.4 551 145 575 4801 29399 7632 2008 28 11
2012 111080 168 1103 12.4 539 138 580 4928 29047 8794 1902 28 13
2013 117315 177 692 8,3 551 139 574 5025 28996 9224 1896 30 13
Increase(d) 6% 5% -37% -33% 2% 1% -1% 2% <1% 5% 0% 8% 1%
Growth promoters, which are no longer used for animals in 
Denmark, are shown in parentheses in Table 3.2. Most of the 
antimicrobial agents used for growth promotion  in Denmark 
had effects on Gram-positive bacteria. Since 1995, the indicator 
enterococci from animals and meat (and in some years from 
healthy humans) have been used as a measure of resistance to 
growth promoters.
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Table 3.2.  Antimicrobial agents marketed for systemic and veterinary intramammary therapeutic use in animals and humans, 
Denmark 2013 DANMAP 2013
ATC / ATCvet codes (a) Therapeutic group Antimicrobial agents within the therapeutic groups
Animals Humans
J01AA / QJ01AA,QJ51AA Tetracyclines Chlortetracycline, doxycycline, oxytetracycline
Doxycycline, lymecycline, 
oxytetracycline, tetracycline, 
tigecycline
J01BA / QJ01BA Amphenicols Florfenicol Chloramphenicol
J01CA / QJ01CA Penicillins with extended spectrum Ampicillin, amoxicillin
Ampicillin, pivampicillin, 
amoxicillin, bacampcillin, 
pivmecillinam, piperacillin, 
mecillinam
J01CE / QJ01CE Beta-lactamase sensitive penicillins
Benzylpenicillin, 
phenoxymethylpenicillin, procaine 
penicillin, penethamate hydroiodide
Benzylpenicillin, 
phenoxymethylpenicillin, 
benzathine benzynpenicillin, 
procaine penicillin
J01CF / QJ51CF Beta-lactamase resistant penicillins Cloxacillin, nafcillin Dicloxacillin, flucloxacillin, cloxacillin, methicillin
J01CR / QJ01CR Comb. of penicillins, incl. beta-lactamase inhibitors Amoxicillin/clavulanate
Amoxicillin/clavulanic acid, 
piperacillin/tazobactam
J01DB / QJ01DB,QJ51DB First-generation cephalosporins Cefalexin, cefadroxil, cefapirin Cefalexin, cefalotin
J01DC Second-generation cephalosporins Cefuroxime, cefoxitime
J01DD / QJ01DD,QJ51DD Third-generation cephalosporins Cefoperazone, ceftiofur, cefovecin Cefotaxime, ceftazidime, ceftriaxone, cefpodoxime
J01DE / QJ51DE Fourth-generation cephalosporins Cefquinome Cefepime
J01DF Monobactams Aztreonam
J01DH Carbapenems Meropenem, ertapenem, imipenem/cilastatin, doripenem
J01EA Trimethoprim and derivatives Trimethoprim
J01EB / QJ01EQ Short-acting sulfonamides Sulfadimidine Sulfamethizole
J01EE / QJ01EW Comb.of sulfonamides and trimethoprim, incl. derivatives
Sulfadiazine/trimethoprim, 
sulfadoxine/trimethoprim,
sulfamethoxasol/trimethoprim  
Sulfamethoxazole/trimethoprim
J01FA / QJ01FA Macrolides
Spiramycin, tylosin, tilmicosin, 
tylvalosintartrat, tulathromycin, 
gamithromycin, tildiprocin
Erythromycine, roxithromycine, 
clarithromycine, azithromycine, 
spiramycine
J01FF / QJ01FF Lincosamides Clindamycin, lincomycin Clindamycin
J01FG / QJ01XX (b) Streptogramins (Virginiamycin)
J01G / QJ01RA,QA07AA Aminoglycosides Streptomycin, dihydrostreptomycin, gentamicin, neomycin, apramycin
Tobramycin, gentamicin, amikacin, 
netilmicin
J01MA / QJ01MA Fluoroquinolones
Enrofloxacin, marbofloxacin, 
difloxacin, ibafloxacin, 
pradofloxacin
Ofloxacin, ciprofloxacin, 
norfloxacin, fleroxacin, 
grepafloxacin, trovafloxacin, 
moxifloxacin
QJ01MB Other quinolones Oxolinic acid Nalidixic acid
QJ01MQ (b) Quinoxalines (Carbadox, olaquindox)
J01XA,A07AA / 
Not in ATCvet (b,c) Glycopeptides (Avoparcin) Vancomycin, teicoplanin
J01XB / QA07AA (b) Polypeptides (incl. polymyxins) Colistin, bacitracin Colistin
J01XC Steroid antibacterials Fusidic acid 
J01XD,P01AB (c) Imidazole derivatives Metronidazole
J01XE Nitrofurane derivatives Nitrofurantoin 
J01XX / QJ01FF Other antibacterials Spectinomycin Methenamine, linezolid, daptomycin
QJ01XQ Pleuromutilins Tiamulin, valnemulin
QP51AG04 Antiprotozoals, sulfonamides Sulfaclozine
Not in ATCvet (b) Oligosaccharides (Avilamycin)
Not in ATCvet (b) Flavofosfolipols (Flavomycin)
a) ATCvet codes starts with a Q
b) Animal growth promoters used before 1999 are listed in parentheses
c) Although intestinal antiinfectives (A07AA) and imidazole derivatives for protozoal diseases (P01AB) are used to treat human patients, they 
are not reported by DANMAP
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4. Antimicrobial consumption in animals
Figure 4.1. Prescribed antimicrobial agents for humans, and for animals compared with the number of pigs produced, Denmark
Sources: Human therapeutics: The Danish Medicines Agency. Veterinary consumption: Until 2001, data are based on reports from the 
pharmaceutical industry of total annual sales from the Federation of Danish pig producers and slaughterhouses (1994-1995) and Danish 
Medicines Agency and Danish Plant Directorate (1996–2000). Data from 2001–2013 originate from VetStat
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4.1 Introduction
The use of antimicrobial agents in humans and animals has been 
monitored by the DANMAP programme since 1995. Since the 
early 1990s, there has been both political and public focus on 
the use of antimicrobial agents in the Danish animal production. 
This resulted in discontinued use of several antimicrobial agents 
used for growth promotion from 1994-1999, and more recently, 
a voluntary ban of use of cephalosporins in the pig production, 
as well as regulatory legislation regarding therapeutic use 
[DANMAP 2010].
Overall, the antimicrobial consumption for both humans and 
animals has increased since the late 1990s. While the consumption 
for humans has gradually increased throughout the period, the 
consumption in animals has fluctuated notably. The increase in 
veterinary consumption can partly be explained by the increase 
in pork production, which constitutes approximately 84% of the 
meat production in Denmark (Table 3.1). Figure 4.1 shows the 
total antimicrobial consumption in animals and humans since 
1994 and 1997, respectively.
The prescription pattern has been clearly influenced by 
implemented legislation. For example, the decrease in 
antimicrobial consumption after 1994 was likely the result of 
1) limitation of veterinarians profit from sales of medicine 2) 
implementation of preventive veterinary strategies with herd 
health contracts and regular monthly visit from the veterinarian 
in order to promote preventive veterinary strategies and 
optimize antimicrobial use, and 3) enforcement of the so 
called “cascade rule” [Order (DK) 142/1993], which limits 
the use of (cheaper) extemporaneously produced medicines 
- this particularly affected the use of tetracyclines from 1994. 
Another important intervention was the restriction on the 
use of fluoroquinolones in production animals through 
legislation implemented in 2002 and 2003. Furthermore, in 
July 2010, the pig industry imposed a voluntary ban on the 
use of cephalosporins, due to concerns regarding extended 
beta-lactamase resistance (ESBL).
From 2010 to 2011, consumption decreased following 
the introduction of threshold values for antimicrobial 
consumption adopted within the “yellow card initiative”. This 
enforces legal actions on pig farmers with high antimicrobial 
agent use per pig [DANMAP 2010]. Effects from other parts 
of the legislation may be less obvious, but are important to 
keep in mind, when interpreting the veterinary prescription 
patterns.
Official guidelines for the selection of antimicrobial agents 
that veterinarians may choose from for pigs and cattle have 
been available since 1996. The guidelines provide specific 
recommendations for the selection of the appropriate 
antimicrobial agents for treatment of all common indications 
in major production animal species. Initially, guidelines were 
developed by the National Veterinary Laboratory (presently, 
National Veterinary Institute, DTU). Since 2005, the 
guidelines have been updated by the Danish Veterinary and 
Food Administration (DVFA) in collaboration with National 
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Veterinary Institute DTU, National Food Institute DTU, the 
Practicing Veterinarians Organization, university experts, 
the Danish Association of the Veterinary Pharmaceutical 
Industry and the Danish Agriculture and Food Council. The 
latest update was in 2010, when new dynamic evidence-based 
treatment guidelines for pigs were launched [DANMAP 2010, 
www.fvst.dk]. In 2012, the Danish Veterinary Association 
published treatment guidelines to promote prudent use of 
antimicrobials in dogs and cats, prepared by clinical specialists 
and expert scientists from the Faculty of Health and Medical 
Sciences at the University of Copenhagen and National Food 
Institute, DTU.
4.1.1 Data sources 
Data on antimicrobial use at the product the level have been 
collected in Denmark since 1996, including historical data back 
to 1990. In Denmark, all therapeutic medicine is by prescription 
only, and since 2001, data on all medicine prescribed for use 
in animals, including vaccines, have been collected (at end 
users) in a national database (VetStat). Data on consumption 
coccidiostatic agents (non-prescription) and antimicrobial 
growth promoters (no longer used), are also collected by 
VetStat.
Consumption data for 2013 - for use in DANMAP - were 
extracted from VetStat by the Danish Veterinary and Food 
Administration (DVFA) on 11 June 2014. The National Food 
Institute, DTU has carried out no further validation of the 
received data.
4.1.2 Methods 
Metrics of antimicrobial consumption are numerous, each 
with its own advantages and limitations. Therefore, the chosen 
measures must depend on the purpose and the available 
information.
The overall amount of antimicrobial agents is measured in kg 
active compound and is used in Section 4.2 for the purpose of an 
overall crude comparison of antimicrobial use in the veterinary 
and human sectors and to enable international comparisons 
(Figure 4.1).
In DANMAP 2012, we introduced two new metrics to follow 
trends in antimicrobial consumption to ensure the robustness 
of the analyses over time and to facilitate comparisons between 
animal species, as well as comparisons between the veterinary 
and human sectors. The new metrics are defined below, and for 
more information on methodology, please refer to Chapter 9 
and the web annex [www.Danmap.org].
DADD (Defined animal daily dose)
DADD is the average maintenance dose per day for a drug used 
for its main indication in the appropriate animal species.
The DADD is not defined at product level but for each 
antimicrobial agent, administration route and animal species; 
and when appropriate, also age group. DADD has been 
specifically defined for use in DANMAP and does not always 
completely match the prescribed daily dose or the recommended 
dosage in the Summaries of Product Characteristics (SPC) or in 
the VetStat database.
Since 2012, the DADD has replaced the ADD (as defined in 
VetStat), which had been used since DANMAP 2003. For more 
details, see Chapter 9, Materials and Methods. The DADDs 
used in DANMAP 2013 are presented in the web annex.
DAPD (DADD per 1,000 animals per day) - estimated 
treatment proportion
Trends in veterinary consumption, both within and across 
species, are presented in DAPD, allowing for comparison 
between sectors and adjusting for changes in live biomass. The 
estimated live biomass is expressed as the number of standard 
animals with an estimated average weight on a given day. This 
may also be referred to as the ‘standard-animals-at-risk’, and 
takes into account species differences in body-mass and life-
span.
DAPD or estimated treatment proportion is a statistical 
measure, providing a rough estimate of the proportion of 
animals treated daily with a particular antimicrobial agent. 
For example, 10 DAPDs indicate that an estimated 1% of 
the population (e.g. broiler population), on average, receives 
a certain treatment on a given day (Section 4.3 and Chapter 
9, Materials and Methods). Furthermore, presenting the 
veterinary consumption in DAPD allows comparisons with the 
antimicrobial consumption in the human sector as expressed 
in defined daily dose per 1,000 inhabitants per day (DID), see 
Chapter 10, Terminology, for a description of DID.
At the European level, the ESVAC (European Surveillance of 
Veterinary Antimicrobial Consumption) project monitors 
veterinary usage in a number of countries. ESVAC monitoring 
is based on the quantity by weight of antimicrobials, using a 
“population correction unit” (PCU) as denominator to adjust 
for changes in size of the production animal population 
within the respective countries over time. A description of the 
methodology used by ESVAC is contained in the first report 
“Trends in the sales of veterinary antimicrobial agents in nine 
European countries 2005-2009” [www.ema.europa.eu].
In the context of DANMAP, we base our comparison on dosages 
in order to keep in focus the newer, potent antimicrobials such 
as fluoroquinolones and cephalosporins that are critically 
important in the treatment of human infections. Furthermore, 
the biomass of the live population is used as denominator to 
allow for comparisons of selection pressure between animal 
populations.
In the text below, unless otherwise stated, DAPD will be used 
to describe patterns in veterinary antimicrobial consumption.
4.2 Total antimicrobial consumption
In 2013, the total veterinary consumption of antimicrobial 
agents, including agents used for companion animals, 
amounted to 116.3 tonnes active compound (Table 4.1), 
representing a 4% increase compared with 2012. The increase 
was mainly attributed to a 6% increase in the amount used in 
pigs. The two major species, cattle and pigs, comprise equal 
proportions of live biomass. However, the vast proportion of 
cattle biomass consists of dairy cows, which have a very low 
consumption of antimicrobial agents compared with growing 
animals. In 2013, the antimicrobial consumption in pigs, 
cattle and poultry comprised 78%, ~10%, and ~1% of the total 
veterinary consumption, respectively (Figure 4.2).
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Pigs, 43%
Cattle >1 yr., 40%
Cattle<1 yr., 7%
Pets, 1%
Horses, 5%
Poultry, 1%
Fur Animals, 1%
Aquaculture , 2%
Live biomass 
Pigs, 78%
Cattle, 10%
Horses, pets and 
others  3%
Poultry, 1%
Fur Animals, 4%
Aquaculture, 3%
Kg active compound
DANMAP 2013
Note: The live biomass is estimated from census (pigs, cattle and pet animals) and production data (poultry, fur animals, aquaculture). The 
estimation procedures are described in Chapter 9. For poultry: the figures comprise only the biomass for the main production types (turkey 
and broiler production)
Figure 4.2. Live biomass (mill kg) and antimicrobial consumption (kg) in main animal species, Denmark
Note: Only the ATCvet group contributing mostly to the antimicrobial group is mentioned. Combination drugs are divided into active compounds
a) Penicillins with extended spectrum, cloxacillin and amoxicillin/clavulanic acid
b) Sulfaclozin (a prescription coccidiostat) is included in the sulfonamide/trimethoprim group
c) Fluoroquinolones reported for use in pigs were used in a clinical trial approved by the Danish Medicine Agency [Source: DVFA]
d) Antimicrobials used for companion animals: DVFA has allocated kg active compound to the appropriate target species (horses/pets) based 
on knowlegde of which products are used for the particular species
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Pigs, total(c) 263 4606 3 11 2173 11118 8958 16631 7740 8908 29797 398 90606
-Sows and piglets 229 1818 2 11 - 475 565 845 8935 3584 6181 2330 58 25033
-Weaners 26 2516 1 - - 787 7166 3303 1639 2938 2296 16807 338 37817
-Finishers 8 272 0 0 - 911 3387 4810 6057 1218 431 10660 2 27756
Cattle, total 503 534 116 0 0 6 195 1 7090 923 1105 1617 17 12106
-Intramammaries - 19 76 - - 2 - - 192 162 5 - 2 458
-Calves < 12 mdr 484 233 2 0 - 3 65 - 365 191 183 425 15 1967
-Cows and bulls 13 286 113 0 - 3 127 1 6636 719 910 1147 2 9957
-Heifers and steers 5 15 1 - - 0 3 - 89 12 12 45 0 182
Poultry, total 9 36 - 0 0 18 280 3 152 190 60 519 1 1270
Poultry incl. broilers, layers 
and other poultry
Turkeys
1 1 - 0 0 0 37 3 110 168 59 110 1 491
8 35 - - - 17 244 - 42 22 1 409 0 779
Other production animal 
species 185 381 0 0 881 187 632 2 1947 3653 578 1 8447
Aquaculture 185 - - - 881 - - - - 9 2506 2 - 3582
Fur animals 0 381 0 0 - 187 632 - 2 1938 1147 576 1 4866
Companion animals (d) 0 150 234 17 0 72 50 11 850 833 1459 192 43 3911
Horses 0 6 5 6 0 0 1 0 813 151 913 27 0 1922
Pets 0 144 229 11 0 72 49 11 37 682 546 165 43 1989
Total 959 5707 353 28 881 2456 12275 8973 24725 11633 15186 32703 461 116339
DANMAP 2013Table 4.1. Antimicrobial agents sold (kg active compound) by animal species and age group, Denmark 
                                                                           
       27DANMAP 2013  
ANTIMICROBIAL CONSUMPTION IN ANIMALS 4.
Historically, the overall consumption – measured as kg active 
compound - was 43% lower in 2013 compared with 1994 - 
while the total meat production increased by 13% during this 
period (Table 3.1 and Figure 4.1). A major part of the decrease 
in consumption can be explained the by discontinued use of 
growth promoters (1994-1999). 
However, from 2001 to 2009, the antimicrobial consumption 
in production animals increased by 36% (Figure 4.1). This 
increase was driven mainly by an increase in consumption 
in pigs and should be seen in the context that the number of 
pigs produced increased by 19% (Table 3.1). At the same time 
the proportion of live pigs (approx. 30 kg) being exported has 
increased and thus resulted in a decrease in the overall biomass 
of the pig population.
4.3 Antimicrobial consumption by animal 
species
4.3.1 Antimicrobial consumption in pigs
In 2013, the total antimicrobial consumption in pigs was 90.6 
tonnes active compound (Table 4.1), an increase of 5.5 tonnes 
(6%) compared with 2012. The treatment proportions (DAPD) 
in the pig population overall and by age group are presented in 
Figure 4.4 and in the web annex (Table A4.1).
The treatment proportion (DAPD) is much higher in the 
weaning pigs, compared with finishers and sows (Figure 4.3). 
However, the biomass of the weaning pigs is very small (7.5-30 
kg, 4 weeks), compared with the finishers (31-107 kg, 12 weeks) 
and the sows.
The DAPD of the total population should reflect the trends in 
selection pressure in the population. Due to the differences in 
treatment proportion between age groups, the DAPD of the total 
population is affected by changes in population structure, e.g. 
increased export of live pigs at 30 kg. The increase in the export 
would in itself cause an increase in DAPD for the remaining 
population, because the DAPD for finishers is relatively low. 
Thus, a true impression of the antimicrobial consumption 
pattern and selection pressure in the pig production requires 
that changes in export and productivity are taken into account. 
Overall, the antimicrobial consumption in pigs increased by 
5% to approximately 30 DAPD (Figure 4.3) when adjusted for 
changes in export. Overall the number of pigs produced in 
2013 was similar to 2012; however the number of pigs exported 
increased by 5% (Table 3.1). 
Within the different age groups, the DAPD increased in all age 
groups; 9% in sow herds, and 5% in both finishers and weaners. 
The increase in consumption was associated primarily with the 
use of pleuromutilins and tetracyclines, and to a lesser extent, 
to the use of penicillins and sulfonamides/trimethroprim 
(Figure 4.4). Tetracyclines and pleuromutilins have been the 
most commonly used antimicrobial agents in the Danish pig 
production for a decade (Figure 4.4). They are almost entirely 
administered orally, and particularly used for treatment of 
gastrointestinal disease in weaning pigs and finishers. The 
overall treatment proportion (DAPD) of pleuromutilins 
increased by 18%, while the use of tetracyclines increased by 
4%.
For the critically important antimicrobial agents, the use 
of flouroquinolones increased for the second year running, 
however remains at a very low level and constitutes less than 1 
per mille of the total consumption in pigs. The increase in 2013 
is largely explained by a clinical trial approved by the DVFA. 
The use of cephalosporins in pigs was low (3 kg), however, 
increased from 1 kg in 2012 (Figure 4.5).
Over the last decade, the treatment proportion (DAPD) 
increased from 2004 to 2009. However, in 2010 and 2011, 
a decrease in DAPD compared with 2009 was observed, 
probably as a response to the DFVA’s implementation of the 
“yellow card initiative” – a special provision for reduction of 
antimicrobial consumption in pig production (See DANMAP 
2010 for further details). The reductions in antimicrobial use 
were associated with increasing use of vaccines and a slight 
temporary decrease in productivity in some herds, but disease 
outbreaks did not increase [Danish Veterinary Bulletin no. 6, 
2012]. With the increase in antimicrobial consumption in pigs 
in 2013, the consumption is still 12% lower than in 2009, and 
similar to the 2008 level (Figure 4.3).
0
20
40
60
80
100
120
04 05 06 07 08 09 10 11 12 13
Sows and piglets Weaners
Finishers Total, adjusted
D
A
P
D
 (D
A
D
D
 p
er
 1
00
0 
an
im
al
s 
pe
r d
ay
)
Figure 4.3. Antimicrobial consumption (a) in the pig production, 
and the distribution on age groups, Denmark
Note:  The” adjusted total” is adjusted for the increasing export of pigs 
at 30 kg (see text). “Sows” includes treatment in piglets pre-weaning
a) The DAPD is calculated as the number of standard doses for one kg 
animal divided by the estimated live biomass in the age group at the 
total population (in tonnes)
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Figure 4.4. Antimicrobial consumption(a) in the total pig production(b), and in finishers, weaners, sows and piglets, Denmark
DANMAP 2013
Note: Amphenicols, colistin, fluoroquinolones, intramammaries, gynecologicals and topical drugs are not included in the figure. Data from 
veterinary practice are not included (<1% of the consumption in pigs)
a) The DAPD is calculated as the number of standard doses for one kg animal divided by the estimated live biomass in the age group or the total 
population (in tonnes)
b) Total pigs produced includes pigs exported at 30 kg, which has increased in numbers from 1.7 million in 2004 to 9.2 million in 2013. 
Consumption in these pigs is included only from birth to 30 kg body weight. See discussion in the DANMAP 2011.
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4.3.2 Antimicrobial consumption in poultry 
In Denmark, poultry production comprises mainly the broiler 
production (Gallus gallus), followed by egg layers (Gallus 
gallus) and turkey production. In addition, there is a very small 
production of ducks, geese, and game birds. 
In Denmark, the antimicrobial consumption in the broiler 
production is generally low compared with other species and, 
a few disease outbreaks in some farms can seriously affect the 
national consumption, causing considerable fluctuations in 
annual consumption data. 
In 2013, the total antimicrobial consumption in poultry (all 
poultry) was 1,270 kg active compound, an increase of 57% 
compared with 2012. In poultry (other than turkeys), the 
increase was mainly in the use of simple penicillins (from 10 
kg in 2012 to 110 kg in 2013), but also in the use of tetracyclines 
(36 kg in 2012 and 110 kg in 2013). In turkeys there was also an 
increase in the use of simple penicillins, but the most significant 
increase was seen in the use of tetracyclines, which increased 
from 127 kg to 409 kg in 2013. The main reason appears to be 
widespread problems with respiratory disease in turkey flocks 
produced early in 2013. Furthermore, an increased occurrence 
of diarrhea in broiler flocks in 2013 may be the reason for the 
increased consumption of penicillins.
For broilers, amoxicillin has been the most commonly used 
antimicrobial agent for at least a decade. Fluoroquinolones 
were the second most commonly used antimicrobial agent 
until 2007 (when new medicines were approved for poultry), 
but has not been used in broilers in 2010-2013.
4.3.3 Antimicrobial consumption in cattle
In DANMAP 2012 we expressed reservations about data on 
antimicrobial consumption in cattle. However, analyses of 
this issue in collaboration with representatives from the cattle 
industry and the veterinary authorities has shown that the data 
quality of reporting of use in cattle has increased markedly 
in recent years and is now as high as that for other major 
production animal species.
The data shows that use of antimicrobials in cattle has declined 
to a total of about 12 tonnes active compound in 2013. During 
this period, the veal and beef production has remained at the 
same level, although with minor fluctuation from year to year, 
and the milk production has increased slightly. 
In general, the majority of the parenteral use in cattle is for 
cows (Table 4.1), and is mainly prescribed for mastitis. The 
systemic use of fluoroquinolones in cattle was close to zero 
in 2013, and has been at a low level since 2003. In 2013, 
systemic use of cephalosporins in cattle declined to 40 kg 
from 47 kg in 2012 (Figure 4.5). Use of 3rd and 4th generation 
cephalosporins in intramammaries has declined steadily from 
a peak at 27 kg in 2007 to 7 kg in 2013 (Table 4.2). This is mainly 
a result of increased focus by the Danish Cattle Association, 
and veterinary practitioners, on the public health aspects of 
antimicrobial resistance caused by high consumption of this 
group of compounds. 
Data on intramammary use show a slight reduction in overall 
level of intramammary treatment from 2005 to 2013 (Table 
4.2). However, drying-off treatment has increased steadily 
during the same period, while therapeutic treatment has 
decreased (Table 4.3). A “milk quality campaign” conducted by 
the Danish Cattle Association (Agriculture and Food Council) 
Table  4.3. Number of treatments with antimicrobial agents for intramammary application in cattle, Denmark 
Note: For intramammary therapeutic treatment, 1 DADD is defined as the dose to treat two teats for 24 hours. For drying off treatment, 1 DADD 
is defined as the dose to treat 4 teats. One product used for both indications is included as half drying off and half therapeutic treatments
2005 2006 2007 2008 2009 2010 2011 2012 2013
Total doses per indication (a) DADDs (1000's)
Drying off treatment  (4 teats) 73 75 71 76 82 99 97 117 125
Therapeutic treatment (2 teats) 420 408 388 377 378 350 307 279 253
DANMAP 2013
DANMAP 2013Table  4.2. Use of antimicrobial agents for intramammary application in cattle, Denmark 
Note: For intramammary treatment, 1 DADD is defined as the dose to treat two teats for 24 hours
a) Includes benzylpenicillin, cloxacillin, and cloxacillin-ampicillin combinations (QJ51CE, QJ51CF, QJ51RC)
b) Mainly dihydrostreptomycin-benzyl benicillin combinations; includes also combinations of penicillin/aminoglycoside with bacitracin or 
nafcillin (QJ51RC)
c) Lincosamides, neomycin-lincomycin combinations and trimethoprim-sulfonamide combinations
2005 2006 2007 2008 2009 2010 2011 2012 2013
Doses per antimicrobial class DADDs (1000's)
Penicillins(a) 201 211 211 236 282 314 318 324 311
Aminoglycoside-benzylpenicillin 
combinations(b) 130 104 101 101 110 93 48 47 58
Cephalosporins,
1st generation 103 98 89 85 89 89 99 105 111
Cephalosporins,
3rd and 4th generation 110 124 127 112 76 51 34 30 24
Others(c) 21 20 16 15 14 12 9 8 0
Total 566 558 544 549 570 559 508 514 504
Total DADD per cow per year 1.0 1.0 1.0 1.0 1.0 1.0 0.9 0.9 0.9
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Figure 4.5. consumption of 3rd and 4th generation 
cephalosporins in pigs and cattle, Denmark
4.3.4 Antimicrobial consumption in aquaculture, 
fur animals and companion animals
The antimicrobial consumption in aquaculture increased 
by 23% to 3,582 kg in 2013 compared with 2012 (Table 4.1). 
Measured in kg active compound sulfonamide/trimethoprim 
comprised 70%, quinolones 25% and amphenicols 5%.The 
antimicrobial consumption in both 2012 and 2011 was very 
low compared to previous years, probably due to cold summers 
in 2011–2012, and the relatively large increase in consumption 
in 2013 is explained mainly by extraordinary high temperatures 
in July and August 2013, leading to higher water temperatures 
and an increase in the occurrence of bacteriological infections 
[personal communication: N.H. Henriksen, Danish 
Aquaculture]. There is, however, in the aquaculture industry, 
increased focus on vaccination to reduce the risk of diseases 
that may require antibiotic treatment.
In 2013, the production of mink increased slightly to 17.5 
million mink from 17 million in 2012 (Source: Kopenhagen 
Fur). Antimicrobial consumption in fur animals decreased 
by approximately 10% to 4.9 tonnes, kg active compound 
compared with 2012 (Table 4.1). This reverses the continuous 
increase in consumption for fur animals seen over the past five 
years (from 2008-2009 consumption increased by 60%). Use of 
fluoroquinolones and cephalosporins in fur animal production 
is close to zero.
since 2010, most likely has contributed to this trend. The goals 
of the campaign are to reduce treatment of clinical mastitis by 
50%, mainly through a reduction of treatment of subclinical 
mastitis, but also by increased monitoring of cell counts to 
determine the need for treatment.
Furthermore, Order (DK) 785/2010 provides legal regulations of 
use of antimicrobial agents for mastitis in cattle (recommending 
using simple penicillins) and the industry has also emphasized 
that farmers should use narrow spectrum penicillins to treat 
mastitis caused by Gram-positive bacteria, unless sensitivity 
testing reveals resistance towards these antimicrobials.
The information available on antimicrobial consumption 
in companion animals is not as detailed as for production 
animals. In 2013 the overall antimicrobial consumption in 
pets amounted to 1,989 kg active compound (1,449 kg in 
2012). The increase was seen for several antimicrobial classes; 
aminoglycosides, macrolides and penicillin’s (b-lactamase 
sensitive), sulfonamides and trimethoprim, as well as for 
tetracyclines (Table 4.1).
The use of fluoroquinolones for use in pets was 11 kg in 2013. 
This means that the total use of fluoroquinolones constitutes 
nearly 40% the total veterinary use (kg) of fluoroquinolones. 
Similarly, they account for a significant proportion of the 
use of cephalosporins. In a One Health perspective, this is 
a cause for concern, because the close contact with their 
owners poses a risk for transmission of extended spectrum 
beta lactamase resistance to humans. Presently, however, 
there is no information available concerning the prevalence of 
antimicrobial resistance in pet animals. 
A large proportion of antimicrobials used for pet animals are 
prescribed for treatment chronic or recurrent disease, mainly 
dermatitis. Particularly the consumption of critically important 
antimicrobial agents in pet animals could pose an important 
risk to owners of diseased dogs that are frequently treated.
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5. Antimicrobial consumptions in humans
5.1  Introduction
In Denmark, the use of antimicrobial agents for humans 
has been monitored since 1995 and presently all data on 
consumption in both the primary healthcare and hospital care 
is registered by the Department of Data Delivery and Medicinal 
Product Statistics at Statens Serum Institut. 
In this section, the term ‘antimicrobial  agents’ covers only 
antibacterial agents for systemic use in humans, agents used 
for treatment of  infections caused by virus or fungi are not 
included. Currently available antimicrobial agents for systemic 
treatment in humans (and in animals) are listed in Table 3.2.
Antimicrobial agents have been classified as either narrow-
spectrum or broad-spectrum agents according to the spectrum 
of the activity (Table 5.1). 
5.2  Total consumption (primary healthcare 
and hospital care)
The overall consumption of antimicrobial agents in Denmark 
is calculated as a combined measure of the consumption in the 
primary healthcare and hospital care. This measure is presented 
in DID and is intended for comparison between sectors and for 
illustration of the consumption in hospital care without taking 
account of hospital activity (discharges) (Figure 5.1). Since the 
first publication of DANMAP, the consumption in primary 
healthcare has accounted for 90% of the total antimicrobial 
consumption in Denmark.
In 2013, the total consumption of antimicrobial agents for 
systemic use (primary healthcare and hospital care) was 1.2% 
higher than the previous year (Figure 5.1). Since 2004, the 
overall consumption of antimicrobial agents has increased by 
20%.
The proportion of broad-spectrum agents was 5% higher 
than in 2012 (Figure 5.2). This continues the trend from the 
past decade where broad-spectrum agents increased by 72%, 
comprising 32% of the total consumption in 2004 and 46% in 
2013. 
The distribution of DIDs between primary healthcare and 
hospital care differed between antimicrobial agents (Figure 
5.3). For most of the antimicrobial agents, the consumption 
was higher in primary healthcare, with exception of 
cephalosporins and other β-lactams, aminoglycosides and 
imidazole derivatives.
In 2013, 51,500 kg of antimicrobial agents for systemic use were 
used in humans in Denmark. This is the highest level observed 
since 1995, representing an increase of 6,500 kg (14%) since 
2004 (Table A5.1 in web annex).
Table 5.1. classification of antimicrobial agents for systemic use 
in humans into narrow-spectrum and broad-spectrum agents, 
Denmark
ATC group(a) Therapeutic group
Narrow-spectrum
J01CE                        Beta-lactamase sensitive penicillins     
J01CF                        Beta-lactamase resistant penicillins     
J01DB
First-generation cephalosporins (included in data 
from primary healthcare as a broad-spectrum agent in 
the group J01D)
J01DF Monobactams
J01EA                        Trimethoprim and derivatives   
J01EB                        Short-acting sulfonamides       
J01FA                        Macrolides                  
J01FF                        Lincosamides                
J01XA Glycopeptides
J01XC                        Steroid antibacterials (fusidic acid)     
J01XD                        Imidazol derivatives
J01XE Nitrofuran derivatives (nitrofurantoin)
J01XX Other antibacterials
Broad-spectrum
J01AA                        Tetracyclines               
J01CA                        Penicillins with extended spectrum
J01CR                        Combinations of penicillins, incl. beta-lactamase inhibitors   
J01D                        Cephalosporins and related substances (primary healthcare only)         
J01DC Second-generation cephalosporins
J01DD Third-generation cephalosporins
J01DH Carbapenems
J01EE                        Combinations of sulfonamides and trimethoprim, incl. derivatives 
J01GB Aminoglycosides
J01MA                        Fluoroquinolones            
J01XB                        Polymyxins                 
a) From the 2013 edition of the Anatomical Therapeutic Chemical 
(ATC) classification system
DANMAP 2013
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Figure 5.1. Total consumption of antimicrobial agents (J01) in humans in primary healthcare vs hospital care, Denmark
Figure 5.2. Total consumption of antimicrobial agents (J01) in humans by narrow-spectrum and broad-spectrum agents, Denmark
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Figure 5.3. Distribution of DIDs between primary healthcare and hospital care, Denmark
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consumption of antimicrobial agents and incidence of multi-resistant bacteria in Greenland
Background: Greenland has a population of 56.370 inhabitants (January 2013) and Nuuk is the capital with around 16.000 
inhabitants. Greenland has its own Ministry of Health and the country is divided into five health regions: Qeqqa (the 
former health districts Sisimiut and Maniitsoq), Disko (the former health districts Aasiaat, Kangaatsiaq, Qeqertarsuaq and 
Qasigiannguit), Avannaa (the former health districts Ilulissat, Uummannaq, Upernavik and Qaanaaq), Sermersooq (the 
former health districts Nuuk, Paamiut/Ivittuut, Tasiilaq and Illoqqortoormiut), and Kujataa (the former health districts 
Qaqortoq, Nanortalik and Narsaq). 
The largest hospital, Dronning Ingrids Hospital, is situated in Nuuk (185 beds). There are several smaller hospitals and 
healthcare centers in the five health regions. Around 15-16.000 persons are admitted to hospital once or several times a 
year. The primary healthcare is organized different from that in Denmark; there are no general practitioners with private 
practice, and the hospital clinics are used for patients from the primary healthcare. In Nuuk, a large healthcare center has 
combined function as medical clinic, emergency room and primary healthcare with doctors and nurses. The settlements 
have nursing stations (supervised by doctors via phone or telemedicine and doctors visiting three to four times a year). 
Medication on prescription is free of charge. Patients with specific/serious diseases are transferred to Denmark or Iceland 
for further treatment (e.g. hemodialysis, cancer treatment, brain surgery etc.).  
Resistant bacteria: From 2004 to 2013, 12 patients have been diagnosed with MRSA, 33 patients with ESBL-producing 
Enterobacteriaceae, and 29 out of 85 patients with Clostridium difficile infection had the 027 type. Most of these resistant 
bacteria were imported from Denmark or abroad, but in some cases, especially in patients with an ESBL-producing 
Enterobacteriaceae, treatment with broad-spectrum antimicrobial agents in Greenland has probably selected for these 
bacteria. Since 2011 there has been an increasing problem with C. difficile infections (mainly type 027) in the hospitals 
and transmission within the country has occurred. A project focusing on identification of risk factors for acquisition of C. 
difficile infections, mapping of C. difficile types and prevention strategies is planned for the near future.
Consumption of antimicrobial agents: All antimicrobial agents in Greenland are purchased and disseminated from 
the National Pharmacy. The total purchase of selected antimicrobial agents from 2007 to 2013 are shown in Figure 1 
From 2007–2013, an increase of narrow-spectrum (18%) and broad-spectrum penicillins (12%) has been seen. From 
2012 to 2013, an increase in piperacillin-tazobactam (37%) and a decrease in broad-spectrum antimicrobial agents such 
as tetracyclines (26%), macrolides (7%), and fluoroquinolones (6%) have been seen. Meropenem has increased with 11% 
whereas cephalosporins (mainly ceftriaxone) have been at the same level from 2012 to 2013. 
Conclusion: Frequent change in workforce and hospitalization abroad are challenges for maintaining a restrictive antibiotic 
policy and of these reasons continued focus on the use of broad-spectrum antimicrobial agents - both in hospitals and in 
primary healthcare  - and the incidence of multi-resistant bacteria in Greenland is very important in the future. 
Anne Kjerulf, Jette Holt, Anne Birgitte Jensen, Turid B. Skifte, Peter Poulsen, Inge Mortensen
For further information: Anne Kjerulf (alf@ssi.dk)
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Figure 1. consumption of selected antimicrobial agents in humans in Greenland (DDD/1,000 inhabitants/day) 2007–
2013: (a) consumption of narrow- and broad-spectrum penicillins, macrolides and tetracyclines; and (b) consumption 
of cephalosporins, meropenem, fluoroquinolones, piperacillin/tazobactam and gentamicin. (Note: Narrow-spectrum 
penicillins include benzylpenicillin, phenoxymethylpenicillin and dicloxacillin, and broad-spectrum penicillins include 
ampicillin, pivampicillin, amoxicillin and amoxicillin with enzyme inhibitor).
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Maintained focus on the use of antimicrobial agents in the Faroe Islands
Background: The Faroe Islands (FI) consists of 18 islands, inhabited by approx. 48,000 inhabitants, 19,000 of whom live 
in the capital Tórshavn. The main hospital (Landssjúkrahúsið, LS, with 170 beds) is located in Tórshavn, and there are 
two smaller hospitals in Klaksvik (36 beds) and Súðuroy (26 beds). The healthcare system is comparable to the Danish 
healthcare system with general practitioners responsible for primary care and secondary care provided by the hospital. LS 
has a local as well as a centralized function. In the case of specified diseases, patients are referred to hospitals in Denmark 
or other foreign hospitals. The healthcare staff constitutes a stable workforce but consultants, mainly from Denmark, 
perform specialized treatment where the number of patients is too small to support full-time specialist employment. 
Data and data sources: Data for antimicrobial consumption for FI and for LS were supplied by the Chief Pharmaceutical 
Office, beginning from 2007. Bed-days and data on MRSA and ESBL-producing bacteria were obtained from LS.
Antimicrobial consumption in primary healthcare: Total antimicrobial consumption outside the hospitals was 
14.23 DDD/1000 inhabitants/day; this is unchanged since 2010, but represents a 16.6% decrease compared to 2007. 
The use of tetracyclines has increased by 32.8% compared to 2007 whereas the consumption of macrolides decreased 
with 31.1% from 2007 to 2013. The reason for this shift remains to be elucidated. Regarding antimicrobial agents 
used for urinary tract infections, marked changes have been seen mainly reflecting identification of a potentially 
fatal carnitine transporter gene defect in 1/3.600 inhabitants of the FI [Joensen  t al. 2006. Ugeskr Laeg 168: 667-670] 
which led to an almost total stop in the use of pivampicillin and pivmecillinam in 2012. In 2013, pivampicillin was 
still not used, whereas pivmecillinam use outside hospitals increased to 13.3% of the 2007 level compared to 3.6% 
in 2012 (Figure 1). Data from hospitals show the same trend. This increase in consumption, although still at a low 
level, is probably due to increased screening for the gene defect. The decreased use of pivmecillinam has led to an 
increase in the use of sulfamethizole (43.0%), trimethoprim (40.2%), and ciprofloxacin (46.7%) compared to 2007. 
 
Antimicrobial consumption in hospital care: The consumption of antimicrobial agents in 2013 was 39.70 DBD 
(DDD/100 bed-days). This is a decline from 2012 (41.45 DBD) and the consumption is now back at the same level as 
in 2007 (Table 1). However, whereas the total consumption of antimicrobial agents at LS is at the 2007 level, the use of 
three antimicrobials, which are well known for their effect on selection of virulent binary-toxin positive C. difficile - 
cefuroxime, ciprofloxacin, and meropenem - has increased to 137.4%, 424.5%, and 175.0% of the 2007 level (Table 1). 
The consumption of cefuroxime, ciprofloxacin, and meropenem and piperacillin with enzyme inhibitor, in a comparison 
between LS and Danish hospitals for 2007 to 2013 are shown in Figure 2. It is thus evident that LS has been on the same 
curve of increase as Danish hospitals in general, only with some 7-8 years’ delay. This is also illustrated by the fact that 
the consumption of the three above antimicrobials together increased from 8.99 DBD in 2007 to 14.54 in 2013 or from 
39.8 to 58.8% of the use in Danish hospitals. However, it seems that the use in LS is now at least stabilizing.
Resistant microorganisms. Since the first case of MRSA in 2004, a total of 36 cases of MRSA have been identified 
(22 with infection and 14 carriers). From 2006–2013, 15 ESBL-producing Escherichia coli and four ESBL-producing 
Klebsiella pneumoniae have been detected, furthermore one patient had both an ESBL-producing E. coli and an ESBL-
producing K. pneumoniae. 
Conclusion: Increased focus on the use of broad-spectrum antimicrobial agents and resistant bacteria is maintained as 
the current strategy of the Faroe Islands. 
Elsebeth Tvenstrup Jensen, Anne Kjerulf, William Smith, Niels Joensen, Hjørdis Reinert and Torkil á Steig 
For further information: Elsebeth Tvenstrup Jensen (etj@ssi.dk)
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Table 1. Total consumption of antimicrobials and consumption of cefuroxime, ciprofloxacin, meropenem, and 
piperacillin w. enzyme inhibitor at LS 2007-2013, shown as DBD (DDD/100 bed-days) and as % of 2007 level DANMAP 2013
2007 2008 2009 2010 2011 2012 2013
Cefuroxime 7.65 8.36 7.87 8.66 10.52 10.86 10.51
(100.0) (109.2) (102.8) (113.2) (137.5) (141.9) (137.4)
Ciprofloxacin 0.68 2.68 2.30 1.83 3.54 3.54 2.87
(100.0) (396.4) (339.3) (271.0) (523.6) (522.8) (424.5)
Meropenem 0.66 0.55 0.67 0.85 0.89 1.35 1.15
(100.0) (83.7) (101.0) (128.4) (135.2) (204.9) (175.0)
Piperacillin + inhibitor 0.14 0.34 0.26 0.29 0.20 0.26 0.23
(100.0) (237.0) (182.4) (199.5) (141.0) (180.1) (159.0)
Total 39.20 40.52 40.56 40.79 46.37 41.45 39.70
(100.0) (103.4) (103.5) (104.0) (118.3) (105.7) (101.3)
Figure 1. consumption of antimicrobial agents used prophylaxis and treatment of urinary tract infections in primary 
healthcare (2007-2013)
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Figure 2. consumption of cefuroxime, ciprofloxacin, meropenem, and piperacillin with enzyme inhibitor at the 
LS hospital and in Danish hospitals (2007-2013)
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The Danish council of Ethics’ statement on the use of antibiotics
Background: In January 2014, The Danish Council of Ethics published a set of recommendations on the ethical use of 
antibiotics in a Danish context. 
The recommendations set out to prescribe action as a response to two specific ethical dilemmas. These are introduced 
below. 
Despite many years of efforts to the contrary, antibiotics use and antimicrobial resistance (AMR) problems have been 
in a steady increase in Denmark and elsewhere. In the view of the Danish Council of Ethics, the presence of ethical 
dilemmas associated with combating AMR is likely to be an important factor behind the challenges encountered.
Ethical dilemmas
Dilemma 1: Rationing antibiotics
The need to prescribe human antibiotics reflects the general living condition of a population, including hygiene 
conditions in homes, in public spaces and at workplaces, day-care facilities and hospitals. The consumption of antibiotics 
in farming is largely a result of the production methods chosen.
Owing to the great mobility of people, animals and foodstuffs, the effect of a cautious approach to using antibiotics on 
the local resistance situation is uncertain.
However, the extent of resistance is inextricably bound up with the consumption of antibiotics. Even well- justified use 
promotes resistance development. Within a fairly short span of years, increasing resistance to antibiotics will reduce 
patients’ access to potent and effective antibiotics.
It is crucial, therefore, to exercise reticence regarding the use of antibiotics, in spite of the fact that greater reticence will 
involve a greater risk for patients, animals and livestock. Examples of obviously unjustifiable use - that is to say where 
antibiotics are prescribed even though the treatment is known to be ineffective, and where reticence is therefore bound 
to have no impact - are probably rare.
How should the doctor, veterinarian and farmer balance consideration for the patient, animal or herd with regard to 
future patients?
Dilemma 2: Preventing infection
Being a carrier of antibiotic-resistant bacteria entails a risk of infection. Infection can entail medical risks and social 
strains and stresses.
Those not infected should be protected against infection. That may call for the use of isolation, restraining measures etc. 
Those not infected should also have the option of deciding which infection risks they want to expose themselves to. That 
advocates openness around infection sources, e.g. by informing the public about infected animal herds or having a duty 
to report knowledge of infected individuals.
For carriers of resistant bacteria, however, such initiatives can be stigmatizing, offensive and involve interfering in the 
individual’s freedom. Furthermore, experience has shown that carrier status, as a consequence of stigma, has been 
concealed to a greater extent, thus causing the risk of infection to rise.
Recommendations
•	 In guidelines the authorities should acknowledge the ethical dilemmas in which doctors, veterinarians, farmers 
and ordinary citizens are placed as a result of endeavours to ration antibiotics and prevent the spread of antibiotic-
resistant bacteria 
•	 The authorities’ efforts to combat antibiotic resistance should be intensified in the health sector with a view to 
reducing the problem both nationally and internationally. Particular heed should be paid to specialist guidelines 
for the use of antibiotics and their implementation 
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•	 The authorities should minimize the stigmatization, isolation and discrimination that may attach to being a carrier of 
antibiotic-resistant bacteria. First and foremost, the risk of infection should be limited by improving general hygiene 
•	 Use of antibiotics “to be on the safe side” or to reduce discomfort should be avoided in interaction between doctors 
and patients 
•	 The authorities should redouble their efforts to combat antibiotic consumption in farming. This can be done, for 
example, by promoting and demanding stricter criteria for healthier forms of production and by limiting the use of 
herd medication 
•	 Nationally and internationally, the authorities should work to promote consumers’ scope for choosing products 
made with limited consumption of antibiotics 
•	 Statement, working papers, an interview and more (in Danish): http://www.dketik.dk/Projekter/Antibiotika.aspx 
On behalf of the Danish Council of Ethics, professor Gorm Greisen, 
chairman of the antibiotics working group
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5.3  Primary healthcare
5.3.1  Total consumption in primary healthcare
In 2013, the consumption of antimicrobial agents in primary 
healthcare was 1.2% higher than that observed in 2012 (Table 
5.2) and thus reversed a large part of the positive decline seen in 
2012. During the past decade, the consumption of antimicrobial 
agents in Danish primary healthcare has increased by 2.61 DID 
(19%).
The proportion of broad-spectrum agents in 2013 was 0.39 
DID (5.7%) higher than in 2012 (Figure 5.4). Since 2004, the 
proportion of broad-spectrum agents has increased by 72%. 
As observed in previous years, beta-lactamase sensitive 
penicillins represented the largest therapeutic group of 
antimicrobial agents consumed (28%) – and penicillins in 
general accounted for 64% of the total consumption in 2013 
(Figure 5.5). For the other therapeutic groups, several changes 
in consumption were observed between 2012 and 2013 (Table 
5.2). Especially noteworthy are an 11% increase in tetracyclines 
(see Textbox 4) and a 16% increase in ‘combination penicillins’. 
The consumption of macrolides was 12% lower in 2013 
compared to 2012, upholding the decrease observed since 2011 
(Figure 5.6).
5.3.2  Measures at treated patient level
In 2013, each treated patient received 21.3 DDDs (Table 5.3) – 
an increase of 3.4% compared to 2012. The number of patients 
treated was, however, 2.3% less (Table A5.2 and A5.3 in web 
annex), which means that in 2013, more DDDs were prescribed 
for each package. During the past decade, the number of DDDs 
per package has increased by 22%, reaching the highest level 
in 2013. Similarly, the number of DDDs per patient has also 
increased significantly since 2004 while the number of packages 
per patient has remained relatively constant (Table 5.3). 
Considering the leading antimicrobial groups, each treated 
patient received 11.8 – 22.6 DDDs in 1.4 – 1.7 packages with 
the exception of tetracyclines (Table 5.3). For tetracyclines, 
both the number of DDDs per patient and DDDs per package 
are significantly higher than any other antimicrobial group, 
primarily due to the fact that tetracyclines are commonly used 
for acne treatment; there higher dosages are given for longer 
periods.
When examining three different indicators at the treated 
patient level (Figure 5.7), a marked increase is observed for 
DIDs while the number of packages and treated patients has 
remained relatively constant since 2004. In other words, the 
dosage prescribed for each patient and in each package has 
increased significantly during the past years. The reasons for 
these changes are as yet unclear.
Table 5.2. consumption of antimicrobial agents for systemic use in primary healthcare (DDD/1000 inhabitant-days), Denmark
a) From the 2013 edition of the Anatomical Therapeutic Chemical (ATC) classification system
ATC 
group(a) Therapeutic group
Year
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
J01AA            Tetracyclines               1.17 1.28 1.38 1.48 1.54 1.61 1.69 1.64 1.76 1.96
J01CA            Penicillins with extended spectrum 2.63 2.79 2.95 3.25 3.26 3.29 3.47 3.41 3.40 3.48
J01CE            Beta-lactamase sensitive penicillins     5.20 5.28 5.40 5.67 5.30 5.12 5.25 5.31 4.68 4.65
J01CF            Beta-lactamase resistant penicillins     0.92 0.97 1.05 1.09 1.12 1.13 1.17 1.14 1.21 1.30
J01CR            Combinations of penicillins, including beta-lactamase inhibitors   0.06 0.08 0.12 0.19 0.27 0.45 0.68 0.89 1.05 1.22
J01D                        Cephalosporins and other β-lactam antibiotics        0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
J01EA            Trimethoprim and derivatives   0.41 0.44 0.47 0.49 0.49 0.48 0.51 0.50 0.52 0.53
J01EB            Short-acting sulfonamides       0.36 0.35 0.35 0.31 0.28 0.27 0.26 0.24 0.22 0.22
J01EE            Combinations of sulfonamides and trimethoprim, including derivatives 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01
J01FA            Macrolides                  2.23 2.41 2.31 2.42 2.28 2.21 2.44 2.47 2.19 1.93
J01FF            Lincosamides                0.01 0.01 0.02 0.02 0.03 0.03 0.04 0.04 0.04 0.05
J01GB Aminoglycosides 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01
J01MA            Fluoroquinolones            0.28 0.33 0.37 0.44 0.51 0.52 0.57 0.57 0.55 0.52
J01XA Glycopeptides 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01XB            Polymyxins                 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02 0.02
J01XC            Steroid antibacterials (fusidic acid)     0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01
J01XD            Imidazole derivatives                  0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
J01XE Nitrofuran derivatives (nitrofurantoin) 0.43 0.45 0.46 0.47 0.47 0.49 0.51 0.50 0.49 0.49
J01XX            Other antibacterials (methenamine >99%)                0.30 0.28 0.27 0.26 0.27 0.26 0.27 0.26 0.25 0.24
J01 Antibacterial agents for systemic use (total) 14.06 14.75 15.23 16.17 15.91 15.95 16.93 17.06 16.47 16.67
DANMAP 2013
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Figure 5.4. consumption of antimicrobial agents (J01) in primary healthcare by narrow-spectrum and broad-spectrum agents, 
Denmark
Note: “Narrow-spectrum” includes: beta-lactamase sensitive penicillins, beta-lactamase resistant penicillins, trimethoprim, sulfonamides, 
macrolides, lincosamides, glycopeptides, fusidic acid, imidazol derivatives, nitrofuran derivatives, and ‘other antibiotics’
“Broad-spectrum” includes: tetracyclines, penicillins with extended spectrum, combinations of penicillins incl. beta-lactamase inhibitors, 
cephalosporins and related substances, combinations of sulfonamides and trimethoprim, aminoglycosides, fluoroquinolones, and polymyxins
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Table 5.3. Number of DDDs and packages per treated patient among leading groups of antimicrobial agents in primary healthcare, 
Denmark
a) From the 2013 edition of the Anatomical Therapeutic Chemical (ATC) classification system
ATC 
group(a) Therapeutic group Indicator
Year
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
J01AA Tetracyclines               
DDDs / patient 36.9 39.0 40.9 43.0 44.4 45.2 45.9 44.0 47.6 51.6
Packages / patient 1.9 2.0 1.9 2.0 2.0 2.0 2.0 1.9 2.1 2.1
DDDs / package 19.0 19.6 21.0 22.0 22.7 22.7 22.7 22.6 23.1 25.5
J01CA
Penicillins with extended 
spectrum
DDDs / patient 13.6 13.9 14.2 14.4 14.7 14.8 14.9 14.8 16.1 16.7
Packages / patient 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.6 1.7 1.7
DDDs / package 8.4 8.5 8.9 9.0 9.2 9.2 9.0 9.2 9.7 10.0
J01CE Beta-lactamase sensitive penicillins     
DDDs / patient 11.1 11.3 11.5 11.7 11.8 11.8 11.8 11.8 11.8 12.0
Packages / patient 1.5 1.5 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4
DDDs / package 7.5 7.7 8.0 8.2 8.2 8.4 8.4 8.4 8.4 8.5
J01CF Beta-lactamase resistant penicillins     
DDDs / patient 12.4 12.7 13.0 13.4 13.7 13.9 14.2 13.8 15.5 16.4
Packages / patient 1.6 1.6 1.5 1.5 1.5 1.5 1.5 1.4 1.6 1.7
DDDs / package 7.8 8.0 8.6 8.7 9.0 9.1 9.3 9.6 9.7 9.4
J01CR
Combinations of 
penicillins, incl. beta-
lactamase inhibitors   
DDDs / patient 17.2 16.8 19.3 19.1 19.9 20.4 21.1 21.9 22.3 22.6
Packages / patient 2.0 2.0 1.8 1.6 1.6 1.5 1.5 1.6 1.6 1.6
DDDs / package 9.1 9.3 10.7 11.7 12.4 13.3 13.7 14.1 14.3 14.3
J01FA Macrolides                  
DDDs / patient 12.4 12.4 12.6 12.4 12.5 12.5 12.2 11.5 12.4 12.6
Packages / patient 1.6 1.6 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.6
DDDs / package 7.9 8.0 8.3 8.1 8.1 8.1 8.1 7.9 8.0 8.0
J01MA Fluoroquinolones            
DDDs / patient 9.5 9.6 10.3 10.6 11.0 11.2 11.2 11.5 11.7 11.8
Packages / patient 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
DDDs / package 6.4 6.5 6.9 7.0 7.5 7.6 7.6 7.7 7.8 7.8
J01 Antibacterial agents for systemic use (total)
DDDs / patient 17.0 17.5 17.9 17.3 18.9 19.2 19.6 19.4 20.6 21.3
Packages / patient 2.1 2.1 2.0 1.9 2.1 2.1 2.1 2.1 2.1 2.1
DDDs / package 8.1 8.3 8.7 8.9 9.1 9.3 9.3 9.3 9.7 9.9
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Figure 5.6. consumption of leading antimicrobial groups for systemic use in primary healthcare, Denmark
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Figure 5.7. Indicators of antimicrobial consumption (J01) in primary healthcare, Denmark
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5.3.3  Tetracyclines
From 2012 to 2013, the overall consumption of tetracyclines 
increased by 11.4%, primarily due to increase in use of 
doxycycline which is now the most used substance (Table 5.2). 
Since 2004, the consumption of tetracyclines has increased 
by 68%, primarily driven by significant increases in both 
doxycycline and lymecycline and a more conservative increase 
in tetracycline consumption (Figure 5.8). See also Textbox 4 
about tetracycline prescription patterns in Denmark. 
5.3.4  Penicillins
The overall consumption of penicillins in 2013 was 3% higher 
than that observed in 2012 (Table 5.2), continuing the generally 
increasing trend observed during the past decade with an 
increased consumption of 21% from 2004–2013. 
For individual penicillin groups, the consumption of narrow 
spectrum penicillins (i.e. phenoxymethylpenicillin) continued 
to decrease whereas increases in consumption were observed 
for ‘combination penicillins’ (16%), beta-lactamase resistant 
penicillins (7.4%) and penicillins with extended spectrum 
(2.4%). The consumption of these three groups in particular 
has also increased significantly over the past decade replacing 
the use of narrow spectrum penicillins (Table 5.2). 
At the substance-level in 2013, phenoxymethylpenicillin 
continues to be the most commonly consumed penicillin 
despite decreasing usage. The consumption of flucloxacillin, 
amoxicillin and enzyme inhibitor, and pivmecillinam increased 
(Figure 5.9). The consumption of ampicillin decreased by 28%. 
‘Combination penicillins’ (primarily amoxicillin/clavulanic 
acid) are currently advocated for broad treatment of 
respiratory infections, including patients with exacerbation of 
chronic obstructive pulmonary disease (COPD). The highest 
consumption of these drugs is observed in people aged 65 and 
older, suggesting that the increase may be related to an increased 
rate of diagnosis and treatment of respiratory infections and 
COPD in this age group. Further, the increase may also partly 
be explained by an increasing tendency of GPs to prescribe the 
sweet-tasting amoxicillin mixture for respiratory infections in 
children rather than benzylpenicillin (beta-lactamase sensitive 
penicillins). 
5.3.5  Macrolides
From 2012–2013, the consumption of macrolides decreased 
by 12% (Table 5.2), and this decrease was apparent for all 
substances (Figure 5.10). The high consumption of macrolides 
in 2010 and 2011 may be explained by two epidemic waves of 
Mycoplasma pneumoniae infection (DANMAP 2010 & 2011) 
and the return to a generally lower consumption in 2012 and 
onwards is most likely related to the absence of significant 
disease outbreaks (DANMAP 2012).
From 2004-2013, the consumption of roxithromycin, 
clarithromycin and azithromycin increased (Figure 5.10). The 
consumption of erythromycin  decreased substantially, most 
likely in response to changes in national guidelines which in 
2004 substituted the first-choice macrolide in primary care 
from erythromycin to roxithromycin and subsequently also to 
clarithromycin in 2007.
Figure 5.8. consumption of tetracyclines in primary healthcare, Denmark
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Figure 5.10. consumption of macrolides in primary healthcare, Denmark
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Temporal and geographical variation in tetracycline prescription patterns in Denmark
Background: In Denmark, tetracyclines are used as treatment for acne vulgaris in young adults. In DANMAP 2011, it was 
shown that a large increase in the consumption of antimicrobial agents in primary healthcare was driven by 15–19 year olds 
with particular increases for tetracyclines. In this age group, tetracyclines are prescribed almost as often as penicillins and 
the level of consumption is steadily increasing [DANMAP 2012]. 
In the present study, Danish tetracycline prescriptions were investigated more closely with particular focus on the variation 
through time (2005-2013) and at the geographical level for different age groups. 
Methods: Data on consumption of tetracyclines (DID, number of persons treated and number of prescriptions) from 2005 
to 2013, the type (GP versus dermatologist) and geographical location of the prescriber were obtained from Data Delivery 
and Medicinal Product Statistics at Statens Serum Institut. Data were analysed by descriptive statistics and two-tailed t-tests 
using the STATA™ software 11.0 (Statacorp., Lakeway, TX, USA). 
Results: From 2005 to 2013, the consumption (DID) of tetracyclines for all ages increased by 54% with large increases 
observed for 10–14 year olds (86%) and 15–19 year olds (58%). When adjusted for population increases, approximately 5.400 
more persons in these age groups were treated with tetracyclines in 2013 than in 2005. 
A large difference at the municipality level (kommuner) in tetracycline consumption was seen for 10 – 19 year olds; adolescents 
in six Danish municipalities had a consumption which was 170 to 200% higher than the national average (Figure 1) while the 
lowest consuming municipalities were 70 to 40% below average. 
Discussion: The current results show that that the observed increases in tetracycline consumption are mainly driven by 
Danish adolescents. In the two age groups 10-14 and 15-19 years, an extra 5.400 persons were treated with tetracyclines from 
2005 to 2013. We further show that the majority of prescriptions, presumably for acne [DANMAP 2012], are prescribed by 
GPs rather than dermatologists, highlighting the ease of access to GPs in comparison to dermatologists where a referral is 
needed. 
The geographical pattern of tetracycline consumption is highly varied with some municipalities showing a consistently high 
consumption in the adolescent age groups and other municipalities having a below-average consumption through time. 
Resistance to broad-spectrum antimicrobial agents is an important problem in Denmark. There is currently a strong need 
to firstly investigate the extent of tetracycline resistance in bacteria from young adults and secondly to establish more firm 
treatment guidelines for adolescents presenting to a GP with acne problems. 
Katrin G. Kuhn 
For further information: Katrin G. Kuhn (kuh@ssi.dk)
Figure 1. The consumption of (DDD/1000 inhabitants) of tetracyclines in 13-19 year olds in Danish municipalities
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5.4  Hospital care
5.4.1  Introduction
Hospital care includes all hospitals (i.e. rehabilitation centres, 
hospices, private-, psychiatric-, specialized-, and somatic 
hospitals). Somatic hospitals account for approximately 97% 
of the antimicrobial consumption within hospital care. As 
specialized hospitals (psychiatric hospitals, hospices and 
rehabilitation centres) contribute a large proportion of bed-days 
and admissions but only a small proportion of antimicrobial 
consumption, the antimicrobial consumption for hospital care 
in Denmark is related only to bed-days and admissions in 
somatic hospitals.
The consumption  of  antimicrobial  agents  in  hospital care 
is  presented  as  DDD  per  100  occupied  bed-days (DBD) 
and as DDD per 100 admissions (DAD) to account for hospital 
activity. Further, data are also presented as DID purely to enable 
comparison with primary healthcare.
During the past decade, the hospitalization pattern in Denmark 
has changed notably: more people are admitted to somatic 
hospitals but the average length of stay has been shortened 
(Figure 5.11, Table A5.4 in web annex) and outpatient 
treatment has increased significantly. Selection pressure for the 
emergence of antimicrobial resistance increases with increasing 
hospital activity (admissions) and thus the selection pressure 
has increased considerably from 2004 to 2013. 
5.4.2 Somatic hospitals – DDD per 100 occupied 
bed-days (DBD) 
In 2013, the consumption of antimicrobial agents in somatic 
hospitals was 1.4% higher than in 2012 (Table 5.4). In the past 
decade the consumption has increased by 66%. This was caused 
by a combination of an increase in DDDs and a decrease in 
the number of hospital bed-days. This was particularly seen for 
broad spectrum agents which increased by 114%. 
Extended spectrum penicillins represented the largest group 
of antimicrobial agents consumed and penicillins in general 
accounted for 51% of the total consumption (Figure 5.12). 
Cephalosporins (14%) and fluoroquinolones (10%) were also 
among the most commonly consumed antimicrobial agents in 
hospital care.
From 2012 to 2013, a higher consumption was observed 
for combinations of sulfonamide and trimethoprim (26%), 
‘combination penicillins’ (14%), beta-lactamase resistant 
penicillins (8.4%), carbapenems (4.1%) and penicillins with 
extended spectrum (1.1%). A lower consumption was observed 
for 2nd generation cephalosporins (13%), macrolides (4.8%), 
tetracyclines (3.8%) and fluoroquinolones (2.5%) (Table 5.4).  
The changes in leading groups of antimicrobial agents used in 
somatic hospitals during 2004–2013 are shown in Figure 5.13. 
Large increases were observed for ‘combinations of penicillins’ 
(1520%), carbapenems (370%) and fluoroquinolones (100%). 
The consumption of beta-lactamase sensitive penicillins, 
however, decreased 16% during the past decade. 
The observed increases in ‘combination penicillins’ is 
most likely attributable to a change in empiric treatment 
from cephalosporins to piperacillin-tazobactam for severe 
infections and an increasing usage of amoxycillin-clavulanic 
acid for treatment of acute exacerbation of chronic obstructive 
pulmonary diseases (COPD). 
5.4.3   Other measures of somatic hospital 
consumption 
DDD per 100 admissions (DAD)
Because of the observed changes in the number of hospital 
bed-days over time, the consumption of antimicrobial agents 
in Danish hospitals may also be measured in relation to 
admissions (i.e. DDD per 100 admissions, DAD).
When expressed as DAD, the total consumption of antimicrobial 
agents in somatic hospitals was 1.6% higher in 2013 compared 
to 2012 (Table 5.5). During the past decade, DAD increased 
by 19.3%; an increase primarily driven by a higher number of 
DDDs but counterbalanced by an increase in the number of 
hospital admissions. 
With respect to individual antimicrobial groups, increases 
were observed for: ’combination penicillins’, combinations 
of sulfonamide and trimethoprim, beta-lactamase resistant 
penicillins and carbapenems. As observed in 2012, the 
consumption of 2nd generation cephalosporins and 
fluoroquinolones also decreased in 2013 by 13% and 2.2%, 
respectively (Table 5.5). The same trends were seen when 
consumption was expressed as DBD (Table 5.4).
DDD per 1,000 inhabitants per day (DID)
The consumption of antimicrobial agents in somatic hospitals 
was 1.5% higher in 2013 compared to 2012. In the past decade, 
the DIDs consumed in hospitals have increased by 31% (Table 
A5.5 in web annex). During the same time, broad-spectrum 
agents have increased by 70%, comprising 68% of the total 
consumption in 2013 compared to 52% in 2004 (Figure 5.14).
Katrin Gaardbo Kuhn and Maja Laursen
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Figure 5.11. Number of bed-days and admissions in somatic hospitals, Denmark
0
0.5
1
1.5
0
1
2
3
4
5
6
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
N
o. adm
issions (m
ill.)
N
o.
 b
ed
-d
ay
s 
(m
ill
.)
Bed-days Admissions
DANMAP 2013
DANMAP 2013
Figure 5.12. Distribution of the total consumption of antimicrobial agents in somatic hospitals, Denmark
Note: Bold highlights indicate broad-spectrum antimicrobial agents
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Figure 5.13. Total somatic hospital consumption (DBD) by leading groups of antimicrobial agents (J01), Denmark
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Figure 5.14. consumption of antimicrobial agents (J01) in hospital care by narrow-spectrum and broad-spectrum agents, Denmark
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Note: “Narrow-spectrum” antibiotics includes: beta-lactamase sensitive penicillins, first-generation cephalosporins, beta-lactamase resistant 
penicillins, monobactams, trimethoprim, sulfonamides, macrolides, lincosamides, glycopeptides, fusidic acid, imidazol derivatives, nitrofuran 
derivatives, and ‘other antibiotics’
“Broad-spectrum” includes: tetracyclines, penicillins with extended spectrum, combinations of penicillins incl. beta-lactamase inhibitors, 
second-generation cephalosporins, third-generation cephalosporins, carbapenems, combinations of sulfonamides and trimethoprim, 
aminoglycosides, fluoroquinolones, and polymyxins
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Table 5.4. consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 occupied bed-days), Denmark
a) From the 2013 edition of the Anatomical Therapeutic Chemical (ATC) classification system
ATC group(a) Therapeutic group
Year
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
J01AA                        Tetracyclines               0.32 0.33 0.39 0.63 0.78 1.04 1.09 1.18 1.58 1.52
J01CA                        Penicillins with extended spectrum 11.51 12.90 13.00 13.42 13.96 15.37 14.61 14.41 14.90 15.06
J01CE                        Beta-lactamase sensitive penicillins     12.02 12.17 10.67 10.79 9.98 9.90 9.49 9.32 10.13 10.13
J01CF                        Beta-lactamase resistant penicillins     6.78 6.71 6.51 6.70 6.81 7.40 7.71 7.30 8.37 9.07
J01CR                        Combinations of penicillins. incl. beta-lactamase inhibitors   0.84 1.16 1.83 2.95 4.00 5.65 7.13 8.51 12.00 13.64
J01DB                  First-generation cephalosporins 0.17 0.15 0.14 0.13 0.18 0.13 0.13 0.13 0.12 0.11
J01DC Second-generation cephalosporins 6.91 8.39 9.38 12.31 13.32 15.76 16.21 16.14 14.15 12.32
J01DD Third-generation cephalosporins 0.67 0.83 0.83 1.03 1.25 1.42 1.26 1.39 1.07 1.08
J01DF Monobactams 0.00 0.00 0.00 0.04 0.07 0.06 0.09 0.19 0.15 0.14
J01DH Carbapenems 0.85 1.16 1.38 2.13 2.70 3.15 4.02 4.16 3.86 4.02
J01EA                        Trimethoprim and derivatives   0.41 0.41 0.42 0.44 0.44 0.44 0.36 0.36 0.38 0.41
J01EB                        Short-acting sulfonamides       1.06 0.99 0.75 0.34 0.35 0.35 0.33 0.25 0.20 0.20
J01EE                        Combinations of sulfonamides and trimethoprim. incl. derivatives 1.86 2.11 2.12 1.52 1.95 2.28 3.04 4.11 3.33 4.21
J01FA                        Macrolides                  2.85 2.89 2.83 3.08 3.06 3.42 3.52 3.69 3.56 3.39
J01FF                        Lincosamides                0.23 0.24 0.31 0.35 0.41 0.50 0.47 0.53 0.62 0.64
J01GB Aminoglycosides 2.00 1.95 1.81 1.79 1.64 1.56 1.71 1.91 2.14 2.13
J01MA                        Fluoroquinolones            4.93 6.14 6.74 8.16 9.53 10.71 10.44 10.70 10.02 9.77
J01XA Glycopeptides 0.47 0.52 0.56 0.63 0.68 0.99 1.07 1.24 1.29 1.29
J01XB                        Polymyxins                 0.06 0.12 0.12 0.05 0.05 0.07 0.10 0.09 0.09 0.16
J01XC                        Steroid antibacterials (fusidic acid)     0.22 0.25 0.28 0.28 0.26 0.31 0.34 0.27 0.23 0.22
J01XD                 Imidazole derivatives 2.43 2.62 2.78 2.62 3.27 3.84 3.93 4.19 4.16 4.08
J01XE Nitrofuran derivatives (nitrofurantoin) 0.28 0.29 0.29 0.28 0.29 0.36 0.31 0.33 0.34 0.38
J01XX05 Methenamine 0.10 0.08 0.11 0.09 0.10 0.09 0.08 0.10 0.09 0.09
J01XX08 Linezolid 0.07 0.15 0.20 0.16 0.21 0.22 0.22 0.32 0.32 0.35
J01XX09 Daptomycin 0.00 0.00 0.00 0.01 0.02 0.02 0.02 0.02 0.02 0.02
J01 Antibacterial agents for systemic use (total) 57.04 62.58 63.47 69.94 75.28 85.03 87.72 90.84 93.12 94.41
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Table 5.5. consumption of antimicrobial agents for systemic use in somatic hospitals (DDD/100 admitted patients), Denmark
a) From the 2013 edition of the Anatomical Therapeutic Chemical (ATC) classification system
b) The number of admissions was affectedly low in 2008 due to a major hospital strike
ATC group(a) Therapeutic group
Year
2004 2005 2006 2007 2008(b) 2009 2010 2011 2012 2013
J01AA                        Tetracyclines               1.45 1.45 1.67 2.59 3.19 3.63 3.55 3.66 5.15 4.97
J01CA                        Penicillins with extended spectrum 52.22 56.43 55.13 55.39 57.18 53.76 47.46 44.77 48.60 47.90
J01CE                        Beta-lactamase sensitive penicillins     54.53 53.20 45.26 44.55 40.90 34.61 30.83 28.98 33.04 33.13
J01CF                        Beta-lactamase resistant penicillins     30.77 29.33 27.60 27.64 27.89 25.86 25.04 22.71 27.30 29.64
J01CR                        Comb. of penicillins. incl. beta-lactamase inhibitors   3.82 5.09 7.77 12.17 16.37 19.74 23.15 26.47 39.14 44.60
J01DB                  First-generation cephalosporins 0.76 0.67 0.60 0.55 0.72 0.46 0.43 0.41 0.40 0.37
J01DC Second-generation cephalosporins 31.36 36.70 39.76 50.81 54.55 55.12 52.65 50.19 46.17 40.27
J01DD Third-generation cephalosporins 3.06 3.62 3.53 4.24 5.10 4.98 4.10 4.33 3.50 3.53
J01DF Monobactams 0.02 0.02 0.00 0.18 0.27 0.21 0.29 0.60 0.48 0.45
J01DH Carbapenems 3.85 5.05 5.86 8.78 11.08 11.01 13.07 12.55 12.60 13.14
J01EA                        Trimethoprim and derivatives   1.86 1.78 1.78 1.81 1.80 1.56 1.17 1.11 1.23 1.33
J01EB                        Short-acting sulfonamides       4.82 4.32 3.18 1.41 1.43 1.21 1.09 0.78 0.63 0.62
J01EE                        Comb. of sulfonamides and trimethoprim. incl. derivatives 8.44 9.21 8.98 6.28 7.98 7.96 9.88 12.79 10.87 13.76
J01FA                        Macrolides                  12.92 12.64 12.01 12.70 12.53 11.97 11.45 11.47 11.61 11.08
J01FF                        Lincosamides                1.04 1.05 1.31 1.46 1.69 1.74 1.52 1.63 2.01 2.09
J01GB Aminoglycosides 9.07 8.55 7.68 7.39 6.71 5.45 5.56 5.95 6.99 6.97
J01MA                        Fluoroquinolones            22.38 26.87 28.58 33.66 39.04 37.45 33.92 33.30 32.67 31.96
J01XA Glycopeptides 2.12 2.28 2.38 2.61 2.77 3.48 3.47 3.87 4.20 4.22
J01XB                        Polymyxins                 0.27 0.54 0.53 0.22 0.21 0.24 0.32 0.28 0.30 0.54
J01XC                        Steroid antibacterials (fusidic acid)     1.01 1.11 1.19 1.17 1.05 1.09 1.12 0.85 0.76 0.71
J01XD                 Imidazole derivatives 11.02 11.47 11.81 10.83 13.39 13.43 12.76 13.03 13.55 13.33
J01XE Nitrofuran derivatives (nitrofurantoin) 1.26 1.28 1.24 1.17 1.19 1.27 1.01 1.02 1.12 1.25
J01XX05 Methenamine 0.45 0.36 0.46 0.38 0.43 0.31 0.27 0.32 0.28 0.30
J01XX08 Linezolid 0.34 0.64 0.86 0.68 0.84 0.76 0.72 0.99 1.04 1.14
J01XX09 Daptomycin 0.00 0.00 0.00 0.03 0.06 0.06 0.07 0.05 0.06 0.07
J01 Antibacterial agents for systemic use (total) 258.81 273.67 269.18 288.70 308.39 297.36 284.89 282.53 303.71 308.70
DANMAP 2013
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6. Resistance in zoonotic bacteria
Zoonoses are infectious diseases that can be transmitted 
between animals and humans, either through direct contact 
with animals or indirectly by contaminated food. Zoonotic 
bacteria, such as Salmonella and Campylobacter, can develop 
resistance towards antimicrobial agents as a result of treatment 
of both animals and humans, which subsequently may lead 
to limited treatment possibilities or even treatment failure 
of human infectious diseases. Especially successful multi-
resistant Salmonella clones have spread extensively during the 
last years, resulting in a very complex relationship between 
antimicrobial use and levels of resistance.  
A more detailed description of the trends and sources of 
zoonoses in Denmark and of national surveillance and control 
programmes can be found in the Annual Report on Zoonoses 
in Denmark 2013 [www.food.dtu.dk].
6.1 Salmonella
Salmonella is the second most important zoonotic bacterial 
pathogen in Denmark and can have a severe impact on both 
animal production and human health.
In Denmark and the rest of European Union, S. Enteritidis 
and S. Typhimurium are the serovars most frequently found 
to be associated with human illness. Human cases caused 
by S. Enteritidis are most commonly associated with the 
consumption of contaminated eggs or poultry meat, whereas S. 
Typhimurium cases are mostly associated with the consumption 
of contaminated pork, beef or poultry meat.
For Salmonella, DANMAP 2013 includes isolates from broiler, 
layer and cattle farms infected during 2013 as well as isolates 
from Danish and imported broiler meat, turkey meat, beef 
and pork collected as part of national surveillance and control 
programmes. From pigs, Salmonella isolates recovered from 
sow herds as well as multiplier and breeding herds as part of 
the Salmonella control programme are included. In addition, 
caecum samples from healthy pigs were collected at the 
slaughterhouses and cultured for Salmonella. Isolates from 
all reported human cases are included. Only one isolate per 
farm, meat sample or human case was included, and data are 
presented in the report where a sufficient number of isolates 
were obtained (>15) from a given source. For details on 
methodology see Chapter 9, Materials and Methods.
In DANMAP 2013, we primarily present resistance among S. 
Typhimurium. During the last ten years, the numbers of poultry 
flocks and meat infected or contaminated with S. Enteritidis 
has decreased, and therefore resistance in S. Enteritidis will not 
be presented in this report. The occurrence of resistance among 
Salmonella spp. from pigs and Danish pork is presented (Table 
6.1).
In DANMAP, S. Typhimurium includes the monophasic 
variants with antigenic formulas S. 4, [5],12:i:, as recommended 
by the European Food Safety Authority [EFSA journal 2010. 
8(10): 1826]. In the text, generic S. Typhimurium indicates 
results only covering isolates of the non-monophasic variants. 
Since 2012, routine analyses of S. Typhimurium phage types 
are no longer performed in Denmark.
MIC distributions for S. Typhimurium from pigs, pork and 
humans, as well as for Salmonella spp. from pigs and Danish 
pork in 2013 are presented in the web annex (Tables A6.1 - 
A6.5). 
An isolate is considered fully sensitive if susceptible to all 
antimicrobial agents included in the test panel, and multi- 
resistant if resistant to three or more of the ten antimicrobial 
classes (see Table 10.3).
6.1.1 Salmonella spp. in pigs and domestic 
produced pork
In 2013, S. Typhimurium (including the monophasic variants) 
and S. Derby were the most common serotypes isolated from 
Danish pigs (44% and 43%, respectively) and pork (46% and 
41%, respectively). In general, the serotype distribution in 
the Danish pork has been similar to the distribution among 
isolates from pigs.  
Note that the isolates from pigs in Table 6.1 and 6.2 include 
isolates from pen faecal samplings from the national control 
programme as well as isolates from the sampling of healthy pigs 
Note: An isolate is considered fully sensitive if susceptible to all 
antimicrobial agents included in the test panel and multi-resistant if 
resistant to three or more of the ten antimicrobial classes (see Table 
9.3)
Pigs Pork
Antimicrobial agent % Danish         %
Tetracycline 47 44
Chloramphenicol 4 3
Florfenicol 3 2
Ampicillin 33 30
Cefotaxime 0 0
Ceftiofur 0 0
Trimethoprim 12 9
Sulfonamide 38 38
Streptomycin 41 41
Gentamicin 2 1
Neomycin 3 0
Apramycin 2 1
Ciprofloxacin 0 0
Nalidixic acid 0 0
Colistin 0 0
Spectinomycin 12 9
Fully sensitive 42 41
Multi-resistant 37 36
Number of isolates 512 148
Table 6.1. Resistance (%) among Salmonella Spp. from pigs 
and pork, Denmark DANMAP 2013
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at slaughter. Thus the serotype distributions differ slightly from 
the ones presented for the slaughter pig herds in Textbox 5.
Among all the Salmonella isolates from Danish pigs (n = 512), 
we observed high levels (range: 33% - 47%) of resistance to 
ampicillin, streptomycin, sulfonamide, and tetracycline (Table 
6.1). Co-resistance of these four antimicrobial agents is often 
called the ASSuT resistance-profile, also when resistant to 
additional antimicrobial agents. Resistance to tetracycline 
increased from 2012 to 2013, whereas resistance to the other 
tested antimicrobial agents was similar to levels reported in 
2012 (Figure 6.1). 
The occurrence of resistance in Salmonella spp. from Danish 
pork resembles the occurrences in the isolates from pigs 
((Figure 6.1).
The majority of the S. Derby isolates were fully sensitive, and 
the overall occurrences of resistance among Salmonella spp. 
in pigs and Danish pork were lower than observed among the 
S. Typhimurium isolates only. Even though S. Derby is very 
common among pigs, only few human S. Derby cases (N=10) 
were reported in Denmark in 2013 [www.SSI.dk].
Overall, it was estimated that in 2013 multi-resistant Salmonella 
was present in 9% of the tested pigs (24% Salmonella positive 
pigs) and on 0.5% of the tested pig carcasses (1.3% Salmonella 
positive carcasses, Textbox  5 and Table 6.1). 
None of the Salmonella spp. isolates from pigs or pork 
were resistant to cephalosporins (ceftiofur, cefotaxime) or 
quinolones (ciprofloxacin, nalidixic acid).
6.1.2 S. Typhimurium in pigs, domestic 
produced and imported pork 
S. Typhimurium isolated from pigs (n = 148) had very high 
levels of resistance to ampicillin (61%), streptomycin (66%), 
sulfonamide (66%), and tetracycline (70%, Table 6.2), and 
the occurrence of resistance for all four antimicrobial agents 
increased over the last five years (Figure 6.2). The occurrence 
of ASSuT resistance as well as multi-resistance in general was 
comparable with the levels in 2012; however ASSuT resistance 
among S. Typhimurium in pigs has been increasing since 2009, 
partly due to an increase in the prevalence of the monophasic 
variants of S. Typhimurium often carrying the ASSuT 
resistance-profile (Figure 6.3).    
The increased occurrence of monophasic S. 4,[5],12:i:- is 
not an isolated Danish phenomenon, but related to new 
pandemic strains of Salmonella in Europe [Hopkins et al. 
2010, Eurosurveillance 3;1]. As the changes in occurrences 
of antimicrobial resistance among Salmonella are highly 
influenced by the spread of such successful multi-resistant 
clones, the relationship between antimicrobial use and levels of 
resistance becomes very complex.  
In 2013, the monophasic S. Typhimurium variants constituted 
52% of the total number of S. Typhimurium isolates from 
pigs, representing 71% of the multi-resistant isolates. This is 
comparable to the occurrence in 2012. 
The prevalence of S. Typhimurium infected slaughter pig herds 
was 11.6% in 2013 [Annual report on Zoonoses in Denmark 
2013], and as 64% of the S. Typhimurium isolates were multi-
resistant, the prevalence of pig herds with multi-resistant S. 
Typhimurium amounts to approximately 7% compared to 3% 
in 2011.
In Danish pork (n = 68), 53% of the isolates were of the 
monophasic variants and high levels (41%) of ASSuT resistance 
were observed. As in S. Typhimurium isolates from pigs, the 
occurrence of monophasic variants as well as multi-resistance 
remained at the same level as in 2012, but has generally 
increased since 2009, accompanied with a reduced occurrence 
of isolates fully sensitive to all the antimicrobial agents included 
in the test panel (Figure 6.3).    
For the isolates from pigs and Danish pork, resistance to the 
other tested antimicrobial agents was similar to levels reported 
in 2012, except for an increase in resistance to trimethoprim 
among S. Typhimurium in pigs (from 6% to 13%). Levels of 
resistance were comparable among S. Typhimurium isolates 
from pigs and Danish pork (Table 6.2). 
None of the S. Typhimurium isolates from Danish pigs and 
pork were resistant to cephalosporins (ceftiofur, cefotaxime), 
quinolones (ciprofloxacin, nalidixic acid) or colistin (Table 
6.2). Only in 2010, a few DANMAP isolates from pigs were 
resistant to ciprofloxacin, resulting in a decreasing trend over 
the last five years (Figure 6.2). Among the ten EU Member 
States reporting resistance in S. Typhimurium from pork in 
2012, most Member States reported no resistance to third 
generation cephalosporins (cefotaxime), whereas quinolone 
resistance was more common ranging up to 19% of the isolates 
[EU Summary report on AMR 2012].
It is also important to note that the occurrence of S. Typhimurium 
isolates fully sensitive to all included antimicrobial agents have 
been decreasing since 2009, this is the case for isolates both 
from pigs and Danish pork (Figure 6.3). Among the generic S. 
Typhimurium isolates from pigs, 41% of the isolates were fully 
sensitive isolates, a level comparable to previous years, whereas 
none of the monophasic isolates from pigs were fully sensitive 
in 2013.
Relatively few S. Typhimurium isolates from imported pork 
(n = 21) are available (Table 6.2), however higher levels of 
resistance to tetracycline, chloramphenicol, flourfenicol and 
spectinomycin was observed compared to isolates from Danish 
pork.
6.1.3 Salmonella in humans
In 2013, Salmonella continued to be the second most frequent 
cause of bacterial intestinal infections in Denmark. A total of 
1,136 human laboratory-confirmed cases of salmonellosis were 
reported (20.3 cases per 100,000 inhabitants) [Annual report on 
Zoonoses in Denmark 2013]. The most common serotype was 
S. Enteritidis and a total of 346 confirmed S. Enteritidis cases 
were reported (6.2 cases per 100,000 inhabitants), of which 
79% were associated with travel outside Denmark especially in 
Turkey. This year, only S. Typhimurium isolates from humans 
were systematically susceptibility tested.
As in previous years, SSI collected information on travel 
history through phone interviews. Patients were asked about 
the date of disease onset and whether they had travelled abroad 
within a seven-day period prior to the onset of the disease. 
Furthermore, patients who had been abroad were asked about 
their destinations. Cases were categorised as “domestically 
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Table 6.2. Resistance (%) among Salmonella Typhimurium(a) from pigs, Danish pork and human cases(b), Denmark
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 9.3)
a) Include isolates verified as monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:-
b) An isolate was categorised as ‘domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of the disease and 
was not reported as being part of an outbreak
DANMAP 2013
Pigs Pork Human
Antimicrobial agent % Danish         %
Imported
%
Domestic
sporadic 
%
Domestic 
outbreak 
%
Travel abroad
%
Unknown 
origin 
%
Tetracycline 70 63 95 53 23 57 61
Chloramphenicol 6 6 33 8 0 20 15
Florfenicol 3 4 33 6 0 16 11
Ampicillin 61 59 81 56 30 55 63
Cefotaxime 0 0 0 1 0 4 2
Ceftiofur 0 0 0 1 0 2 2
Trimethoprim 13 9 14 8 7 8 8
Sulfonamide 66 72 81 54 36 59 66
Streptomycin 66 68 81 56 36 61 57
Gentamicin 3 1 0 2 0 6 2
Neomycin 4 0 5 1 0 4 3
Apramycin 3 1 0 1 0 2 1
Ciprofloxacin 0 0 0 3 1 20 8
Nalidixic acid 0 0 0 1 0 10 5
Colistin 0 0 0 7 6 0 5
Spectinomycin 12 12 43 10 4 16 18
Fully sensitive 20 19 0 28 58 27 27
Multi-resistant 64 71 76 54 36 59 63
Number of isolates 148 68 21 106 69 51 93
acquired” if the patients had not travelled within the last week 
prior to the onset of the disease. Patients were categorised as 
of ‘unknown origin’ if no telephone interview was conducted 
and travel information had not been reported to the general 
practitioners. In 2013, travel information was obtained for 68% 
of all reported Salmonella cases [Annual report on Zoonoses in 
Denmark 2013].
All human cases associated with a detected outbreak reported 
in the Annual Report on Zoonoses in Denmark in 2013 were 
considered ‘outbreak-related’ and all other domestic cases were 
considered ‘sporadic domestic’ in this report.
6.1.4 Salmonella Typhimurium in humans
 
S. Typhimurium was for the first time since 2008 only the 
second most common serotype among the human cases (337 
cases), and isolates with valid results from susceptibility testing 
of all antimicrobial agents included in the test panel (n = 319) 
were included.
Among the reported human S. Typhimurium isolates included 
in DANMAP, 16% of the cases were categorised as travel-
associated whereas 33% and 22% most likely had acquired 
their infection in Denmark as sporadic incidences or as part 
of detected outbreaks, respectively (Table 6.2). Among the 
cases where the origin of infection was unknown (29%), 
the occurrence of resistance falls within the ranges of both 
domestic cases and travel-associated cases.
There were reported several domestic foodborne outbreaks 
with S. Typhimurium, and compared with 2012 the proportion 
of outbreak related cases (n = 69) increased from 13% to 22%. 
In 2013, only 13% of isolates from the outbreak related cases 
was of the multi-resistant monophasic variants compared with 
92% in 2012.  
Among the S. Typhimurium isolates from domestic as well 
as travel-associated cases, we observed very high levels of 
resistance to ampicillin, streptomycin, sulfonamide, and 
tetracycline. High levels of ASSuT resistance occurred among 
isolates from sporadic domestic cases (43%, n = 106) as well as 
and travel-associated cases (47%, n = 51).
Occurrences of the resistance to the other antimicrobial agents 
were similar to most levels reported in 2012 for the domestic 
sporadic cases and similar for all antimicrobial agents for the 
travel-associated cases.
There were no significant changes in levels of resistance from 
2012 to 2013 for either domestic sporadic or travel-associated 
cases. The increasing trend in resistance to ampicillin, 
streptomycin, sulfonamide and tetracycline, observed previous 
years discontinued, and for both domestic sporadic cases as 
well as among the travel associated cases (Figure 6.2).  Among 
the domestic sporadic cases, fluoroquinolone (ciprofloxacin) 
resistance has decreased over the last five years. In general, 
the levels of resistance for the domestic cases were similar 
to those of Danish pork, except for the low occurrence of 
fluoroquinolone resistance, a resistance not observed among 
the isolates from Danish pork. 
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Figure 6.1. Resistance (%) in Salmonella Spp. in pigs and Danish 
pork, Denmark
Note: The number of isolates varies between years (pigs: n = 340-
512, Danish pork: n = 81-148).  Before 2011, not all serotypes were 
susceptibility tested
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Figure 6.2. Resistance (%) in Salmonella Typhimurium in(a) pigs, pork and human cases(b), Denmark
Note: The number of isolates varies between years (pigs: n = 144-434, Danish pork: n = 26-70, domestic sporadic human cases: n = 106-227 and 
travel related human cases: n = 51-95)
b) An isolate is categorised as ‘domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of disease and was 
not reported as being part of an outbreak
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Since 2009, the proportion of multi-resistant isolates from 
sporadic domestic cases has increased (no significant change 
from 2012 to 2013), probably as a consequence of an increasing 
occurrence of multi-resistant monophasic variants of S. 
Typhimurium (Figure 6.3). In 2013, the monophasic variants 
represented 44% of all domestic sporadic isolates and 70% of 
all multi-resistant isolates. Also in line with this, the proportion 
of fully sensitive S. Typhimurium isolates of domestic sporadic 
origin (28% in 2013) has decreased over the last five years (no 
significant change from 2012 to 2013). 
Among the S. Typhimurium from travel-associated cases, 
resistance to chloramphenicol, ciprofloxacin, florfenicol 
and nalidixic acid was more frequent than among isolates of 
domestic sporadic origin, whereas the level of resistance to the 
other agents included in the panel as well as the proportion of 
multi-resistant isolates were comparable. 
In most of the Member States reporting data on monophasic 
variants of S. Typhimurium from human to the European Food 
Safety Authority, the number of reported cases was higher in 
2012 compared with 2011. Overall, the monophasic variants 
represented 7.2% of all human Salmonella cases in EU in 2012 
[EU Summary Report on Zoonoses 2012, EFSA, 2013].
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Figure 6.3. Occurrence (%) of multi-resistance(a b) and monophasic variants (c) in Salmonella Typhimurium in pigs, pork and human 
cases(d), Denmark
DANMAP 2013
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Note: The number of isolates varies between years (pigs: n = 144–434, Danish pork: n = 26–70, domestic sporadic human cases: n = 106–227 
and travel related human cases: n= 51-95)
a) An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 10.3). Data on resistance to colistin and trimethoprim are not available for 2007, thus 
the proportions of multi-resistant or fully sensitive are not calculated
b) ‘ASSuT’ isolates are resistant to ampicillin, streptomycin, sulfonamide and tetracycline, but can include resistant to other antimicrobial agents 
such as chloramphenicol
c) Recording of the monophasic variants of S. Typhimurium with antigenic formulas S. 4,[5],12:i:- in the database was not fully implemented in 
2007 and 2008, thus data are not presented
d) An isolate is categorised as ‘domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of disease and was 
not reported as being part of an outbreak
Regarding resistance to antimicrobial agents critical for 
treatment of human infections, resistance to 3rd generation 
cephalosporins (ceftiofur) was low and only found in isolates 
from one travel-associated case, one sporadic domestic case 
and two cases of unknown origin.
As also observed in previous years, a marked difference in 
fluoroquinolone (ciprofloxacin) resistance was found between 
domestically acquired infections (3%) and travel-associated 
infections (20%). The higher level of ciprofloxacin resistance in 
the travel-associated S. Typhimurium infections may reflect a 
higher prescription of fluoroquinolones in production animals 
in the countries of destination. In Denmark, fluoroquinolones 
are rarely used in animal husbandry (except for pet animals) 
since the implementation of legal restrictions in 2002-2003 
[DANMAP 2010].
Although the MIC of the observed fluoroquinolone resistant 
isolates was below the clinical breakpoint, it should be noted 
that ciprofloxacin or other fluoroquinolones are often used for 
empiric treatment of adults with severe bacterial gastroenteritis.
Helle Korsgaard, Lars Stehr Larsen and Mia Torpdahl
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Surveillance of Salmonella and Campylobacter in Denmark
Background: In Denmark, all flocks of laying hens, broilers and turkeys, including breeder flocks, are monitored 
for Salmonella according to the EU requirements and the Danish legislation. A Salmonella surveillance and control 
programme is also running in the Danish pig production, as well as a S. Dublin monitoring programme in cattle. 
Since January 2010, a mandatory surveillance of Campylobacter in broiler flocks at the farm has also been in place. 
Salmonella and Campylobacter in fresh meat are surveyed at the slaughterhouses and at the retail level, and finally, an 
intensified control of Salmonella and Campylobacter in fresh meat, based on a case-by-case risk assessment, has been 
in place for Danish and imported meat ready for retail since 2007. Human salmonellosis and campylobacteriosis 
are notifiable illnesses in Denmark, and all cases are reported to SSI and recorded in a national database. More 
information regarding trends and sources of zoonotic infections in humans and animals in 2013 is available in the 
Annual Report on Zoonoses in Denmark at www.food.dtu.dk.
Salmonella: In layer and broiler flocks, the Salmonella prevalence has been low for more than a decade and only 
1.1% and 1.0%, respectively, of flocks were positive in 2013. From 2008, all Danish flocks that test positive at the 
farm are heat treated at slaughter, and as it was in 2011 and 2012, none of the slaughter batches tested at slaughter 
were Salmonella positive in 2013.
The prevalence of Salmonella in cattle is low, and in 2013 only 0.3% of the cattle carcasses tested at slaughter were 
positive. Furthermore, 95.5% of the non-milk producing herds and 92.1% of the milk-producing herds were classified 
as “probably S. Dublin free”. Among pigs sampled prior to slaughter, 24.2% were found Salmonella positive, while 
1.3% of the pig carcasses tested at slaughter were positive. As in previous years, the most common serotype in pigs 
and pork in 2013 was S. Derby (60% and 39%, respectively) followed by S. Typhimurium (30% and 44%, respectively) 
when including the monophasic variants with antigenic formulas S. 4,[5],12:i- (Figure 1).   
Only 1,136 cases of human salmonellosis were reported in 2013 with an incidence on 20.3 cases per 100,000 
inhabitants. This is the lowest number for several decades and a result of the intensive Salmonella control programmes 
in animal production.  In total, six domestic Salmonella outbreaks were reported, and five of these were caused by S. 
Typhimurium of which two of the outbreaks were caused by Danish pork. 
As in previous years, the Salmonella source account estimated that approximately half of the human cases of 
salmonellosis were acquired during international travel. Similar to previous years, more than 75% of the S. Enteritidis 
cases were acquired abroad whereas the majority of the S. Typhimurium cases was acquired in Denmark. The model 
could not attribute around a quarter of the humane cases to the included food sources, and as previous years Danish 
pork was estimated to be the most important domestic food source, followed by different types of imported meat 
(Figure 2).
Campylobacter: The proportion of Campylobacter positive broiler flocks has decreased since 2010, however in 2013 
the decrease leveled out and 13.1% of all broiler flocks tested Campylobacter positive. At retail, Campylobacter was 
detected in 17.8% of the chilled broiler meat of Danish origin, compared with 9.7% in 2012 (Figure 3). The most 
common Campylobacter species in broilers are C. jejuni (91.7% in 2013). Broilers were also tested at slaughter, where 
28.2% of the conventional and 90.3% of the organic-free-range birds were positive. Campylobacter is also found in 
cattle and pigs, where C. jejuni is dominant in the cattle and C. coli is dominant in pigs.   
Campylobacter is the most frequently reported foodborne pathogen in Denmark; however, the number of human 
campylobacteriosis cases in 2013 (67.1 cases per 100,000 inhabitants) at a  a level comparable to 2012. Since 2007, 
approximately one-third of the cases have been related to international travel. Consumption and handling of broiler 
meat is assumed to be the most important source of human campylobacteriosis (estimated more than 50% of 
domestic sporadic cases), however other sources such as contaminated water, vegetables and direct contact to farm 
animals cattle exist.
Helle Korsgaard, Birgitte Helwigh and Anna Vedel Sørensen
For further information: Birgitte Helwigh (bhel@food.dtu.dk)
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Figure 1. Occurrence (%) of Salmonella serovars in pigs at farm(a) and in Danish pork, Denmark
a) Faecal samples from healthy pigs collected at the slaughterhouses and cultured for Salmonella as part of the DANMAP programme
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Figure 2. Estimated sources of(a) 1,136 cases of human salmonellosis, Denmark 2013
Source: Danish Zoonosis Centre, National Food Institute
a) Sporadic and outbreak-related cases with unknown source include all sources not in the model
DANMAP 2013
a) Boot swabs collected in the stable 7-10 days before slaughter (detection limit: <10 cfu/g)
b) Non-heat treated chilled broiler meat at retail (detection limit:  <10 cfu/g). The prevalence was calculated as a mean of quarterly 
prevalences
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Figure 3. Occurrence of Campylobacter in broiler flocks(a) and fresh chilled broiler meat(b), Denmark
DANMAP 2013
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6.2 Campylobacter
Thermotolerant Campylobacter are the most commonly 
reported causes of gastrointestinal bacterial infections in 
humans in Denmark as well as in the European Union [ECDC, 
2014]. The species most commonly associated with human 
infections is C. jejuni, but other species may also cause infections. 
In Denmark, 85%-95% of the human campylobacteriosis cases 
are caused by C. jejuni.
Campylobacter are widespread in nature and the most important 
reservoirs are the alimentary tract of wild and domesticated 
birds and mammals. Among sporadic human cases, broilers 
have been identified as the primary source of infection, though 
other sources also exist, e.g. water from untreated water sources 
and other infected animals.
For Campylobacter, DANMAP 2013 includes randomly 
collected isolates from broilers and cattle at slaughter and 
from fresh broiler meat sold at wholesale and retail outlets. 
Isolates from human cases originates from three out of five 
geographical regions in Denmark. One isolate per farm, meat 
sample or human case is included, and data are only presented 
if a sufficient number of isolates were obtained (>15) from a 
given source. For details see Chapter 9, Materials and Methods.
MIC distributions for C. jejuni from broilers and cattle, broiler 
meat and humans, as well as for C. coli from pigs and broiler 
meat in 2013 are presented in the web annex (Tables A6.6-A6.9). 
An isolate is considered fully sensitive if susceptible to all 
antimicrobial agents included in the test panel, and multi-
resistant if resistant to three or more of the six included 
antimicrobial classes (see Table 10.3).
 
6.2.1 C. jejuni in broilers and domestic 
produced broiler meat 
In 2013, we observed moderate levels of resistance to 
fluoroquinolones (ciprofloxacin) and tetracycline (26% and 
20%, respectively) among C. jejuni isolates from broilers (n = 
54, Table 6.3) compared with 2012 (15% for both compounds).
The consumption of antimicrobial agents in broilers is generally 
low, but tetracycline has been one of the most commonly used 
antimicrobial agents in Danish broilers over the last five years 
The consumption of tetracycline increased considerably from 
2008 to 2010, decreased from 2011 to 2012, but increased again 
in 2013. For C. jejuni isolates from broilers, the resistance and 
consumption patterns for tetracycline appear to follow each 
other (Figure 6.4). We did not observe a similar agreement 
between the consumption and resistance patterns for 
fluoroquinolones (ciprofloxacin) in C. jejuni broiler isolates. 
Even though fluoroquinolones have not been used in the broiler 
production since 2009, the resistance level has increased to a 
moderate level (26%) during the last five years (Figure 6.4).
In C. jejuni isolates from Danish broiler meat (n = 70), we 
observed levels of resistance to ciprofloxacin (20%) and 
tetracycline (10%) that were slightly lower than in 2012. The 
resistance to ciprofloxacin and tetracycline has fluctuated over 
the last five years, however the ciprofloxacin resistance level 
observed in 2012 was the highest since 2007.
The levels of antimicrobial resistance were comparable between 
C. jejuni isolated from Danish broilers and Danish broiler meat 
(Figure 6.4), and macrolide (erythromycin) resistance has 
remained at a very low level for a decade.
6.2.2 C. jejuni from imported meat
In C. jejuni isolates from imported broiler meat (n = 30), 
the levels of resistance to tetracycline (80%) and quinolones 
(nalidixic acid and ciprofloxacin, 53% and 57%, respectively) 
remained high (Table 6.3). From 2009 to 2013 there has been 
an overall decrease in the proportion of fully sensitive C. jejuni 
isolates among isolates from imported broiler meat (from 32% 
to 13%). 
Also, over the past five years, the level of resistance to tetracycline 
and ciprofloxacin has generally been higher in isolates from 
imported broiler meat compared with Danish broiler meat. 
This corresponds with the data reported by EFSA, where 
Denmark has reported the lowest proportions of resistance 
among C. jejuni isolates from broiler meat [EFSA, 2013].
DANMAP 2013
Table 6.3. Resistance (%) in Campylobacter jejuni from animals, meat of Danish and imported origin and human cases(a), Denmark
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the six antimicrobial classes (see Table 10.3)
a) An isolate is categorised as ‘domestic sporadic’ if the patient did not travel outside Denmark one week prior to the onset of disease
Cattle Broilers Broiler meat Humans
Antimicrobial agent Danish%
Danish
%
Danish
%
Import
%
Domestically 
acquired
%
Travel
abroad
%
Tetracycline 3 20 10 80 19 54
Chloramphenicol 0 0 0 0 0 0
Erythromycin 0 2 0 0 0 0
Streptomycin 0 4 3 0 0 0
Gentamicin 0 0 0 0 0 4
Ciprofloxacin 21 26 20 53 24 92
Nalidixic acid 22 26 20 57 24 92
Fully sensitive 76 67 76 13 67 8
Multi-resistant 0 2 0 0 0 4
Number of isolates 86 54 70 30 42 24
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6.2.3 C. jejuni in cattle
In C. jejuni isolates from cattle (n= 86), we observed moderate 
levels (21%) of resistance to fluoroquinolones (ciprofloxacin) 
and low levels (3%) of resistance to tetracycline (Table 6.3).
Resistance to fluoroquinolones (ciprofloxacin) among C. 
jejuni from cattle has remained at a moderate level (16%-21%) 
since 2006 (Figure 6.5). As described in previous DANMAP 
reports, we observed an increase in the level of fluoroquinolone 
resistance in 2005 despite low consumption of fluoroquinolones 
in cattle. In 2012, only one of the fluoroquinolone resistant 
isolates was also resistant to tetracycline, indicating that co- 
selection by tetracycline (one of the major drugs for treatment 
of calves) was not the explanation for the observed levels of 
fluoroquinolone resistance. It has been discussed [DANMAP 
2007] that clonal spread, particularly between farms, could be 
an explanation for the observed resistance to fluoroquinolones.
Initially, fluoroquinolone-resistant C. jejuni isolates came from 
cattle farms in Southern Jutland, but as in recent years, isolates 
were obtained from farms distributed throughout Jutland and 
other parts of Denmark.
From 2004 to 2010, we observed a general increase in the 
resistance to tetracycline. However, this trend was discontinued 
in 2011, and in 2013 the level of tetracycline resistance is 
comparable to 2006-2009 (3%, Figure 6.4).
6.2.4 C. jejuni in humans
In 2013, Campylobacter continued to be the most frequent 
cause of bacterial intestinal infections in Denmark. A total of 
3,766 human laboratory confirmed cases of campylobacteriosis 
were reported (67.1 per 100,000 inhabitants) [Annual report 
on Zoonoses in Denmark 2013].
A subset (n = 66) of the C. jejuni isolates submitted to SSI were 
selected for susceptibility testing continuously over the year. The 
isolates were randomly selected from all of the Campylobacter 
isolated from stool samples in the three geographical regions 
included in the surveillance. Among the tested isolates, 37% 
were from travel-associated cases and 63% were considered to 
be domestically acquired. As in previous years, SSI collected 
information on travel history through phone interviews. 
Patients were asked about the date of disease onset and whether 
they had travelled abroad within a seven-day period prior to the 
onset of disease. Furthermore, patients who had been abroad 
were asked about their destinations. Cases were categorised as 
“domestically acquired” if the patients had not travelled within 
the week prior to the onset of disease.
DANMAP 201
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Figure 6.4. Resistance (%) in Campylobacter jejuni from broilers, broiler meat and human cases(a), Denmark
Note: The number of isolates varies between years (broilers: n = 41–75, Danish broiler meat: n = 26–70, imported broiler meat: n = 26–70, 
domestic sporadic human cases: n = 42–104 and travel-associated human cases: n = 24–78)
a) An isolate was categorised as ‘domestic’ if the patient did not travel outside Denmark one week prior to the onset of the disease
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Figure 6.5. Resistance (%) in Campylobacter jejuni from cattle, 
Denmark
Note: The number of isolates varies between years (n = 41–98)
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Among the domestically acquired infections, 67% were fully 
sensitive to all the antimicrobial agents tested, while the 
percentage of fully sensitive isolates was much lower (8%) 
among isolates from travel associated cases (Table 6.3). The 
level of multi-resistance was low (0%-4%) among both groups, 
but among the travel-associated cases with resistant C. jejuni, 
all (22/22) were resistant to fluoroquinolones (ciprofloxacin), 
compared with 71% (10/14) among isolates from the 
domestically acquired infections.
The occurrence of resistance to ciprofloxacin and tetracycline 
continued to be significantly higher in travel-associated 
C. jejuni isolates (92% and 54%, respectively) compared to 
isolates from domestically acquired infections (24% and 19%, 
respectively, Table 6.3 and Figure 6.4). 
Ciprofloxacin or other fluoroquinolones are often used for 
empiric treatment of adults with severe bacterial gastroenteritis, 
and the level of resistance to these antimicrobial agents is 
therefore of major importance. In Denmark, fluoroquinolones 
are rarely used in animal husbandry (except for pet animals) 
since the implementation of legal restrictions in 2002-2003 
[DANMAP 2010]. Travelling to, or eating meat from countries 
where fluoroquinolone restrictions are not implemented can 
be associated with a higher risk of acquiring infection with 
ciprofloxacin-resistant C. jejuni.
Birgitte Borck Høg, Lars Stehr Larsen, Mia Torpdahl 
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7. Resistance in indicator bacteria
Indicator bacteria (Enterococcus faecalis, Enterococcus 
faecium and Escherichia coli) have been included in the 
DANMAP programme since 1995. Enterococci are included 
to monitor resistance in Gram-positive bacteria and E. coli as 
representative of Gram-negative bacteria. These bacteria were 
selected as indicators for occurrence of antimicrobial resistance 
for several reasons: they are ubiquitous and present as major 
commensals in both the animal and human reservoirs, they 
can acquire antimicrobial resistance as response to selective 
pressures and finally they have the potential for transferring 
resistance to pathogenic bacteria and between reservoirs and 
can cause infection in humans.
7.1 Enterococci
For Enterococci, DANMAP 2013 includes randomly collected 
Enterococcus isolates from healthy pigs and broilers at slaughter 
(E. faecalis only) and from domestic fresh broiler meat, pork 
and beef sold at wholesale and retail outlets (both E. faecalis 
and E. faecium). In addition, enterococci from imported 
broiler meat, beef and pork were included. We included only 
one isolate per farm or meat sample, and data are presented in 
the report where a sufficient number of isolates were obtained 
(>15) from a given source. For details on methodology, see 
Chapter 9, Materials and Methods.
An isolate is considered fully sensitive if susceptible to all 
antimicrobial agents included in the test panel, and multi-
resistant if resistant to three or more of the ten included 
antimicrobial classes (see Table 9.3).
The MIC distributions and occurrence of resistance among E. 
faecium and E. faecalis are presented in the web annex (Tables 
A7.1 - A7.3).
7.1.1 E. faecalis from broilers and domestic 
produced broiler meat
In E. faecalis isolates from broilers (n = 114), 38% of isolates 
were tetracycline resistant followed by erythromycin (20%) 
and salinomycin (5%). Antimicrobial resistance to salinomycin 
increased from 0% in 2012 to 5% in 2013, a level comparable to 
the occurrence in 2011(4%). Only four isolates (4%) were multi-
resistant while 52% were susceptible to all tested antimicrobials 
(Table 7.1), a level comparable to 2012. All four multi-resistant 
isolates were resistant to tetracycline and erythromycin.
The levels of resistance in E. faecalis isolates from broiler meat 
were comparable to E. faecalis isolates from broilers (Figure 7.1) 
except for streptomycin where significantly higher prevalence 
(10%) was found in broiler meat. Only three isolates (5%) were 
multi-resistant and all of these were resistant to tetracycline. 
Prevalence of multi-resistance has been lowered from 13% 
in 2009 to 5% in 2013, while resistance to erythromycin has 
increased from 17% in 2010 to 23% in 2013.
7.1.2 E. faecalis from pigs and domestic 
produced pork
Very high occurrence of resistance to tetracycline (91%) and 
occurrence of resistance to erythromycin (45%), streptomycin 
(34%) and kanamycin (28%) was found in E. faecalis 
isolates from pigs (n = 109). Resistance to fluoroquinolones 
Figure 7.1. Resistance (%) in Enterococcus faecalis from animals and meat of Danish and imported origin, Denmark
Note: The number of isolates varies between years (broilers: n = 100–112, Danish broiler meat: n = 34–75, imported broiler meat: n 
= 69–104, Pigs: n = 109–157, Danish pork: n = 84–150 and imported pork: n = 45–140)
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Table 7.1. Resistance (%) among Enterococcus faecalis from animals and meat of Danish and imported origin, Denmark
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 10.3)
Antimicrobial agent
Broilers Broiler meat Beef Pigs Pork
Danish Danish Imported Danish Imported Danish Danish Imported
% % % % % % % %
Tetracycline 38 47 66 29 25 91 11 40
Tigecycline 0 0 0 0 0 0 0 0
Chloramphenicol 1 2 3 8 2 17 3 1
Ampicillin 0 0 0 0 0 0 0 0
Penicillin 0 0 0 0 0 0 0 0
Erythromycin 20 23 63 12 0 45 5 3
Streptomycin 1 10 40 12 6 34 4 1
Gentamicin 0 0 0 0 0 16 3 1
Kanamycin 1 0 33 8 0 28 4 1
Ciprofloxacin 0 0 6 4 0 1 1 0
Vancomycin 0 0 0 0 0 0 0 0
Teicoplanin 0 0 0 0 0 0 0 0
Linezolid 0 0 0 0 0 0 0 0
Salinomycin 5 8 1 0 0 0 0 0
Fully sensitive 52 42 23 71 75 9 88 59
Multi-resistant 4 5 39 13 2 34 5 2
Number of isolates 114 62 93 24 51 109 150 140
DANMAP 2013
Table 7.2. Resistance (%) among Enterococcus faecium from meat of Danish and imported origin, Denmark
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 10.3)
DANMAP 2013
Antimicrobial agent
Broiler meat Pork
Danish
%
Imported
%
Danish 
%
Imported
%
Tetracycline 9 42 0 19
Tigecycline 0 0 0 0
Chloramphenicol 0 0 0 0
Ampicillin 2 22 0 0
Penicillin 2 22 0 0
Erythromycin 8 53 0 3
Quinupristin/dalfopristin 3 11 0 0
Streptomycin 3 31 0 0
Gentamicin 0 2 0 0
Kanamycin 0 17 0 0
Ciprofloxacin 0 2 0 0
Vancomycin 0 0 0 0
Teicoplanin 0 0 0 0
Linezolid 0 2 0 0
Salinomycin 64 36 5 0
Fully sensitive 26 23 95 77
Multi-resistant 5 34 0 0
Number of isolates 66 64 22 31
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(ciprofloxacin) was observed in one isolate (1%) from pigs 
(Table 7.1).  The levels of resistance were comparable with 2012. 
Tetracyclines and macrolides are the most commonly used 
antimicrobial agents in the Danish pig production, whereas the 
use of fluoroquinolones cephalosporins in pigs was very low.
All the chloramphenicol (n = 19), kanamycin (n = 30) and 
gentamicin (n = 17) resistant isolates from pigs were resistant 
to both tetracycline and erythromycin, while all erythromycin 
resistant isolates (n = 49) were resistant to tetracycline. 
Overall, 34% of the isolates were multi-resistant (Table 7.1). 
Nine percent of the tested isolates were fully sensitive to all the 
antimicrobial agents tested. 
Since 2010 the occurrence of macrolide (erythromycin) 
resistance among E. faecalis isolated from pigs has increased 
from 44% to 56%, but from 2012 to 2013 a decline to 45% was 
observed (Figure 7.1). Prevalence of multi-resistant E. faecalis 
(34%) from pigs was comparable to 2012, but lower than in 
2011 (40%). 
Most of the E. faecalis isolates from Danish pork (n = 150) were 
fully sensitive to all of the antimicrobial agents tested (88%, 
Table 7.1). The highest prevalence of resistance was seen for 
tetracycline (11%) followed by erythromycin (5%), and the 
aminoglycosides streptomycin (4%) and kanamycin (4%). 
Resistance to flouroquinolones (ciprofloxacin) was observed in 
one isolate (1%) from Danish pork. Resistance to tetracycline 
has been declining from 20% in 2009 to 11% in 2013, a trend 
that is not observed in the isolates from pigs where tetracycline 
resistance has been 80%-90% over the last ten years.
7.1.3 E. faecalis from domestic produced beef 
In E. faecalis from beef (n = 24), 29% of the isolates were 
resistant to tetracycline, 12% resistant to erythromycin and 
streptomycin and 8% resistant to chloramphenicol and 
kanamycin (Table 7.1). Levels of antimicrobial resistances were 
comparable with 2012.
7.1.4 E. faecalis from imported meat 
Compared with Danish broiler meat, E. faecalis from imported 
broiler meat (n = 93) had higher levels of resistance to 
tetracycline, erythromycin, kanamycin and streptomycin and 
were more often multi-resistant (Figure 7.1). Overall, 39% of 
the E. faecalis from imported broiler meat were multi-resistant 
(all tetracycline resistance) compared with 5% among isolates 
from Danish broiler meat. Among the multi-resistant isolates 
from imported broiler meat 72% (26 of 36 isolates) had the same 
resistance profile (erythromycin, kanamycin, streptomycin and 
tetracycline) coming from multiple countries in Europe.  For 
salinomycin, occurrence of resistance was higher in Danish 
broiler meat compared with imported broiler meat (Table 7.1).
Compared with Danish pork, E. faecalis isolates from imported 
pork (n = 140) were more frequently resistant to tetracycline, 
whereas resistance levels to all other antimicrobial agents were 
comparable. Fifty-nine percent of the E. faecalis isolates from 
imported meat were fully sensitive to all of the antimicrobial 
agents tested compared to 88% in isolates from Danish pork. 
All resistant isolates from imported pork were at least resistant 
to tetracycline. Only 2% were multi-resistant compared with 
5% in isolates from Danish pork (Table 7.1).
The levels of resistance in E. faecalis isolates in Danish (n = 
24) and imported beef (n = 51) were comparable, except for 
erythromycin and kanamycin where Danish produced beef 
were more frequently resistant (Table 7.1). Only resistance to 
tetracycline (25%), streptomycin (6%) and chloramphenicol 
(2%) was detected in imported beef. Only one isolate (2%) of 
the tested isolates from imported beef were multi-resistant, 
compared to 13% among isolates from Danish beef. Overall 
75% of the tested isolates from imported beef were fully 
susceptible to all tested antimicrobials compared to 71% in 
Danish produced beef.
7.1.5 E. faecium from domestic produced 
broiler meat and pork 
High and increased occurrence of salinomycin resistance 
(64%) was observed in E. faecium isolates from Danish broiler 
meat (n = 66, Table 7.2) followed by resistance to tetracycline 
(9%) and erythromycin (8%). Only three isolates (5%) from 
the Danish broilers were multi-resistant, and most of the 
resistant isolates (n = 40) were only resistant to salinomycin 
(78%). Occurrences of the resistance and multi-resistance 
were similar to levels reported in 2012. However since 2010, 
resistance to erythromycin and tetracycline has decreased 
whereas resistance to salinomycin has increased (from 38% in 
2009 to 64% in 2013, Figure 7.2).
In E. faecium isolates (n = 22) recovered from Danish pork only 
one isolate was resistant (to salinomycin only, Table 7.2). Thus, 
occurrences of resistance were lower than reported in 2012 but 
no significant differences were detected.
As in 2012, none of the isolates from domestic broiler meat 
and pork were resistant to fluoroquinolone (ciprofloxacin) 
or glycopeptides (vancomycin) in 2013. Two isolates from 
Danish broiler meat and none from pork were resistant to 
virginiamycin (quinupristin/dalfopristin, Table 7.2). 
7.1.5 E. faecium from imported meat
As in 2012, resistance to tetracycline, ampicillin, penicillin, 
erythromycin, quinupristin/dalfopristin, streptomycin and 
kanamycin, as well as multi-resistance was significantly more 
frequent in E. faecium from imported broiler meat (n = 64) 
compared with isolates from Danish broiler meat (n = 66). 
Resistance to salinomycin was higher in Danish broiler meat 
compared with imported (Table 7.2). Overall, 34% of the 
E. faecium isolates from imported broiler meat were multi-
resistant, and among the resistant isolates (n = 41), 30% of the 
isolates were resistant to both erythromycin and tetracycline. 
In imported pork, 77% of the E. faecium isolates (n = 31) were 
fully sensitive to the tested antimicrobial agents (Table 7.2), 
and only resistance to tetracycline (19%) and erythromycin 
(3%) were detected. Occurrences of resistance were similar 
between Danish and imported pork, except for a higher level 
of resistance to tetracycline in imported pork.
 
7.1.6 One Health perspective
Occurrence of antimicrobial resistance in enterococci 
isolated from production animals and food are used as 
indicators for prevalence and transmission of antimicrobial 
resistance through the food chain to the consumer. Changes 
in occurrences of antimicrobial resistance in enterococci from 
production animals are thought to be directly related to the use 
of antimicrobial agents.
The level of resistant E. faecalis is generally higher in pigs than 
in broilers, indicating that pig production is a potential greater 
reservoir for resistance genes. Tetracycline is predominantly 
used against E. coli infections in pigs and since resistance 
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among E. coli isolates from pigs is still low (35%, Table 7.3) 
tetracycline can still be used. However, a side effect of this usage 
has given resistance levels of 91% in E. faecalis and most likely 
in other bacterial species isolated from pigs (62% resistance in 
E. faecium from pigs in 2012). A very high and increasing level 
of resistance to tetracycline (80%-90%) has occurred over the 
last years.  
Apart from tetracycline, significantly higher resistance to 
chloramphenicol, erythromycin, streptomycin, gentamicin 
and kanamycin was found among E. faecalis isolated from 
pigs when compared to broilers; reflecting the higher usage 
of antimicrobials in pigs. All these antimicrobial agents are 
used for human treatment (chloramphenicol for eye infections 
only). Higher occurrence of salinomycin resistance was found 
in isolates from broilers when compared to pig isolates (5% 
vs 0%). Salinomycin is not used to treat human infections, so 
salinomycin resistance in itself does not pose a public health 
problem. However, continuously growing prevalence and co-
resistance with other antimicrobial agents can be of importance, 
and in 2013, 4 out of 6 salinomycin-resistant isolates were also 
resistant to other antimicrobial agents, especially tetracycline. 
No vancomycin resistant enterococci were detected in Danish 
produced meat in 2013 and only very few vancomycin resistant 
DANMAP isolates have been reported from pigs during the 
last decade. An increased occurrence of vancomycin resistant 
E faecium infections has been observed in Danish hospitals 
(Textbox 8), however, it does not seem likely that, these 
infections are related to Danish meat or pigs. The clones 
causing the hospital infections are all resistant to ampicillin, 
in contrast to the vancomycin resistant E. faecium previous 
isolates from pigs.
As in previous years, the occurrence of antimicrobial resistance 
in E. faecalis  from Danish pork is much lower than from 
Danish pigs. This is not observed among E. faecalis from broiler 
meat where equal levels of resistance are observed except for 
streptomycin.  These results may indicate that enterococcal 
populations in the live animal and on pork constitute different 
sub populations. Pork cuts for sampling are collected from 
wholesale and retail outlets. Possibly, enterococci on the 
product may reflect the processing environment, rather 
than direct contamination of the meat during slaughter and 
dressing. In contrast, cutting of broilers is done in slaughter 
plants, which may explain why the enterococcal populations 
from live broilers and from broiler meat do not appear too 
dissimilar. 
In isolates from imported broiler meat, especially the prevalence 
of fluoroquinolone resistance is noticeable and could be of 
importance for human treatment but also the presence of multi-
resistant E. faecalis (erythromycin, kanamycin, streptomycin 
and tetracycline) among poultry meat isolates from multiple 
countries raise concern. Imported broiler meat contains 
resistant Enterococcus isolates more often than Danish broiler 
meat, especially tetracycline, erythromycin, streptomycin and 
kanamycin (also ampicillin and penicillin in E. faecium). 
The tendency that imported meat contains higher prevalence 
of resistance is also seen for pork (tetracycline), but not for 
beef. There is a significantly higher occurrence of resistance to 
erythromycin and kanamycin in Danish beef compared with 
imported beef.
Lars Bogø Jensen, Lars Stehr Larsen og Helle Korsgaard
DANMAP 2013
Figure 7.2. Resistance (%) in Enterococcus faecium from Danish 
and imported broiler meat, Denmark
Note: The number of isolates varies between years (Danish broiler 
meat: n = 66–145, imported broiler meat: n = 64–107)
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7.2 Indicator Escherichia coli
For indicator E. coli, DANMAP 2013 includes randomly 
collected isolates from healthy pigs, broilers and cattle at 
slaughter and from fresh broiler meat, beef and pork sold at 
wholesale and retail outlets. We included only one isolate per 
farm or meat sample, and present only data where a sufficient 
number of isolates were obtained (>15). For details on 
methodology see Chapter 9, Materials and Methods.
The MIC distributions and occurrence of resistance among E. 
coli are presented in the web annex (Tables A7.4 and A7.5). 
Data for each of the figures are also presented in the web 
annex. Carbapenems are not included in the test panel, but 
E. coli isolated after selective enrichment with 3rd generation 
cephalosporins are examined for carbapenemase and ESBL 
resistance genes (see Textbox 6).
An isolate is considered fully sensitive if susceptible to all 
antimicrobial agents included in the test panel, and multi-
resistant if resistant to three or more of the ten included 
antimicrobial classes (see Table 10.3).
7.2.1 Indicator E. coli from broilers and domestic 
broiler meat
E. coli isolates from broilers (n = 125) were most often resistant 
to sulfonamide and ampicillin (both 26%, Table 7.3). Resistance 
was comparable to the levels observed in 2012, except for an 
increase in trimethoprim resistance. Over the last five years 
resistance to ampicillin and sulfonamide has increased whereas 
resistance to fluoroquinolones (ciprofloxacin) has declined 
(Figure 7.3). In 2013, resistance to tetracycline increased, 
apparently reflecting the increased use of this antibiotic in 
poultry production.
Ampicillin resistance conveys cross-resistance to amoxicillin 
which has been the most frequently used antimicrobial 
agent in the broiler production for at least a decade whereas 
sulfonamides have only been used in the last 2-3 years. Historical 
use of sulfonamide and co-selection by ampicillin may partly 
explain the occurrence of sulfonamide resistance, however in 
2013 sulfonamide use in poultry increased markedly. 
We found 3% of the E. coli broiler isolates resistant to nalidixic 
acid and 6% to ciprofloxacin. During the period 2003-2007, 
fluoroquinolone consumption in poultry was significantly 
higher than for the other production animal species in 
Denmark, because antimicrobial agents approved for poultry 
were limited to amoxicillin and fluoroquinolones. However, 
since 2008, fluoroquinolone usage in the broilers has been very 
low. One isolate was resistant to colistin but with a MIC <16, 
which is seen occasionally.
Among E. coli isolates (n = 116) from domestic broiler meat, we 
found the highest levels of resistance for ampicillin (24%) and 
sulfonamide (18%). Resistance was comparable to the levels 
observed in 2012 and the the occurrence of ciprofloxacin and 
nalidixic acid resistance remained at a low level (5%).
The levels of resistance in E. coli from Danish broiler meat were 
similar to what was found among isolates from Danish broilers 
(Table 7.3).
Among E. coli isolates from Danish broilers and broiler meat, it 
is noteworthy that the level of multi-resistance has more than 
doubled within the past five years; reaching 16% - 18% in 2013, 
while the level of fully sensitive strain has remained relatively 
stable. The increase in multi-resistance is mainly driven by an 
Table 7.3. Resistance (%) among Escherichia coli from animals and meat of Danish and imported origin, Denmark
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 10.3)
DANMAP 2013
Antimicrobial agent
Broilers Broiler meat Cattle Beef Pigs Pork
Danish
%
Danish
%
Imported
%
Danish
%
Danish
%
Imported
%
Danish
%
Danish
%
Imported
%
Tetracycline 15 11 53 12 4 11 35 34 44
Chloramphenicol 0 0 14 2 4 6 5 6 4
Florfenicol 0 0 5 2 4 6 1 0 0
Ampicillin 26 24 64 4 4 9 29 27 36
Cefotaxime 1 2 9 0 0 3 0 1 0
Ceftiofur 2 2 9 0 0 0 0 1 0
Trimethoprim 19 12 40 1 0 6 28 25 34
Sulfonamide 26 18 57 8 4 9 37 34 36
Streptomycin 8 9 48 8 4 9 42 44 44
Gentamicin 0 0 2 0 0 3 2 0 2
Neomycin 1 0 7 0 0 0 2 4 4
Apramycin 0 0 1 0 0 0 1 0 0
Ciprofloxacin 6 5 36 0 0 3 1 1 10
Nalidixic acid 3 5 35 0 0 3 1 1 10
Colistin 1 0 1 0 0 0 1 0 0
Spectinomycin 2 2 34 1 0 3 19 19 20
Fully sensitive 57 62 15 88 96 86 42 46 38
Multi-resistant 18 16 67 8 4 9 35 31 38
Number of isolates 125 116 136 103 24 35 146 93 50
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increase in occurrence of the ASSuTr phenotype (Figure 7.4) 
and the increased use of tetracycline in poultry may be a driver 
in this trend.
Resistance to cephalosporins (ceftiofur and cefotaxime) was 
observed in 1%-2% of the E. coli isolates from Danish broiler 
meat. Based on a more sensitive selective enrichment method, 
a high level of cephalo spori nase producing E. coli (ESC) was 
also observed in broiler meat (see Textbox 6).
 
7.2.2 Indicator E. coli from cattle and domestic 
beef 
In cattle, we found similar levels of resistance in E. coli isolates 
(n = 103) as in 2012. The highest levels of resistance were found 
for tetracycline (12%), sulfonamide (8%) and streptomycin 
(8%, Table 7.3). The level of multi-resistance has remained at 
the same level, fluctuating between 2% and 8% during the past 
five years. 
As in cattle, the levels of resistance in E. coli isolates (n = 24) 
from Danish beef were very low, and at the same level as in 
2012.
None of the E. coli isolates from cattle or Danish beef were 
resistant to cephalosporins (ceftiofur and cefotaxime) or to 
quinolones (ciprofloxacin and nalidixic acid). The use of 
fluoroquinolones in cattle has been negligible since 2003, and 
the use of 3rd and 4th generation cephalosporins has been 
gradually decreased since 2008 (Figure 4.5).
7.2.3 Indicator E. coli from pigs and pork 
Resistance to ampicillin (29%), streptomycin (42%), 
sulfonamide (37%) and tetracycline (35%) was common in 
E. coli isolates from pigs (n = 146, Table 7.3). Resistance was 
comparable to the levels observed in 2012, and the trend analysis 
over the period 2009-2013 shows an increasing occurrence of 
resistance to ampicillin (Figure 7.3). 
Overall, we found 35% of the isolates from pigs were multi-
resistant (Table 7.3. The level of multi-resistance in E. coli from 
Danish pigs has been comparable during 2008-2013. This 
coincides with an increasing use of antibiotics, among them 
tetracyclines, in Danish pig production in recent years.
Among the E. coli isolates (n = 146) from Danish pork the level 
of resistance to streptomycin (44%), tetracycline (34%), and 
sulfonamide (34%), ampicillin (27%) as well as multi-resistance 
was similar to 2012  (Figure 7.3 and Table 7.3). 
The level of fluoroquinolone (ciprofloxacin) resistance remained 
very low at one percent. This reflects the low consumption of 
fluoroquinolones in pigs since 2002–2003 (web annex, Table 
A4.1), when the use in production animals was restricted 
by legislation. Also, occurrence of cephalosporin (ceftiofur 
and cefotaxime) resistance remained very low; we observed 
only one such resistant isolate from Danish pork. The use of 
cephalosporins in pigs has been close to zero since July 2010, 
when a voluntary ban was adopted by the industry. 
Surveillance based on selective methods has shown a decrease 
in the number of cephalosporin resistant (ESC) in samples 
from pigs at slaughter in 2011–2013 compared with 2009–2010 
(see Textbox 6).
 
Figure 7.3. Resistance (%) in Escherichia coli  from animals and meat of Danish and imported origin, Denmark
Note: The number of isolates varies between years (broilers: n = 115-152, Danish broiler meat: n = 116–197, imported broiler meat: n =136–221, 
pigs: n = 146–160, Danish pork: n = 68–106 and imported pork: n = 30–65)
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Figure 7.4. Occurence (%) of multi-resistant(a b c) and fully sensitive Escherichia coli from animals and meat of Danish and imported 
origin, Denmark
Note: The number of isolates varies between years (broilers: n = 115–152, Danish broiler meat: n = 116–197, imported broiler meat:
n = 136–221, pigs: n = 146-160, Danish pork: n = 68–106, imported pork: n = 30–65)
a) An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the test panel and multi-resistant if resistant to 
three or more of the ten antimicrobial classes (see Table 10.3)
b) ‘ASSuT’ isolates are resistant to ampicillin, streptomycin, sulfonamide and tetracycline, but can include resistant to other antimicrobial agents 
such as chloramphenicol
c) ‘ASuTr’ isolates are resistant to ampicillin, sulfonamide and trimethoprim, but can include resistant to other antimicrobial agents such as 
chloramphenicol
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7.2.4 Indicator E. coli from imported meat
The level of multi-resistance (67%) in imported broiler meat 
was considerably higher compared to Danish broiler meat 
(16%, Table 7.3), and also compared to other Danish meat 
types included in the DANMAP programme.
The highest occurrences of resistance in E. coli isolates (n = 136) 
from imported broiler meat were found for ampicillin (64%), 
sulfonamide (57%), tetracycline (53%) and streptomycin 
(48%). One isolate was resistant to colistin with a MIC <16. 
For almost all antimicrobial agents in the test panel (except for 
gentamycin, apramycin and colistin) the level of resistance was 
significantly higher for imported broiler meat than in broiler 
meat of domestic origin (Figure 7.3, Table 7.3). The exceptions 
were gentamycin, apramycin og colistin, where only one isolate 
among the isolates from imported broiler meat was resistant 
and none from the Danish broiler Meat.
In imported beef, 86% of the E. coli isolates (n = 35) were fully 
sensitive and three isolates (9%) multi-resistant (Table 7.3). The 
level of fully sensitive and multi-resistant isolates in imported 
beef has not changed during the past 5 years, and is similar 
to what we find in Danish beef. One isolate was resistant to 
quinolones (ciprofloxacin and nalidixic acid) and one to 3rd 
generation cephalosporins (cefotaxime).
The highest occurrence of resistance in E. coli isolates (n = 50) 
from imported pork was for tetracycline and streptomycin 
(44%), ampicillin and sulfonamide (36%), and trimethoprim 
(34%), Table 7.3). Overall, 38% of the isolates were multi-
resistant, a decline from 47% in 2012 (Figure 7.4). Resistance 
to fluoroquinolones (ciprofloxacin) was found in five isolates 
whereas cephalosporin (ceftiofur cefotaxime) resistance was 
not observed. Compared with Danish pork, resistance to 
quinolones (ciprofloxacin and nalidixic acid) was significantly 
higher in imported pork (Figure 7.4). 
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7.2.5 One Health Perspective 
We use E. coli as an indicator organism for antimicrobial 
resistance because it is a commensal in both mammals and 
birds and commonly present on raw meat. Using phenotypic 
resistance as a marker, our data indicate that E. coli in slaughter 
animals and in the derived meat constitute overlapping bacterial 
populations (Table 7.3). Therefore, meat has the potential to 
act as a vehicle transferring antimicrobial resistance from food 
animals to humans. Furthermore, some of these E. coli strains 
are virulent with a zoonotic potential for disease in humans 
[DANMAP 2010, Textbox 6].
Transfer of genes coding for resistance to antimicrobial 
agents that are critically important in human medicine such 
as third generation cephalosporins is especially worrisome, 
as is transmission through food of E. coli resistant to 
fluoroquinolones. Resistance to fluoroquinolones is generally 
low in Danish animals, but higher in imported meats, in 
particular broiler meat (Figure 7.4). This also applies to 
cephalosporin resistance. Resistance to cephalosporins is 
presently increasing internationally in the animal reservoir, 
causing great concern both nationally and internationally. 
Cephalosporin resistance commonly resides on mobile genetic 
elements, e.g. plasmids, and therefore may be transferred 
between bacteria, in addition to clonal spread of E. coli strains.
Multi-resistance is of importance, because high levels of 
resistance decrease the number of good first choice antibiotics 
available for treatment of infections in humans and because it 
increases the risk of selection of antimicrobial resistance. As 
an example, if resistance to fluoroquinolone (chromosomal) 
or ESBL (plasmid) develops, the risk of co-selection through 
use of “old antimicrobial agents” (such as tetracycline, 
sulfonamide and penicillin) in the same bacterium increases 
with the occurrence of multi-resistance. Resistance to these 
antimicrobial agents is common in E. coli from Danish pigs and 
pork, as well as imported broiler meat, where we also observed 
high levels (>30%) of multi-resistance (Figure 7.3 and 7.4).
With co-resistance to critically important antimicrobial agents, 
the risk of maintenance and spread of the critical important 
antimicrobial resistance through use of another class of 
antimicrobial agents increases markedly, in particular when 
resistance determinants are located on mobile genetic elements. 
High levels of resistance and multi-resistance contribute to a 
reduced number of antimicrobial agents available for use in 
human medicine, thus limiting the solutions for treating human 
illness, se section 8.1 regarding human E. coli infections.
Flemming Bager, Lars Stehr Larsen and Helle Korsgaard
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Occurrence of Extended spectrum beta-lactamase (ESBL)-producing Escherichia coli in 
meat and slaughter pigs, but no sign of carbapenemase producing E. coli
Background: Extended spectrum beta-lactamase (ESBL)-producing bacteria is one of the fastest emerging resistance 
problems worldwide in both humans and production animals. Lately, several studies have found the same ESBL genes, 
plasmids and clones of E. coli isolates originating from animals and involved in human infections, suggesting a zoonotic 
link. 
The occurrence of Enterobacteriaceae resistant to carbapenems is a growing threat in human medicine as carbapenems 
are the last line antimicrobial agents for treatment of infections caused by multidrug resistant Gram-negative bacteria; 
this has been pointed out by both EFSA and ECDC. The presence of carbapenemase producing bacteria in food-
producing animals is not known, but recently carbapenemase producing E. coli has been detected in livestock pigs in 
Germany, and carbapenemase producing Salmonella enterica subsp. enterica has been detected in both livestock pigs 
and poultry in Germany [Fischer et al. 2012. J. Antimicrob Chemother. 67:1793-5]. The presence and possible spread 
of carbapenemase producing bacteria in production animals is thus considered extremely important for the assessment 
of potential zoonotic risks.
Carbapenems are not used in the Danish animal production. Both ESBL and carbapenem resistance can be driven by 
use of cephalosporins. In July 2010, the use of cephalosporins in the Danish pig production was discontinued, but it is 
still used for systemic and intramammary treatment in cattle. Cephalosporins have not been used in the Danish broiler 
production for at least a decade, but was used outside of Denmark in the production of grandparent animals of the 
Danish broilers before 2012. 
The aim of this study was to investigate the occurrence of ESBL/carbapenemase-producing E. coli in pigs at slaugther 
and in meat at retail (see Chapter 10. for definition of ESBL).
Materials and methods: During January through December 2013, faecal samples were taken from pigs at slaughter (n 
= 381). One animal represented one herd and no herds were sampled more than once in the same month. In the same 
period, broiler meat (Danish: n = 146, imported: n = 172), beef (Danish: n = 70, imported: n = 102) and pork (Danish: n 
= 238, imported: n = 225) samples were collected randomly in retail stores and outlets in all regions of Denmark. E. coli 
was isolated from 1 g of faecal sample or 5 g of meat after selective enrichment in McConkey media with ceftriaxone (1 
µg/ml). The genetic background for ESBL-resistance was revealed by use of whole genome sequencing (WGS). The reads 
were assembled de novo prior to prediction of genes. The web-server ResFinder (www.genomicepidemiology.org.) was 
used to identify acquired ESBL and carbapenemase genes in the WGS data. For isolates where no genes were detected, 
the sequences were investigated for up-regulation of chromosomal ampC by use of CLCbio Genomic Workbench v6. 
Results: For pigs at slaughter, 5.8% (22/381) contained ESBL-producing E. coli, which was significantly lower than in 
2009 (11%) and in 2010 (12%). Among the ESBL producing E. coli isolates from pigs the most commonly detected gene 
was, as in previous years, CTX-M-1 (59%) followed by CMY-2 (18%), ampC upregulation (14%) and CTX-M-14 (9%) 
(Figure 1). From meat samples, the highest prevalence of ceftriaxone resistant E. coli was found among imported broiler 
meat (52%, 89/172) and were at the same level as in 2010 to 2012 (between 50 % to 62%). The prevalence (25%, 36/146) 
of ceftriaxone resistant E. coli in Danish broiler meat was significantly lower than in 2012 and a decreasing trend 
since 2011, where the occurrence of ceftriaxone resistant E. coli (44%) was the  highest  observed. The occurrence of 
ceftriaxone resistant E. coli was significantly higher in imported broiler meat when compared with Danish broiler meat.
 
Among ESBL producing E. coli isolates the most commonly detected gene in Danish broiler meat was, as found in 
previous years, CMY-2 (83%), whereas CTX-M-1 (37%) and CMY-2(42%) were almost equally present in imported 
broiler meat. Eight isolates of the ESBL-producing isolates from broiler meat contained two ESBL genes. In the other 
meat types the prevalence was generally low (0-1.4%, Figure 2). None of the isolates from meat and slaughter pigs 
contained any known carbapenemase genes.
Discussion: The usage of cephalosporins was still low (approximately 3 kg in total, Table 4.1) compared with usage of 
other antimicrobial agents, and the occurrence of cephalosporinase producing E. coli in slaughter pigs was significantly 
lower than than before the voluntary ban of cephalosporin usage in the Danish pig production was effectuated.
The occurrence of cephalosporinase producing E. coli in Danish produced broiler meat was significantly lower in 
2012 than in 2011, which could be explained by the voluntary discontinuation of the use of 3rd generation 
cephalosporins in the top of the breeding pyramid (in the country producing the grandparents for the Danish 
broilers) leading to a reduction in imported parentflocks, but other explanations may also exist.
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Since none of the tested ESBL-producing E. coli isolates contained known carbapenemase genes, meat or food-producing 
animals in Denmark are most likely not a source to carbapenemase producing bacteria causing human infections in 
Denmark; however monitoring of carbapenemase producing bacteria in animals and meat is still important as the situation 
may change over time.
Conclusion: The voluntary ban of cephalosporins in the pig production seems to retain the ESBL producing E.coli in pigs 
at slaughter at a low level. For the first time a significant reduction in the occurrence of ESBL producing E. coli in Danish 
broiler meat was observed, which could be due to less introduction of ESBL producing E. coli from imported parent 
animals, but this was not investigated in this study and also other factors may influence the occurence. 
ESBL genes found in ESBL-producing E. coli from human infections are still present in pork and pigs, and broiler meat 
from both Danish and imported origin. A possible zoonotic link will be studied further in the coming years.
Currently, and based on the data presented here, carbapenemase producing E. coli from meat or food-producing animals 
are considered a low ,if any, risk to human health.
Yvonne Agersø, Rolf Sommer Kaas, Henrik Hasman 
For further information: Yvonne Agersø (yvoa@food.dtu.dk)
Figure 1.  Occurrence (%) of ESBL Escherichia coli and genes in pig from samples collected at farm and slaughterhouse 
level, Denmark
Note: E. coli was isolated after selective enrichment in McConkey media with ceftriaxone (1 μg/ml). The genetic background for 
ESBL resistance was revealed by use of PCR, micro array and DNA sequencing
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Figure 2. Occurrence (%) of ESBL Escherichia coli and genes in meat(a), Denmark
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8. Resistance in human clinical bacteria
8.1 Escherichia coli
Escherichia coli is part of the normal intestinal flora of both 
humans and animals but also cause infections. In humans, E. 
coli is the most frequent cause of bacteraemia and community- 
and hospital-acquired urinary tract infections. For E. coli, 
DANMAP 2013 includes data from 10 out of 11 Departments 
of Clinical Microbiology (DCM), representing 95% of the 
Danish population. Nine of the 10 DCM working with primary 
healthcare isolates contributed data on antimicrobial resistance 
in urine isolates of E. coli from primary healthcare (Table 8.1).
 
Blood isolates from hospital patients           
DANMAP received data on the antimicrobial susceptibility of 
approximately 4,000 E. coli isolates from blood (Table 8.1 and 
Figure 8.1).
In 2013, resistance to 2nd generation cephalosporins 
(cefuroxime) was 9% and resistance to 3rd generation 
cephalosporins 8%. Both levels are similar to the levels reported 
in 2012. The level of 3rd generation cephalosporin resistance 
in Denmark was above the level reported to EARS-Net by the 
other Nordic countries and corresponded to the occurrence 
reported by other European countries in 2012 [EARS-Net 
2012].
DANMAP 2013Table 8.1. Resistance (%) in Escherichia coli isolates from humans, Denmark
#) A number sign indicates a significant decrease from 2012 to 2013
a) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime and cefotaxime
Substance Blood isolates, hospitals Urine isolates, hospitals Urine isolates, primary healthcare
% % %
Ampicillin 46 42 40
Mecillinam 10 8 6
Piperacillin/tazobactam 4
Sulfonamide 33 33
Gentamicin 7 5
Ciprofloxacin 12 # 12 10
Cefuroxime 9 6
3rd generation cephalosporins a) 8 6 4
Meropenem <1 <1 <1
Max. number of isolates tested 3967 39820 43770
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Figure 8.1. Resistance (%) in Escherichia coli blood isolates from humans, Denmark
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2013
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One carbapenem (meropenem) resistant E. coli blood isolate 
was reported in 2012.
The occurrence of ciprofloxacin resistance decreased from 14% 
in 2012 to 12% in 2013. This level was the same as reported by 
many other countries in Europe [EARS-Net 2012].
Aminoglycoside (gentamicin) resistance was 7%, which is at 
the same level as reported in 2012. This level was the same as 
reported by many other countries in Europe [EARS-Net 2012].
Mecillinam resistance was 10% and ampicillin resistance 
was 46% in 2013, which are at the same levels as in 2012. 
Resistance data on piperacillin/tazobactam was reported for 
the first time in the present DANMAP report. The DCMs were 
asked to report resistance data for five years (2009-2013) (Table 
8.1 and Figure 8.1). In all five years, the resistance was at the 
same level around 4%.
In the 10-year period from 2004 to 2013, resistance in E. 
coli blood isolates has increased steadily: resistance to 2nd 
generation cephalosporins from 3% to 9%; ciprofloxacin 
resistance from 5% to 12%; aminoglycoside (gentamicin) 
resistance from 2% to 7%. These increases parallel the increased 
antimicrobial consumption, which has been seen in the same 
period (Table 5.4).
Urine isolates from hospital patients
DANMAP received data on the antimicrobial susceptibility of 
approximately 40,000 E. coli isolates from hospital patients with 
a urinary tract infection (Table 8.1 and Figure 8.2).
The occurrence of resistance to 2nd generation cephalosporin 
(cefuroxime) (6%) and 3rd generation cephalosporin (6%) 
were at the same level as in 2012.
In 2013, carbapenem (meropenem) resistance was observed in 
five E. coli urine isolates from hospitalised patients.
The occurrence of ciprofloxacin resistance was at the same level 
as in 2012, but a steady increase has been seen in ciprofloxacin 
resistance from 3% in 2004 to 12% in 2013 (Figure 8.2).
Aminoglycoside (gentamicin) resistance was 5% and 
sulfonamide resistance was 33%, which are at the same levels 
as in 2012.
Urine isolates from primary healthcare
DANMAP received data on the antimicrobial susceptibility 
of approximately 44,000 E. coli isolates from urinary tract 
infection in patients from primary healthcare (Table 8.1 and 
Figure 8.3).
The occurrence of resistance to 3rd generation cephalosporin 
was 4% and this was the same level as reported in 2012.
Since 2003, the level of ciprofloxacin resistance has increased 
steadily from 3% in 2004 to 10% in 2013 (Figure 8.3), which 
parallels the increasing trend observed in the consumption of 
fluoroquinolones during the last decade (Table 5.2).
The occurrence of ampicillin resistance was 40% and 
sulfonamide resistance was 33%, both levels were similar to 
levels reported in 2012. 
In 2013, carbapenem (meropenem) resistance was observed in 
five E. coli urine isolates from primary healthcare. 
Line Skjøt-Rasmussen, Stefan S. Olsen 
and Anette M. Hammerum
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Figure 8.2. Resistance (%) in Escherichia coli urine isolates from humans in hospitals, Denmark
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2013
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Figure 8.3. Resistance (%) in Escherichia coli urine isolates from humans in primary healthcare, Denmark
Note: The number (n) in parentheses represents the number of isolates tested for susceptibility in 2013
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8.2 Klebsiella pneumoniae
Klebsiella pneumoniae is part of the normal intestinal flora 
in humans but also cause infections such as urinary tract-, 
respiratory tract-, wound- and bloodstream infections. Many of 
these infections are hospital acquired and can be life threatening, 
especially if the strains are resistant to antimicrobial agents. K. 
pneumoniae is intrinsically resistant to aminopenicillins (e.g. 
ampicillin). Therefore, infections caused by K. pneumoniae 
are treated with broad spectrum antimicrobial agents such as 
ciprofloxacin, gentamicin, cephalosporins and carbapenems. 
For K. pneumoniae, DANMAP 2013 includes data from 10 
out of 11 DCM, representing 95% of the Danish population. 
Nine of the 10 DCM working with primary healthcare isolates 
contributed data on antimicrobial resistance in urine isolates of 
K. pneumoniae from primary healthcare (Table 8.2).
Blood isolates from hospital patients
DANMAP received data on the antimicrobial susceptibility of 
approximately 900 K. pneumoniae isolates from blood (Table 
8.2 and Figure 8.4).
Ciprofloxacin resistance (9%), and resistance to aminoglycoside 
(gentamicin) (4%) were similar to the level reported in 2012.
The level of resistance to ciprofloxacin was above the level 
reported from the other Nordic countries and the same 
as reported to EARS-Net by other European countries in 
2012 [EARS-Net 2012]. Whereas, the level of resistance to 
aminoglycosides was the same as in the other Nordic countries 
reporting to EARS-Net [EARS-Net 2012].
#) A number sign indicates a significant decrease from 2012 to 2013
a) Tested 3rd generation cephalosporins were ceftazidime, ceftriaxone, cefpodoxime and cefotaxime
DANMAP 2013Table 8.2. Resistance (%) in Klebsiella pneumoniae isolates from humans, Denmark
Substance
Blood isolates, hospitals Urine isolates, hospitals Urine isolates, primary healthcare
% % %
Mecillinam 8 10 # 10
Piperacillin/tazobactam 6
Sulfonamide 20 # 22 #
Gentamicin 4 4 #
Ciprofloxacin 9 8 7
Cefuroxime 12 9 #
3rd generation cephalosporins a) 9 7 # 6
Meropenem <1 <1 <1
Max. number of isolates tested 879 5919 3660
In general, the level of antimicrobial resistance in 2013 was 
similar to 2012 (Figure 8.4).
Resistance to 2nd generation cephalosporins (cefuroxime) was 
12% and resistance to 3rd generation cephalosporins was 9%. 
In 2013, 3rd generation cephalosporin resistance was above the 
level reported to EARS-Net by the other Nordic countries and 
corresponded to the occurrence reported by other European 
countries in 2012 [EARS-Net 2012]. 
In 2013, two carbapenem (meropenem) resistant K. pneumoniae 
blood isolates were detected.
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Urine isolates from hospital patients
DANMAP received data on the antimicrobial susceptibility 
of approximately 5,900 K. pneumoniae isolates from hospital 
patients with a urinary tract infection (Table 8.2 and Figure 
8.5).
Resistance to mecillinam (10%), sulfonamide (20%), 
gentamicin (4%), 2nd generation cephalosporins (cefuroxime) 
(9%) and to 3rd generation cephalosporins (7%) decreased 
from 2012 to 2013. Ciprofloxacin resistance was at the same 
level as reported in 2012.
In 2013, carbapenem (meropenem) resistance was observed in 
eight K. pneumoniae urine isolates from hospitalised patients. 
Urine isolates from primary healthcare
DANMAP received data on the antimicrobial susceptibility of 
approximately 3,600 K. pneumoniae isolates from urinary tract 
infection in patients from primary healthcare (Table 8.2 and 
Figure 8.6).
In 2013, resistance to 3rd generation cephalosporins was 6%, 
which is similar to the level reported in 2012. 
In 2013, three carbapenem (meropenem) resistant K. 
pneumoniae urine isolates from patients in primary healthcare 
were found.
Resistance to ciprofloxacin was 7% and resistance to mecillinam 
was 10%, which were similar to the levels reported in 2012. 
Sulfonamide resistance decreased from 26% in 2012 to 22% 
in 2013.
Line Skjøt-Rasmussen, Stefan S. Olsen 
and Anette M. Hammerum
Figure 8.5. Resistance (%) in Klebsiella pneumoniae urine 
isolates from humans in hospitals, Denmark
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2013
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Figure 8.6. Resistance (%) in Klebsiella pneumoniae urine 
isolates from humans in primary healthcare, Denmark
Note: The number (n) in parentheses represents the number of 
isolates tested for susceptibility in 2013
DANMAP 2013
Figure 8.4. Resistance (%) in Klebsiella pneumoniae blood 
isolates from humans, Denmark
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2013
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carbapenemase producing bacteria in Denmark
Background: Carbapenems comprise one of the only classes of antimicrobial agents that can be used for treatment 
of infections with multi-resistant bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa 
and Acinetobacter baumannii. Treatment options for infections with carbapenem resistant bacteria are often none 
or suboptimal. Resistance can be caused by the presence of various carbapenemases of which the most frequently 
occurring are K. pneumoniae carbapenemase (KPC), Oxacillinase (OXA), Verona integron-encoded metallo-β-
lactamase (VIM), and New Delhi metallo-β-lactamase (NDM). Furthermore, Imipenemase (IMP) can be detected in 
P. aeruginosa isolates.
In recent years, Danish Departments of Clinical Microbiology (DCM) have, on a voluntary basis, submitted carbapenem 
resistant isolates for verification and genotyping at the Antimicrobial Resistance Reference Laboratory at Statens Serum 
Institut. The present textbox describes carbapenemase producing Enterobacteriaceae (CPE), and carbapenemase 
producing P. aeruginosa and A. baumannii. 
During 2013, 35 carbapenemase producing bacteria were detected. More than one isolate from the same patient were 
included, if the isolates belonged to different bacterial species and/or if the isolates harboured different carbapenemases. 
In many of the cases, the carbapenemase producing isolates were related to travelling, but spread between patients in 
Denmark was also reported for both Enterobacteriaceae and A. baumanii in 2013.
Enterobacteriaceae: In 2013, 18 CPE were detected compared to 19 CPE during 2008–2012 (Figure 1). Fifteen of  the 18 
isolates harboured NDM genes (K. pneumoniae (n = 4), Citrobacter freundii (n = 4), E. coli (n = 2), Providencia stuartii 
(n = 2) and Proteus mirabilis (n = 1)), OXA-48 was detected in 3 isolates (K. pneumonia (n = 2), E. coli (n = 1)), and 
KPC (K. pneumoniae (n = 1)) and VIM (Klebsiella oxytoca (n = 1)) in one isolate each.  
During 2013, the first spread of CPE in Denmark was confirmed by comparing epidemiological information with 
molecular data. The first spread of CPE was between two patients, who had been admitted to the same ward in a hospital 
in the North Denmark Region in 2012. None of these patients had a prior history of travel noted in their hospital 
records. In 2013, it was shown by molecular typing that the patients shared the same VIM-4 producing E. coli. This was 
the first detected spread of CPE in Denmark. The origin of VIM-4 producing E. coli was unknown. 
In 2013, NDM-1 producing C. freundii isolates were detected from four patients at the same hospital ward in the North 
Denmark Region. Spread of NDM-1 C. freundii was shown by molecular typing and comparison of epidemiological 
data. None of the four patients had been travelling recently and the origin of the NDM-1 producing C. freundii was 
unknown. Besides the NDM-1 producing C. freundii, two of the four patients had NDM-1 producing K. pneumoniae. 
A. baumannii: During 2013, seven OXA-23 producing A. baumannii isolates were detected. Spread of OXA-23 
producing A. baumannii was detected two times from one patient to another patient.  Furthermore, three OXA-40-
like producing A. baumannii were detected, two of these being part of the same transmission chain. Furthermore, two 
NDM-1 producing A. baumannii isolates were detected.
 
P. aeruginosa: In 2013, three VIM producing P. aeruginosa isolates were detected. Furthermore, an NDM and VIM 
producing P. aeruginosa was detected. For the first time, an IMP producing P. aeruginosa isolate was detected in 
Denmark. Both patients had been hospitalized abroad prior to detection of these isolates.    
Conclusion: The occurrence of carbapenemase-producing bacteria in Denmark is increasing. Most isolates were 
multi-resistant, which makes infections caused by these bacteria extremely difficult to treat with antimicrobial agents. 
The increasing trend of carbapenemase producing bacteria is therefore worrying. Especially the spread of CPE is of 
concern, since Enterobacteriaceae can be carried in the intestine for a long time without any symptoms of infections, 
which makes infection control difficult.   
Anette M. Hammerum, Frank Hansen and Lotte Jakobsen 
For further information: Anette M. Hammerum (ama@ssi.dk)
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Figure 1. Numbers of carbapenemase-producing Enterobacteriaceae (cPE)
Note: More than one isolate was included from the same patient, if the isolates belonged to different bacterial species and/or 
harboured different carbapenemases.
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8.3 Pseudomonas aeruginosa
Pseudomonas aeruginosa is an opportunistic pathogen of 
immunocompromised individuals. P. aeruginosa typically 
infects the pulmonary tract, urinary tract, burns, wounds, and 
also causes other bloodstream infections. It is the most frequent 
coloniser of medical devices (e.g. catheters). P. aeruginosa 
infection is a serious problem in patients hospitalised with 
cancer, cystic fibrosis and burns. The case fatality rate in these 
patients is high. P. aeruginosa is intrinsically resistant to the 
majority of antimicrobial agents. The antimicrobial classes 
which can be used for treatment include some fluoroquinolones 
(e.g. ciprofloxacin and levofloxacin), aminoglycosides (e.g. 
gentamicin, tobramycin and amikacin), some beta-lactams 
(piperacillin-tazobactam, ceftazidime, and carbapenems) and 
colistin.
P. aeruginosa blood isolates obtained from hospitalised 
patients
For P. aeruginosa, DANMAP 2013 includes data from 10 out of 
11 Departments of Clinical Microbiology (DCM), representing 
95% of the Danish population. DANMAP received data on the 
antimicrobial susceptibility of approximately 414 P. aeruginosa 
isolates from blood. Resistance to all the tested antimicrobial 
agents was not significantly different from the level in 2012, 
but an increasing trend has been observed for gentamicin 
during 2007–2013 (Figure 8.7). The occurrence of resistance to 
fluoroquinolones, carbapenems, ceftazidime and piperacillin/
tazobactam was at the same level or lower than most of the 
other countries reporting to EARS-Net in 2012 [EARS-Net 
2012].
Meropenem resistance was observed for 3% (n = 12) of the P. 
aeruginosa isolates in 2013. A Danish study of P. aeruginosa 
carbapenem non-susceptible isolates from 2011 showed that 
carbapenemases were present in a minority of the isolates 
(7%) [Textbox 11, DANMAP 2012]. As in previous years, 
presumable carbapenemase producing  P. aeruginosa isolates 
were sent  on  a voluntary basis from the DCM to SSI for 
national surveillance on carbapenemase producing bacteria, 
including not only isolates from bloodstream infections but 
also from other origins. During 2013, three VIM producing P. 
aeruginosa isolates and an NDM and VIM producing isolate 
were identified. For the first time an IMP producing isolate was 
detected in Denmark [Textbox 7].
Anette M. Hammerum, Stefan S. Olsen 
and Line Skjøt-Rasmussen
Figure 8.7. Resistance (%) in Pseudomonas aeruginosa blood 
isolates from humans, Denmark
Note: The number (n) in parentheses represents the number of isolates 
tested for susceptibility in 2013
DANMAP 2013
8.4  Streptococci
Streptococci are part of the normal commensal flora of 
the mouth, skin, intestine, and upper respiratory tract of 
humans, however they also cause infections such as otitis 
media, tonsillitis, bacterial pneumonia, bacteraemia/sepsis, 
endocarditis and meningitis.
In this report, data on resistance in invasive streptococcal 
isolates (only from blood or cerebrospinal fluid) were obtained 
from the Neisseria and Streptococcus Reference laboratory 
covering all DCM in Denmark. Infections with streptococci are 
primarily treated with penicillins and macrolides. All invasive 
non-duplicate Streptococcus pneumoniae and group A, B, C and 
G streptococci were susceptibility tested against erythromycin 
and penicillin.
Streptococcus pneumoniae
S. pneumoniae is a leading cause of bacterial pneumonia, otitis 
media, bacteraemia and meningitis. In 2013, susceptibility 
testing was performed on 824 non-duplicate S. pneumoniae 
isolates from invasive infections (blood and spinal fluid) 
(Figure 8.8).
A total of 42 (5.1%) S. pneumoniae invasive isolates from blood 
and cerebrospinal fluid were non-susceptible (resistant and 
intermediary resistant) to erythromycin in 2013 compared to 
5.4% in 2012 (Figure 8.8). The 42 isolates belonged to 12 different 
serotypes and the most commonly found erythromycin non-
susceptible serotypes were type 15A (n = 19), 19A (n = 7) and 
24F (n = 4). 
Regarding penicillin, 52 (6.3%) invasive isolates from blood 
and cerebrospinal fluid were non-susceptible (resistant and 
intermediary resistant) in 2013 compared to 5.1% in 2012 
(Figure 8.8). The 52 isolates belonged to 12 different serotypes 
and the most commonly found penicillin non-susceptible 
serotypes were type 15A (n = 20), 23B (n = 10) 19A (n = 8) and 
24F (n = 4). None of the isolates were resistant to penicillin 
according to EUCAST.
Four serotypes were particularly non-susceptible to either 
penicillin or erythromycin or both, namely 15A (20 of 32 
received isolates), 23B (10 of 16 received isolates), 19A (8 of 29 
received isolates) and 24F (4 of 22 received isolates). 
The levels of erythromycin (macrolide) and penicillin non-
susceptibility in Denmark were similar to the levels reported 
in 2012 to EARS-Net by the neighboring countries Norway, 
Sweden, Germany and the United Kingdom. Many other 
European countries reported considerably higher levels of 
resistance in 2012 [EARS-Net 2012].
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Figure 8.8. Nonsusceptibility (%) in Streptococcus pneumoniae 
blood and spinal fluid isolates from humans, Denmark
DANMAP 2013
Group A streptococci
In 2013, susceptibility testing was performed on 167 non-
duplicate group A streptococci (GAS, Streptococcus pyogenes) 
isolates from invasive infections (blood and spinal fluid). 
Erythromycin resistance was detected in five isolates (3.0%) as 
compared to one isolate in 2012 (0.6% of 167). No resistance to 
penicillin was detected.
Group B, C and G streptococci
In 2013, susceptibility testing was performed on 129 non-
duplicate group B streptococci (GBS, Streptococcus agalactiae) 
isolates from invasive infections (blood and spinal fluid). 
Erythromycin resistance was detected in 22 isolates (17.1 %) 
as compared to 17 in 2012 (12.7% of 134). No resistance to 
penicillin was detected.
In 2013, susceptibility testing was performed on 66 non-
duplicate group C streptococci (GCS, Streptococcus equisimilis 
and S. zooepidemicus) isolates from invasive infections (blood 
and spinal fluid). Erythromycin resistance was detected in 
3 isolates (4.5%) as compared to 4 in 2012 (5.5% of 73). No 
resistance to penicillin was found.
In 2013, susceptibility testing was performed on 154 non-
duplicate group G streptococci isolates from invasive infections 
(blood and spinal fluid). Erythromycin resistance was detected 
in 16 isolates (10.4%) as compared to 17 in 2012 (10.6% of 160). 
No resistance to penicillin was found.
Tine Dalby, Hans-Christian Slotved and Steen Hoffmann
8.5 Enterococci
Enterococci are part of the normal intestinal flora of both 
humans and animals but also cause infections. Important 
clinical infections caused by Enterococcus species include 
urinary tract infections, bacteraemia and bacterial endocarditis. 
E. faecalis and E. faecium can cause life-threatening infections in 
humans, especially in the hospital environment. The naturally 
high level of antimicrobial resistance found in E. faecalis and 
E. faecium makes infections difficult to treat. Antimicrobial 
therapy for serious enterococcal infections requires the use 
of synergistic combinations of a cell-wall-active agent such as 
penicillin (ampicillin) and an aminoglycoside (gentamicin) or 
a glycopeptide (vancomycin).
For E. faecalis and E. faecium, data from 10 of the 11 DCM were 
obtained, representing 95% of the Danish population.
Enterococcus faecium and Enterococcus faecalis blood 
isolates obtained from hospitalised patients 
DANMAP received data on the antimicrobial susceptibility of 
657 E. faecium isolates and 579 E. faecalis isolates from blood.
As in previous years, most of the E. faecium isolates from 
bloodstream infections were ampicillin resistant. In 2013, 93% 
of the E. faecium isolates were resistant to ampicillin. Treatment 
with fluoroquinolones, cephalosporins or carbapenems has 
been described as a risk factor for development of an E. faecium 
infection. An increasing consumption of these antimicrobial 
agents has been observed in hospitals in Denmark during the 
last decade. The antimicrobial selection pressure in a hospital 
environment might be a reason for the high level of ampicillin 
resistant E. faecium as a cause of bloodstream infections.
Only one of the DCMs (Aalborg) tested all enterococcal blood 
isolates for high-level gentamicin resistance (HLGR). Among 
the tested E. faecalis isolates, 27% were HLGR, whereas 68% of 
the tested E. faecium isolates were HLGR. The level of HLGR E. 
faecalis and HLGR E. faecium was similar to or higher than the 
level detected in many European countries reporting to EARS- 
Net in 2012 [EARS-Net 2012].
In 2013, vancomycin resistance was detected in 3.4% of 
the E. faecium isolates (n = 22) and 0.2% (n = 1) of the E. 
faecalis isolates from bloodstream infections. The E. faecium 
bloodstream isolates were part of outbreaks with vancomycin 
resistant (vanA) E. faecium, which is described in Textbox 8. 
The level of vancomycin resistant E. faecium was above the 
level reported to EARS-Net 2012 by the other Nordic countries 
[EARS-Net 2012].
Anette M. Hammerum, Stefan S. Olsen 
and Line Skjøt-Rasmussen
DANMAP 2013  
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Increased occurrence of vancomycin resistant enterococci in Danish hospitals 
Background: Enterococcus faecalis and Enterococcus faecium are commensal bacteria in the intestine of humans. E. faecalis 
and E. faecium can also cause urinary tract infections (UTI) and fatal infections like sepsis and endocarditis, especially 
among older patients. Enterococci are intrinsically resistant to a number of first-line antimicrobial agents including 
cephalosporins. Therefore therapy of enterococcal infections may be difficult. Severe enterococcal infections are primarily 
treated with vancomycin, but recently an increase in the occurrence of vancomycin resistant enterococci (VRE) has been 
observed in Denmark and internationally. Many of the VRE are also resistant to ampicillin and gentamicin limiting the 
treatment possibilities. Newer antibiotics such as linezolid and daptomycin can be used for treatment of VRE, but both 
antimicrobial agents have many side effects. 
Surveillance of  VRE: Since 2005, Danish Departments of Clinical Microbiology (DCM) have, on a voluntary basis, 
submitted vancomycin resistant enterococci for species identification, genotyping (vanA, vanB, vanC) and surveillance 
to the Antimicrobial Resistance Reference Laboratory at Statens Serum Institut (Figure 1). 
In 2010 and 2011, an increase in the number of vanA E. faecium was detected at hospital wards in the Central Denmark 
Region and screening of faecal samples was initiated [DANMAP 2010 and DANMAP 2011]. 
In 2012, 54 VRE isolates from clinical infections (UTI, wounds and bloodstream infections) were received at SSI (only 
one isolate per patient was included) (Figure 1). In 2013, the number increased further to 248 clinical isolates. In addition, 
168 faecal screening isolates were received. Most of the patients with VRE were 60 years of age or older. Nearly all VRE 
isolates from 2012 and 2013 were vanA E. faecium isolates (Figure 1). They were primarily detected at hospitals in the 
Capital Region, but also from The Zealand Region and the Central Denmark Region. VRE was detected in the two other 
regions of Denmark too, but to a much lower extent. Pulsed-field gel electrophoresis typing showed spread of several 
vanA E. faecium types both inside hospitals and between hospitals.  
  
Conclusion: The increasing number and spread of VRE in Denmark is worrying, since only limited number of 
antimicrobial agents are left for treatment of infections. VRE can be carried in the intestine for a long period without any 
symptoms of infection and likewise persist in the hospital environment, which makes infection control difficult. National 
infection control guidelines are needed to contain the current increase and spread of VRE. The guidelines should include 
proper cleaning, good hand hygiene, screening for VRE and isolation of patients. 
Lotte Jakobsen, Brian Kristensen, Robert Skov and Anette M. Hammerum
For further information: Lotte Jakobsen (lja@ssi.dk)
Figure 1. Numbers of vancomycin resistant Enterococcus faecium and Enterococcus faecalis isolates and van genes, 
Denmark 
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Neisseria gonorrhoeae 2013
Background: Neisseria gonorrhoeae is the causative agent of the sexually transmitted infection gonorrhoea, which is 
usually located in the urethra in males and cervix in females. N. gonorrhoeae (gonococci) may sometimes be demonstrated 
in specimens from the pharynx or rectum in either gender, although infections in these sites are generally asymptomatic. 
Complications of gonorrhoea  include e.g. salpingitis, epididymitis, orchitis, and prostatitis. Further, conjunctivitis 
may occur in newborns after transmission from an infected mother during labour and rarely in adults following direct 
inoculation.
Methods: Through decades, all Departments of Clinical Microbiology in Denmark have submitted their isolates of 
gonococci to the Neisseria and Streptococcus Reference (NSR) laboratory at Statens Serum Institut for national surveillance 
of antimicrobial resistance. Most of the received isolates are from urethra or cervix, while specimens from rectum and 
pharynx are only rarely obtained by clinicians. Occasionally, the NSR laboratory receives strains isolated from other 
anatomical sites, such as conjunctivae, joint fluid, blood, Bartholin’s abscess, etc.
At the NSR laboratory ceftriaxone and ciprofloxacin MICs were determined using the Etest® on chocolate agar incubated 
at 35°C in 5% CO2. The breakpoints used were those defined by the EUCAST, as modified by ECDC. Both fully and 
intermediary resistant isolates were categorized as resistant. Penicillinase production was tested using the nitrocephin 
technique.
As part of NSRs participation in ECDCs surveillance of sexually transmitted infections since 2009, approximately 60 
gonococcus isolates are investigated twice per year for susceptibility to an expanded panel of antimicrobial agents. In 
addition to ceftriaxone and ciprofloxacin, this panel includes azithromycin, cefixime, spectinomycin, and gentamicin.
Results and discussion: The ciprofloxacin resistance rate increased steadily from 30% in 2003 reaching a peak of 75% 
in 2009, followed by a decrease to 56% in 2013 (Figure 1). The percentage of strains producing penicillinase fluctuated 
between 24% in 2003 and 11% in 2013.
Ceftriaxone resistant gonococci (MIC > 0.125 mg/L) as well as ceftriaxone treatment failure in patients with gonorrhoea 
have been reported from several countries during recent years. No cases from Denmark have ever been reported. During 
2003 through 2009 the proportion of isolates with MIC ≥  0.008 mg/L gradually increased from 40% to nearly 75% (Figure 
2), but during recent years this shift has nearly reversed. Thus, there is no evidence of emerging ceftriaxone resistance in 
Denmark.
In 2013, azithromycin resistance including intermediary resistance (MIC > 0.25 mg/L) in gonococci was 45%, corresponding 
to the rate in 2009 (Table 1). It is worth noting that several recent guidelines for the treatment of gonorrhoea recommend 
the combination of high dose ceftriaxone and azithromycin (1 g or 2 g).
Resistance against cefixime (MIC > 0.125 mg/L) was 9% in 2013, i.e. unchanged compared to 2012. Cefixime is an 
oral cephalosporin which has never been used in Denmark. During 2009–2013 none of the isolates were resistant to 
spectinomycin (MIC > 64 mg/L); however, this parenteral drug is not marketed in Denmark and is not readily accessible 
in most countries.
Gentamicin has been used successfully for the treatment of gonorrhoea in several countries in Africa but no randomized 
clinical trials evaluating its efficacy have been published. Gentamicin breakpoints for gonococci have not been determined. 
In 2011 through 2013, 98% of the examined strains from Denmark had gentamicin MIC ≤ 4 mg/L.
Conclusions: The centralised national surveillance of antimicrobial resistance in gonococci should be continued.
Steen Hoffmann
For further information: Steen Hoffmann (hof@ssi.dk)
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Figure 1. ciprofloxacin resistance and penicillinase production in gonococci, Denmark, 2003–2013
Figure 2. Distribution of ceftriaxone MIc values in gonococci, Denmark, 2003–2013
DANMAP 2013
DANMAP 2013
Table 1. Resistance rates (%) against azithromycin, cefixime and spectinomycin in gonococci, Denmark, 2009–2013
Antimicrobial agent 2009 2010 2011 2012 2013
Azithromycin 46 23 12 12 45
Cefixime 15 18 21 11 9
Spectinomycin 0 0 0 0 0
Number of isolates 119 111 126 114 111
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8.6 Staphylococcus aureus
Staphylococcus aureus is part of the normal flora from skin and 
mucosa in approximately 50% of humans. Some people only 
carry S. aureus intermittently whereas others carry S. aureus for 
longer time. However, in addition S. aureus also cause infections 
ranging from superficial skin infections i.e. impetigo and boils 
to invasive infections such as post-operative wound infections, 
infections related to intravenous catheters and prosthetic 
devices, bacteraemia, osteomyelitis, endocarditis and arthritis.
In Denmark, a voluntary surveillance programme of all S. 
aureus bacteraemia cases was established in 1957. Methicillin-
resistant S. aureus (MRSA) has been both laboratory and 
clinical notifiable since November 2006. At SSI, all isolates are 
typed by spa typing and epidemiological information registered. 
Based on this information each case is classified with respect 
to possible place of acquisition: hospital (HA), community 
(CA), healthcare-associated with a community onset (HACO) 
and import (IMP). MRSA belonging to clonal complex 398 
(CC398) has in recent years attracted special attention as this 
type has been closely connected to livestock animals, especially 
pigs, and increasingly affects people in direct contact with pigs.
The CC398  cases have in the past years constituted an increasing 
part of the CA cases and due to these increasing numbers, cases 
belonging to CC398 are analysed as a separate group as both 
epidemiology and exposition are different.
Surveillance of bacteraemia
In 2013, 1,769 S. aureus bacteraemia cases, corresponding 
to 32.9 per 100,000 inhabitants, were reported from the 
Departments of Clinical Microbiology (DCM) in Denmark. 
This is somewhat higher than in the previous five years (c. 
1,500 annual cases) and may likely reflect underreporting in 
previous years rather than a true increase. Thirty (1.7%) of 
the cases were caused by MRSA. This is at the same level as in 
previous years, and very low compared to most other countries 
reporting to EARS-Net [EARS-Net 2012]. 
Antimicrobial resistance in S. aureus bacteraemia isolates from 
2008–2013 is presented in Table 8.3. The highest frequency of 
resistance to other than penicillin was observed for fusidic acid 
(15%), erythromycin (7%), clindamycin (6%) and norfloxacin 
(5%). Susceptibility to all tested antimicrobial agents was at the 
same level as in 2012, but both fusidic acid and norfloxacin 
resistance have increased steadily since 2008 (Table 8.3). 
Resistance to at least 1, 2 or 3 other antimicrobial agents in 
addition to penicillin was demonstrated in 22%, 8% and 4% of 
the cases, respectively.
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Figure 8.9. Number of MRSA cases, with a three years moving average, Denmark
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Table 8.3. Resistance (%) in isolates from Staphylococcus aureus bacteraemia cases, Denmark
Antimicrobial agent
2008 2009 2010 2011 2012 2013
% % % % % %
Methicillin 1.3 1.6 1.4 1.4 1.2 1.7
Penicillin 77 77 75 77 74 76
Erythromycin 5 7 5 7 6 7
Clindamycin 4 6 4 6 6 6
Tetracycline 3 2 3 2 2 3
Fusidic acid 9 9 13 13 14 15
Rifampicin <1 <1 <1 <1 <1 0
Norfloxacin 2 2 3 4 4 5
Kanamycin 1 1 1 <1 1 2
Linezolid 0 0 0 0 0 0
Mupirocin <1 <1 <1 <1 <1 <1
Trimethoprim-sulfamethoxazole nt nt nt <1 1 1
Number of isolates 1344 1480 1418 1525 1528 1769
Note: nt = not tested. 
DANMAP 2013  
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Surveillance of methicillin-resistant S. aureus
In 2013, 2,094 new MRSA cases were detected (37.4 per 100,000 
inhabitants). This is the highest number of cases observed in 
over 25 years (Figure 8.9). A case was a person found positive 
for the first time with a specific MRSA strain regardless whether 
the patient was infected or colonised only.
In 2013, the number of MRSA increased by 31% compared 
to 2012. The number of new cases was more than three times 
as high as in 2007. In 2013, 24 persons were found with their 
second case of MRSA (i.e. MRSA of a new subtype). At the 
time of diagnosis, 45% (n = 940) of cases had infection which is 
lower than in 2012 (57%). CC398 cases increased substantially 
in 2013 and constituted 31% of new MRSA cases in 2013 (Table 
8.4). The increase was for a large part due to inclusion of contact 
to pigs as a risk factor in December 2012, requiring screening 
for MRSA when admitted to hospitals. This also explains the 
lower fraction of infections seen for CC398 compared to other 
CC groups. See also Textbox 10.
The total number of cases and the number of cases presenting 
with infection according to epidemiological classification are 
shown in Table 8.4. Most of the cases (83%) were acquired 
in Denmark. The epidemiological classification of MRSA 
infections 2007–2013 is shown in Figure 8.10. Despite the 
increasing total number of cases, both the number of hospital 
acquired infections and the number of healthcare-associated 
with community onset (HACO) infections were at a stable 
very low level. The number of CA infections continued the 
increasing trend in 2013 and was by far the largest group (n = 
404) (Figure 8.10). The proportion of bloodstream infections 
with MRSA was 1.7% in 2013 (see surveillance of S. aureus 
bacteraemia).
DANMAP 2013
DANMAP 2013Table 8.4. Epidemiological classification of new MRSA cases, Denmark
Note: Numbers shown in bold are totals
Unresolved cases in 2013 (notifications not received): 1
Epidemiologic classification Exposure
2012 2013
No. of cases 
(% of total)
No. (%) of 
cases with 
infections 
No. of cases 
(% of total)
No. (%) of 
cases with 
infections 
Imported (IMP) 324 (21) 218 (67) 366 (17) 222 (61)
Hospital-acquired (HA) 67 (4) 42 (63) 52 (2) 27 (52)
Healthcare associated, 
community onset (HACO) with healthcare risk 178 (11) 158 (8)
      with known exposure 60 24 (40) 39 17 (44)
      without known exposure 118 88 (75) 119 96 (81)
Healthcare worker 29 (2) 5 (17) 40 (2) 17 (43)
Community-acquired (CA) without healthcare risk 726 (47) 834 (40)
      with known exposure 378 69 (18) 408 75 (18)
      without known exposure 348 300 (86) 426 329 (77)
CC398 232 (15) 92 (40) 643 (31) 157 (24)
Figure 8.10. Number of MRSA infections according to epidemiological classification, Denmark
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Molecular typing of the MRSA strains
In total, spa typing revealed 270 different strain types of which 
194 types were associated with clinical infections. The number 
of isolates belonging to the 10 dominating spa types isolated in 
2013 is shown in Table 8.5. They constituted 61% of the total 
number of MRSA isolates. Ten spa types constituted 56% of the 
940 clinical infections with MRSA. Most prevalent spa types 
causing clinical infections at time of presentation were t034 (n 
= 126), t002 (n = 90), t008 (n = 72), t019 (n = 67), t127 (n = 43), 
t024 (n = 28), t044 (n = 28), t304 (n = 26), t437 (n = 25) and t032 
(n = 21). The PVL encoding gene lukF-PV was demonstrated in 
36% of the infections and in 14% of the asymptomatic carriers 
and most often in relation to isolates with spa types t008 (n = 
97), t019 (n = 90), t002 (n = 59) and t044 (n = 45).
Table 8.5. The ten most prevalent spa types demonstrated in 
MRSA cases, Denmark
a) CC = Clonal complex
spa type CC group(a) No. of cases No. causing infections (%)
t034 CC398 527 126 (24)
t002 CC5 161 90 (56)
t008 CC8 113 72 (64)
t019 CC30 92 67 (73)
t127 CC1 87 43 (49)
t304 CC8 76 26 (34)
t011 CC398 73 19 (26)
t032 CC22 49 21 (43)
t223 CC22 48 16 (33)
t044 CC80 47 28 (60)
DANMAP 2013
Table 8.6. Resistance (%) in the six most prevalent spa types demonstrated in MRSA cases compared with all MRSA cases, Denmark 
2013
spa type t034 t002 t008 t019 t127 t304 All cases
Clonal complex CC398 CC5 CC8 CC30 CC1 CC8
% % % % % % %
Erythromycin 44 33 54 0 61 1 36
Clindamycin 94 26 12 0 57 1 44
Tetracycline 100 8 10 0 59 1 45
Fusidic acid 3 27 6 0 26 4 13
Rifampicin 0 0 0 0 1 0 1
Norfloxacin 28 19 51 5 11 3 24
Kanamycin 7 17 50 2 68 3 23
Linezolid <1 <1 0 0 0 0 <1
Mupirocin 0 0 1 2 0 0 <1
Trimethoprim-sulfamethoxazole 1 0 0 0 2 0 3
Number of isolates 527 161 113 92 87 76 2094
DANMAP 2013
Resistance among MRSA isolates
The resistance patterns varied considerably between spa types 
(Table 8.6). In 2013, 100% of CC398 spa type t034 isolates 
were resistant to tetracycline and 94% of t034 were resistant 
to clindamycin. In contrast, the majority of t019, a primarily 
community-acquired spa type, and t304 were susceptible to 
all tested antimicrobial agents except for beta-lactams. It is 
noteworthy that 47% (304 of 643) of CC398 isolates had the 
unusual phenotype of being susceptible to erythromycin while 
resistant to clindamycin. Whole genome sequencing of 25 
CC398 isolates showed that this was due to presence of the lnu(B) 
gene – a gene previously reported in MRSA CC398 strains from 
Spain, Portugal and USA. Whether lnu(B) is responsible for 
this phenotype in general needs to be investigated. Resistance 
to at least 1, 2 or 3 other antimicrobial agents in addition to 
β-lactam antibiotics (cefoxitin/penicillin) was demonstrated in 
73%, 62% and 43% of the cases, respectively.
Andreas Petersen, Robert L. Skov and 
Anders Rhod Larsen
DANMAP 2013  
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Textbox 10
Livestock associated methicillin-resistant Staphylococcus aureus (LA-MRSA) among 
humans in 2013
Background: Since 2003, livestock associated methicillin-resistant Staphylococcus aureus (LA-MRSA) has emerged 
worldwide. LA-MRSA primarily belong to clonal complex 398 (CC398) and is especially associated with pigs. In humans 
MRSA CC398 has especially been found in persons with contact to pigs. 
A new type of MRSA carrying a different resistance determinant mecC has been found in humans, cattle and sheep in 
Denmark and internationally but do not appear to have the same close relationship to animals as CC398 [García-Álvarez 
et al. 2011. Lancet Infect Dis. 11: 595–603].
Livestock associated MRSA in humans: The number of persons positive for MRSA CC398 steeply increased to 643 cases 
in 2013 (42 in 2009, 111 in 2010, 164 in 2011 and 232 in 2012). A significant part of the increase was associated with 
inclusion of contact to pigs as a risk factor requiring screening for MRSA when admitted to hospitals in December 2012 
[http://sundhedsstyrelsen.dk/publ/Publ2012/11nov/MRSAvejl2udg.pdf]. The most frequent spa type related to CC398 
was type t034 (n = 527). The majority of CC398 cases (n = 562, 87%) were in persons with documented close contact to 
pigs or being a household member to a person with direct contact. This resembles the proportion from previous years, 
which means that the actual number of CC398 cases without documented contact to livestock increased concordantly 
from the previous years. There were however, no signs of significant spread of CC398 to urban areas.
One hundred and fifty-seven CC398 cases (24%) presented with infections. In 2013, four bacteraemia cases were MRSA 
CC398. Two of the patients died within 30 days. In both cases, the patients had severe comorbidity. The patients did not 
have any direct contact to pigs. 
MRSA isolates carrying the new mecA homologue mecC, were demonstrated in 41 cases (2%) in 2013 (9 in 2009, 21 in 
2010, 37 in 2011, and 24 in 2012). Twenty-eight of the cases (68%) had infections, including one bacteraemia at the time 
of diagnosis. Only one possible livestock contact was registered for the 41 mecC cases. 
In 2013, no animal surveillance of LA-MRSA was performed, but sampling at farm level is ongoing and expected to be 
finalized in 2014.  
Conclusions: In 2013, a steep increase in CC398 cases was detected and CC398 became the most common CC group 
among human MRSA cases. An increasing number of CC398 cases had no documented contact to pigs. The number of 
MRSA isolates carrying the mecC gene seems to have stabilized.
Andreas Petersen, Anders Rhod Larsen and Robert L. Skov
For further information: Robert L. Skov (rsk@ssi.dk)
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9. Materials and methods
9.1 General information
For the DANMAP 2013 report, population sizes and 
geographical data were obtained from Statistics Denmark 
[www.dst.dk] and data on general practitioners from the 
Danish Medical Association [www.laeger.dk].
The epidemiological unit for pigs and cattle was defined 
as the individual farm, meaning that only one isolate per 
bacterial species per farm was included in the report. The 
same epidemiological unit was applied for broilers, except for 
Salmonella where the individual flock of broilers was defined 
as the epidemiological unit. For food, the epidemiological unit 
was defined as the individual meat sample. For humans, the 
epidemiological unit was defined as the individual patient and 
the first isolate per patient per year was included.
Unless stated specifically, all differences and temporal trends 
noted in the text are statistically significant (p<0.05) using 
either Chi-square tests or linear logistic regression (see Section 
10.6.4).
9.2 Data on antimicrobial consumption
Antimicrobial agents used for humans and animals in Denmark 
are presented in Table 3.2.
9.2.1 Data on antimicrobial consumption in 
animals
Since 2001, consumption data presented in this report have 
been obtained from the national monitoring programme 
VetStat, which is a database hosted by the Danish Veterinary 
and Food Administration. Prior to 2001, data were based on 
national sales figures from the pharmaceutical industry.
Data registration
In Denmark, all therapeutic drugs are prescription-only and 
VetStat collects data on all medicines prescribed by veterinarians 
for use in animals, except in a few instances when medicines 
are prescribed on special license (i.e. medicines not approved 
for marketing in Denmark). In addition, data on consumption 
of coccidiostatics as feed additives (non-prescription) and 
antimicrobial growth promoters (not in use since 2000) are 
collected by VetStat.
Until 2007, antimicrobial agents could only be purchased at the 
pharmacy or in medicated feed from the feed mills. From April 
2007, the monopoly was suspended and private companies 
(two in 2011) were permitted - on certain conditions (identical 
conditions as for pharmacies) - to sell prescribed veterinary 
medical products for animals. In addition, price setting was 
liberalised, which allowed for discounts corresponding to 
lower administration costs related to sale of large quantities to 
the veterinarians.
The pharmacy or company either sells the medicines to 
veterinarians for own use in practice or for re-sale to farmers, or 
sells the medicines directly to the animal holder on presentation 
of a prescription. By law, the profit that veterinarians may make 
on the sale of medicine is very small (5%), thereby limiting the 
economic incentive to sell medicine.
In 2013, the animal owners and veterinarians purchased the 
antimicrobial agents almost equally between the pharmacies 
and the veterinary drug trading companies, while only 2% was 
purchased from the feed mills. Sales from feed mills additionally 
comprised zinc chloride for the pig production on veterinary 
prescription, and non-prescription sales of coccidiostatic 
agents for domestic fowl (Gallus gallus).
Data on all sales of veterinary prescription medicine from the 
pharmacies, private companies, feed mills and veterinarians 
are sent electronically to VetStat. Veterinarians are required by 
law to report to VetStat all use and prescriptions for production 
animals (monthly submissions). For most veterinarians, the 
registration of data is linked to the writing of invoices. However, 
errors in the veterinarians invoice system sometimes cause 
errors in amounts reported, and these data are not validated at 
entry to Vetstat. The electronic registration of the sales at the 
pharmacies is linked to the billing process and stock accounts at 
the pharmacy, which ensures a very high data quality regarding 
amounts and identity of drugs.
The VetStat database contains detailed information about 
source and consumption for each prescription item: date of 
sale, identity of prescribing veterinarian, source ID (identity 
of the pharmacy, feed mill, or veterinarian practice reporting), 
package identity code and amount, animal species, age-group, 
disease category and code for farm-identity (CHR - Danish 
Central Husbandry Register). The package code is a unique 
identifier, relating to all information on the medicinal product, 
such as active ingredient, content as number of unit doses (e.g. 
number of tablets), package size, and code of the antimicrobial 
agent in the Veterinary Anatomical Therapeutic Chemical 
(ATCvet) classification system.
Knowledge of the target animal species enables the presentation 
of consumption data in “defined animal daily doses” - a national 
veterinary equivalent to the international defined daily doses 
(DDDs) system applied in the human field [www.whocc.no]. 
See further description of the ADD system in the DANMAP 
2009 report [www.danmap.org].
Methods
In DANMAP, we want to compare consumption of 
antimicrobials between different animal populations and 
between veterinary and human sectors. In order to do this, we 
need to take into account the quantity of antimicrobials used, 
their potency, their formulation, the route of administration 
and – sometimes – the age of the animals in which they are 
used. We also need to know the size of the populations to which 
the antimicrobials are administered. 
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The animal daily doses (ADDs) used in previous DANMAP 
reports are an integrated part of the VetStat database and have 
been described elsewhere [DANMAP 2009; Jensen et al., Prev 
Vet Med. vol: 64, 201-215, 2004]. In principle, the ADD should 
be identical for all products within medicinal groups and 
defined by the active compound, route of administration and 
the formulation. However, in VetStat, the ADDs are defined by 
the dosage level that was part of the product registration, and 
over time doses for products within the same medicinal group 
sometimes have changed. The greatest variation occurs when 
the ADD for some products have been defined solely based on 
the approved dosage. For example, the approved dosage of a 
product registered in 2011 may differ from a similar product 
registered in 2001.
In DANMAP 2012, we therefore introduced two new metrics 
to follow trends in antimicrobial consumption to ensure 
robustness of the analyses over time. The new metrics, DADD 
and DAPD, are defined below in the highlighted boxes.
DADD - Defined animal daily dose
DADD is the average maintenance dose per day for a drug 
used for its main indication in the appropriate animal 
species. The DADD is not defined at product level but for 
each antimicrobial agent, administration route and animal 
species and when appropriate, also age group. DADD has 
been specifically defined for use in DANMAP and does 
not always completely match the “prescribed daily dose” 
or the recommended dosage in the Summaries of Product 
Characteristics (SPC).
The DADDs used in DANMAP 2013 are presented in the web 
annex.
The basic principles for the DADD are similar to the principles 
previously described for the ADD. The designation of the 
DADD is based on the VetStat ADDs, but re-defined for 
each group of antimicrobial agents, i.e. for each combination 
of active compound, administration route, formulation, 
considering the following principles:
1. Minor inconsistencies, e.g. due to rounding of numbers, 
have been corrected;
2. Approved dosage for the most widely used antimicrobial 
products were given priority above dosage for products 
that are rarely used;
3. Approved dosage for older products within the group are 
maintained as the common DADD even if a new product 
is approved with a higher dosage;
4. In determining the dosage for a group with large variation 
between approved dosages of the products, the dosages 
in accordance with the dose given in ”The Veterinary 
Formulary” [British Veterinary Association, 2005, 6th 
edition] are applied;
5. Dosages may vary within active compound and 
administration route, if different dosages have been 
approved for different age group/indication or formulation. 
When principle 2 and 3 are conflicting, principle 4 is applied.
Denominator
Trends in veterinary consumption, both within and across 
species, are presented in DADD per 1,000 animals per 
day – DAPD. The number of animals in a population (in 
epidemiological terms: the population at risk) is represented 
by their live biomass. The biomass of a species is calculated, 
taking into account average live body-weight and the average 
life-span of the species.
DAPD - DADD per 1,000 animals per day
The number of DADDs administered to a specific animal 
species during a year (in thousands) divided by the 
number of standard animals at risk per day. The number of 
standard animals at risk per day takes into account species 
differences in average body-mass and lifespan. When 
relevant, the numbers of DADDs and standard animals 
at risk are estimated for specific age groups, or simply as 
number of doses (DADDs) used to treat one kg of animal 
divided with the total estimated biomass (in tonnes).
DAPD is a statistical measure, providing a rough estimate 
of the proportion (in thousands) of animals treated 
daily with an average maintenance dose of a particular 
antimicrobial agent. For example, 10 DAPDs indicate that 
an estimated 1% of the population, on average, receives 
a certain treatment on a given day. The DAPD is also 
referred to as the treatment proportion.
In principle, the metric DAPD is parallel to the metric 
used in pharmaco-epidemiology for the human sector, 
Defined daily dose per 1,000 inhabitants per day (DID), 
see Section 9.2.3.
Due to a relative high number of pigs exported around 30 kg 
(30% of pigs produced in 2013, Table 3.1), an adjusted measure 
of consumption per pig was calculated. The adjustment is based 
on the assumption that pigs exported at 30 kg, on average, 
received the same amount of antimicrobial agents before 
export as other pigs from farrowing to 30 kg.
Antimicrobial use per pig produced (adjusted) = [DADDs 
+DADDw + (1+Q)*DADDf ] / (biomass-days-total+ Nw* 
5800(kg*days)), where DADDs = amount of antimicrobial 
agents used in sows; DADDw = amount of antimicrobial 
agents used in weaners; DADDf = amount of antimicrobial 
agents used in finishers; Q is the proportion of weaning pigs 
exported around 30 kg. Nw = number of pigs exported at 30 
kg bodyweight, and Nw*5800 is the number of biomass days 
the exported pigs would have contributed to the live biomass 
if not exported.
9.2.2 Estimation of live biomass of animals 
The estimation of live biomass and thus the number of standard 
animals at risk per day depends on the available data sources 
for each species. 
Broiler and layer production (Gallus gallus). 
The live biomass is estimated based on number of broilers 
produced (Table 3.1), and an average live weight at slaughter of 
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1.97 kg [Statistics Denmark, 2013] after an estimated average 
life span of 30 days. The mean live biomass per broiler is 
assumed to be half of the weight at slaughter. In addition, the 
biomass of the parental animals (rearing and breeding) for the 
broiler production was estimated for 2011 based on number of 
hens per year (2,9 mill) annual rotations, length of the empty 
periods, percentage of cocks, and average weight of the cocks 
and hens in rearing and in breeding [DANHATCH, 2013; 
S. Kabell, Danish Agriculture and Food Council, personal 
communication]. For the other years, the biomass of rearing 
and breeders was assumed to be proportionate to the broiler 
production as in 2011.
In the layer production chain, the biomass of the parent flocks 
is estimated separately for each production type, based on 
number of eggs produced, eggs per hen ,and average production 
length [Danish Poultry Producers, Statistics Denmark]. We 
have assumed an average weight of 2.3 kg per hen, based on 
slaughter weight [Statistics Denmark, 2013].
Turkey production. The live biomass is estimated based on 
the number of turkeys produced (Table 3.1) and an average 
live weight at slaughter of 21 kg for male turkeys and 11 kg 
for hens after an estimated average life span of 20 weeks and 
15.5 weeks, respectively [Danish Agro; S. Astrup, personal 
communication]. The estimated mean live biomass per turkey 
is assumed to be half of the weight at slaughter.
Pig production. The estimation was based on number of 
pigs produced, including exports at different ages [Statistics 
Denmark; Danish Agriculture and Food Council], productivity 
data for each year [Danish Agriculture and Food Council] 
and census data for breeding animals [Statistics Denmark]. 
The average weight and lifespan for the growing animals 
(piglets, weaners and finishers) were estimated from the 
productivity number. The estimation methods were developed 
in cooperation with Danish Agriculture and Food Council. 
There are no statistics on average weight of breeding animals 
available, so an estimated average weight had to be assumed. 
However, the size of the breeding animals has probably 
increased over the last decade, but this could not be accounted 
for.
Cattle production. The live biomass of the cattle population is 
estimated from census data [Statistics Denmark, 2014] and the 
average live weight of the different age groups. The Danish cattle 
population is mainly dairy, particularly Holstein Friesian, but 
also other breeds such as Jersey and a small population of beef 
cattle. Most of the cattle slaughtered are dairy cows and bull 
calves of dairy origin. The average live weight was estimated 
for 10 different age and gender categories.
Fur animals. The live biomass of mink is estimated from 
production data [Statistics Denmark, 2013; Kopenhagen 
Fur, 2013] and the average weight at pelting was 2.45 kg 
[Kopenhagen Fur, 2013]. The progeny live for approximately 
7 months. The biomass for the breeding animals (female) was 
estimated based on census data and an assumed average live 
weight of 2 kg.
Pet animals. Only dogs and cats are taken into account, as the 
other population sizes are negligible in Denmark, and relatively 
rare in veterinary practice. The 2011 population is based on 
census data [Statistics Denmark, 2000] estimating 650,000 cats 
and 550,000 dogs. The number of dogs in Denmark has been 
relatively stable during the last ten years [Danish Dog register, 
2012]. The average live weight for cats and dogs were estimated 
to 4 kg and 20 kg, respectively (based on pedigree registration 
data).
Aquaculture. The estimation is based on data from the Danish 
AgriFish Agency (NaturErhvervstyrelsen) on produced 
amounts in each subtype of production, and information on 
the typical lifespan and entrance and exit body weights, and 
were calculated in cooperation with Danish Aquaculture [NH 
Henriksen, Danish Aquaculture]. Data from 2012 were not 
available at the time of publication.
9.2.3 Data on antimicrobial consumption in 
humans
Data on consumption of antibacterial agents in humans were 
obtained from Statens Serum Institut (SSI), National Register of 
Medicinal Products Statistics. SSI has the legal responsibility for 
monitoring the consumption of all human medicinal products. 
This is performed by monthly reporting of consumption from 
all pharmacies in Denmark, including hospital pharmacies, 
to SSI. Data from the primary healthcare sector have been 
collected since 1994, whereas data on consumption in hospitals 
are available from 1997.
Certain categories of hospitals were excluded when the 
consumption was measured by occupied bed-days and 
admissions. Data from private hospitals and clinics, psychiatric 
hospitals, specialised non-acute care clinics, rehabilitation 
centres and hospices were excluded from DANMAP 
(representing approximately 3% of the antimicrobial 
consumption at hospitals and of the number of bed-days).
In Denmark, all antimicrobial agents for human use are 
prescription-only medicines and are sold by pharmacies in 
defined packages. Each package is uniquely identified by a 
code, which can be related to package size, content as number 
of unit doses (e.g. number of tablets), content as number of 
Defined Daily Doses (DDDs), code of the antimicrobial agent 
in the Anatomical Therapeutic Chemical (ATC) classification 
system, and producer. In addition, the following information 
is collected for each transaction: social security number (CPR 
number) of the patient, code identifying the prescribing 
physician, date and place (pharmacy, hospital pharmacy, 
institution) of the transaction, and information regarding 
reimbursement of cost, if applicable. The data are transferred 
monthly to SSI in an electronic format.
From DANMAP 2012 and onwards, the consumption 
of certain infusion substances, such as cephalosporins, 
carbapenems and trimethoprim, has been directly reported by 
the hospital pharmacies to SSI. In previous DANMAP reports, 
the consumption of these substances was corrected by direct 
data collection from all Danish hospital pharmacies; however, 
since DANMAP 2012 all data were delivered only by SSI.
The present report includes data on the consumption of 
antibacterial agents for systemic use, or group J01, of the 
2013 update of the ATC classification, in primary healthcare 
and in hospitals. As recommended by the World Health 
Organization (WHO), consumption of antibacterial agents in 
primary healthcare is expressed as DIDs, i.e. the number of 
DDDs per 1,000 inhabitants per day (DDD/1,000 inhabitant-
days). Consumption in primary healthcare is also reported as 
a number of packages per 1,000 inhabitants. Consumption 
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of antibacterial agents in hospitals is expressed as DIDs, for 
comparison with primary healthcare, and DBDs, the number 
of DDDs per 100 occupied beds per day (DDD/100 occupied 
bed-days).
Since antimicrobial consumption expressed as DDD/100 
occupied bed-days does not necessarily reflect changes in 
hospital activity and production, consumption in hospitals is 
also presented as DAD (the number of DDDs per 100 admitted 
patients).
The number of occupied bed-days is calculated as the date of 
discharge minus the date of admission (minimum one day), 
and the number of admissions is calculated as one admission 
whenever a patient is admitted to one specific ward (one patient 
can be registered as admitted multiple times if transferred 
between wards during one hospital stay). Data on the number 
of occupied bed-days (or patient-days) and number of 
admissions in each hospital were obtained from the National 
Patient Registry at the National Board of Health [www.sst.dk].
9.3. collection of bacterial isolates
9.3.1 Animals
Samples from animals are collected from healthy production 
animals randomly selected at slaughter. From pigs, isolates of 
Escherichia coli, Enterococcus faecium, Enterococcus faecalis, 
and thermophilic Campylobacter spp. were collected. From 
cattle, isolates of E. coli and thermophilic Campylobacter spp. 
were collected, and from broilers isolates of E. coli, thermophilic 
Campylobacter spp., E. faecalis and E. faecium were collected. 
In addition, isolates of E. coli O149, were collected from 
diagnostic submissions.
Campylobacter spp., indicator E. coli and enterococci. Samples 
from healthy pigs, cattle and broilers were collected for the 
DANMAP programme at slaughter by meat inspection staff or 
abattoir personnel and sent for examination at DTU National 
Food Institute. For broilers, cloacal swabs were collected weekly 
from May through October and the sampling programme 
represented 86% of all broiler farms in Denmark. A Danish 
broiler farm is typically comprised of more than one unit each 
generating several flocks per year, but even though a farm was 
sampled more than once through the sampling period, only 
one isolate per farm of each bacterial species was included.
For pigs and cattle, the slaughter plants included in the 
DANMAP programme accounted for 99% and 95% of the 
total number of animals slaughtered in Denmark during 2013, 
respectively. The number of pigs and cattle samples from each 
slaughter plant was proportional to the annual number of 
animals slaughtered at the plant. Samples were collected once 
a month from January through November as caecum samples 
from pigs and rectum samples from cattle. Only one isolate per 
farm of each bacterial species was included.
Accordingly, the bacterial isolates from the Danish production 
animals may be regarded as representing a stratified random 
sample of the respective populations, and the observed 
prevalence of resistant isolates provides an estimate of the true 
occurrence in the population.
An overview of the number of samples analysed, isolates 
obtained and MIC determinations performed for pigs, cattle 
and broilers is presented in Table 9.1. The isolation rates of C. 
jejuni from pigs and C. coli from cattle and broilers were low 
and therefore MIC-analyses were not performed.
Salmonella. National Food Institute DTU is the national 
reference laboratory for Salmonella in animals and food and 
receives all isolates for typing. Only one isolate per serotype 
per farm was selected for the DANMAP report, except for 
isolates from broilers, where one isolate per flock was included. 
Isolates of S. Typhimurium include the monophasic variants 
with antigenic formulas S. 4,5,12:i:- and S. 4,12:i:-.
The Salmonella isolates from pigs originated both from 
the random sampling of healthy animals at slaughter for 
DANMAP and from the national Salmonella surveillance 
programme where the results of a serological surveillance at 
the slaughterhouses and in all breeding herds appoint risk 
herds to be further examined by microbiological analysis of 
pen-faecal samples.
No Salmonella data from layers, broilers and cattle are presented 
in DANMAP 2013 due to the low findings of serotype S. 
Enteritidis and S. Typhimurium. Salmonella isolates from 
diagnostic submissions were not included in DANMAP 2013.
Further details on the sampling procedures and the findings of 
the Danish Salmonella surveillance programs are presented in 
Textbox 5, and in the Annual Report on Zoonoses in Denmark, 
2013 [www.food.dtu.dk].
Isolates from diagnostic submissions were specifically 
collected for the DANMAP programme at the Laboratory of 
Swine Diseases, the Danish Agriculture and Food Council, 
Kjellerup (E. coli O149 from diarrheic pigs). Only one isolate 
per farm was included. 
9.3.2 Meat
Campylobacter, indicator E. coli and enterococci. The meat 
isolates originated from meat samples collected at wholesale 
and retail outlets in all regions of Denmark. All samples were 
collected by the Danish Veterinary and Food Administration’s 
(DVFA) Food Control Offices and were collected during the 
routine inspection by the authorities or on specific request 
from the for the DANMAP programme. The sampling included 
both Danish and imported meat. Only one isolate per bacterial 
species per meat sample was selected for DANMAP.
Salmonella. The Salmonella isolates from Danish pork 
originated from the national Salmonella surveillance 
programme (swab samples from pork and beef carcasses taken 
at the slaughterhouse after cooling). Salmonella isolates from 
imported poultry meat and other imported fresh meats derived 
from a case-by-case risk assessment control programme 
(DFVA), are not presented due to the low number of isolates 
(<15). Further details on findings are presented in Textbox 5. 
Only one isolate per positive swab sample or batch of meat was 
included for DANMAP. Isolates of S. Typhimurium include 
the monophasic variants, antigenic formula S. 4,5,12:i:- and S. 
4,12:i:-.
9.3.3 Humans
S. Typhimurium, S. Enteritidis and C. jejuni. Antimicrobial 
susceptibility was performed on human faecal isolates submitted 
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to Statens Serum Institut (SSI). Campylobacter isolates were 
submitted from Departments of Clinical Microbiology (DCM) 
covering three geographical regions: Northern Jutland, Funen 
and Roskilde/Køge. Information on travel history was obtained 
for the patients. Salmonella isolates were submitted from all 
DCM in Denmark. Exact figures of the proportion tested and 
the sampling strategy for the different species can be found in 
Sections 6.1 and 6.2. 
Staphylococcus aureus. All blood isolates were referred to 
the Staphylococcus reference laboratory at SSI on a voluntary 
basis. In November 2006, methicillin-resistant S. aureus 
(MRSA) became a notifiable disease in Denmark and it became 
mandatory to submit all MRSA isolates to the reference 
laboratory.
Invasive Streptococcus pneumoniae, Streptococcus pyogenes 
(group A streptococci), group B, C and G streptococci. 
Invasive pneumococcal disease is a notifiable disease in 
Denmark, and therefore all invasive isolates nationwide are sent 
to SSI for identification or confirmation as well as susceptibility 
testing and typing. Invasive group A, B, C and G streptococcal 
isolates are referred to SSI on a voluntary basis. Traditionally, 
only isolates from blood and spinal fluid are included in the 
DANMAP report.
E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, 
invasive E. faecium and invasive E. faecalis. Data were 
provided on all isolates recorded from either blood samples (E. 
coli, K. pneumoniae, P. aeruginosa, E. faecium and E. faecalis) 
or urine samples (E. coli and K. pneumoniae) submitted for 
susceptibility testing to the DCM at the following hospitals: 
Rigshospitalet, Hvidovre, Herlev/Hillerød, Region Zealand, 
Odense, Esbjerg, Vejle, Herning/Viborg, Aarhus and Aalborg.
No samples were collected from healthy humans.
 
9.4 Isolation and identification of bacteria
9.4.1 Animals
Campylobacter. The samples from broilers was inoculated 
directly onto mCCD agar (Oxoid, Denmark) and incubated 
in microaerophilic atmosphere for 2-3 days at 41.5°C. For 
samples from cattle, selective enrichment in Preston broth at 
a ratio of 1:10 incubated in microaerophilic atmosphere for 24 
h at 41.5°C was performed followed by inoculation of 10 µl 
of the enrichment broth to mCCD agar. Campylobacter-like 
colonies were verified by microscopy and species identification 
of C. jejuni and C. coli was performed by a real-time PCR assay 
[Mayr et al. 2010, J Food Prot. 73(2):241-50]. All isolates of C. 
jejuni and C. coli were stored at -80°C.
Indicator E. coli. The material was inoculated directly onto 
Drigalski agar (SSI Diagnostica, Denmark) and incubated o/n 
at 37°C. Yellow colonies were inoculated onto BBL CHROM 
agar Orientation Medium (Becton Dickinson, Germany) and 
red colonies were collected as E. coli after o/n incubation at 
37°C. All isolates were stored at -80°C.
Indicator enterococci. An adequate amount of material 
suspended in 2 ml of sodium chloride (0.9%) was inoculated 
on Slanetz Bartley agar and incubated two days at 42°C. 
Three colonies resembling typical E. faecalis and E. faecium 
morphology were sub-cultivated on blood agar. E. faecalis and 
E. faecium were identified by motility- and arginine dihydrolase 
tests and the ability to ferment mannitol, sorbitol, arabinose 
and raffinose. All isolates of E. faecium and E. faecalis were 
stored at -80°C.
9.4.2 Meat
Salmonella was isolated by the regional laboratories at the 
DVFA according to the open reference methods issued by the 
NMKL (NMKL No. 187, 2007 or NMKL No. 71, 1999), the 
ISO 6579:2002 or alternative methods validated against the 
reference method according to ISO 16140:2001. Sero-typing 
was performed at the National Food Institute, DTU.
Campylobacter was isolated according to the guidelines 
for microbiological examination of food (NMKL No. 119, 
2007). Identification was performed by microscopy and by 
oxidase activity, catalase activity and the ability to hydrolyse 
indoxyl acetate and hippurate. Isolation and identification 
was performed by the laboratories at the DVFA in Ringsted, 
Denmark. All isolates of C. jejuni, C. coli and C. lari were sent to 
the National Food Institute, DTU for MIC-testing and storage 
at -80°C.
Indicator E. coli was isolated by the regional laboratories at 
the DVFA by adding 5 g of the sample to 45 ml of MacConkey- 
or laurylsulphate-broth, which was incubated o/n at 44°C, 
subsequently streaked onto violet red bile agar and incubated 
for 24 h at 44°C. Presumptive E. coli was identified using TBX 
agar (β-glucoronidase activity) incubated o/n at 44°C. E. coli 
isolates were sent to DTU National Food Institute for MIC- 
testing and storage at -80°C.
Indicator enterococci were isolated by the regional laboratories 
at the DVFA by adding 5 g of the sample to 45 ml azide dextrose 
broth, incubated o/n at 44°C and subsequently streake onto 
Slanetz-Bartley agar. After incubation at 44°C for 48 h, colonies 
typically for E. faecium and E. faecalis were identified by a real-
time PCR assay, and sent to DTU National Food Institute for 
MIC-testing and storage at -80°C.
9.4.3 Humans
Salmonella isolates were serotyped by slide agglutination 
according to the Kauffman-White Scheme.
Campylobacter. Species identification was performed using a 
species-specific PCR assay [Klena et al. 2004. J Clin Microbiol. 
42: 5549–5557].
Staphylococcus aureus. Sequencing of the S. aureus specific spa 
gene was performed for species confirmation and typing. Spa-
negative isolates were confirmed as S. aureus by MALDI-TOF. 
The spa-typing [Harmsen et al. 2003. J Clin Microbiol. 41: 5442–
5448] and additional typing by multi locus sequence typing 
(MLST) [Enright et al. 2000. J Clin Microbiol. 38: 1008–1015] 
were annotated using eBURST v.3 software (www. mlst.net). 
Based on the spa and MLST typing, each isolate was assigned 
to a clonal complex (CC). For MRSA isolates, presence of the 
mecA or mecC methicillin resistance genes was confirmed by 
PCR [Larsen et al. 2008. Clin Microbiol Infect. 14: 611–614; 
Stegger et al. 2012. Clin Microbiol Infect. 18: 395–400]. For all 
isolates, presence of lukF-PV gene (PVL) was demonstrated by 
PCR [Larsen et al. 2008. Clin Microbiol Infect. 14: 611–614; 
Stegger et al. 2012. Clin Microbiol Infect.18: 395–400].
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Invasive Streptococcus pneumoniae. Serotype identification of 
invasive S. pneumoniae was performed by latex agglutination 
(ImmuLex™ Pneumotest Kit, SSI Diagnostica, Hillerød, 
Denmark) and further with factor specific antisera by the 
Neufeld quellung test (SSI Diagnostica, Hillerød, Denmark).  
Invasive Streptococcus pyogenes (group A streptococci), 
group B, C and G streptococci. Identification of groups were 
performed by latex agglutination (Streptococcal Grouping 
Reagent, Oxoid, Roskilde, Denmark).
9.5 Susceptibility testing
Antimicrobial susceptibility testing of Salmonella, 
Campylobacter, indicator E. coli, Enterococcus, Staphylococcus 
aureus and the veterinary pathogens was performed as 
microbroth dilution MIC with Sensititre (Trek Diagnostic 
Systems Ltd., East Grinstead, UK). Inoculation and incubation 
procedures were in accordance with the CLSI guidelines 
[Clinical and Laboratory Standards Institute, USA] and the 
European standard ISO 20776-1:2006.
The quality control strains Staphylococcus aureus ATCC 29213, 
Escherichia coli ATCC 25922, Pseudomonas   aeruginosa ATCC 
27853, Enterococcus faecalis ATCC 29212 and Campylobacter 
jejuni ATCC 33560 were used.
Isolates from animals and meat were tested at DTU National 
Food Institute, and the Salmonella, Campylobacter and 
Staphylococcus aureus isolates of human origin were tested at 
SSI. MIC-testing at DTU National Food Institute is accredited 
by DANAK (the national body for accreditation).
One isolate per bacterial species per farm, per meat sample 
or per patient was tested for antimicrobial susceptibility. For 
Salmonella isolates from poultry, one isolate per serotype per 
flock was tested. For isolates in excess numbers (e.g. isolates 
from healthy animals), a random selection was appointed to 
MIC.
Table 10.2 presents the interpretation of MIC-values used for 
any combination of bacteria and antimicrobial agent. Since 
2007, data were interpreted by EUCAST epidemiological cut-off 
values (ECOFFs) with a few exceptions described in Table 10.2. 
The corresponding clinical breakpoints validated by EUCAST 
are presented both in Table 10.2 and in the MIC-distribution 
tables to visualize the impact of the use of ECOFFs contra 
clinical breakpoints. In general, if ECOFFs were re-validated 
and changed by EUCAST during the past year, all data presented 
from previous years were interpreted using the changed 
ECOFFs. Data from susceptibility testing of Staphylococcus 
aureus were interpreted using EUCAST clinical breakpoints. 
All MIC-distributions are presented in the web annex at www.
danmap.org. Each of the tables provides information on the 
number of isolates, the applied interpretation of MIC-values 
and the estimated level of resistance and confidence intervals.
Multi-resistance was defined as resistance to three or more 
of the antimicrobial classes listed in Table 10.3. Isolates were 
considered fully sensitive if susceptible to all the antimicrobial 
agents included in the test.
Invasive Streptococcus pneumoniae from humans. Screening 
for penicillin- and erythromycin-resistant  S. pneumoniae  was 
performed with 1 μg oxacillin discs and 15 μg erythromycin 
discs (Oxoid, Roskilde, Denmark),  respectively, on Müller-
Hinton agar (Müller-Hinton plate, 5% blood, 20 mg beta-
NAD, SSI Diagnostica, Hillerød, Denmark). Penicillin and 
erythromycin MICs were determined using STP6F plate, 
Sensititre (Trek Diagnostic Systems Ltd., East Grinstead, UK) 
as recommended by the manufacturer. All breakpoints used 
were as defined by the EUCAST. Both fully and intermediary 
resistant isolates were defined as resistant.
 
Invasive Streptococcus pyogenes (group A), group B, C 
and G streptococci from humans. Screening for penicillin-, 
erythromycin- and clindamycin-resistant streptococci was 
performed with 1 unit penicillin G discs, 15 μg erythromycin 
discs and 2µg clindamycin discs (Oxoid, Roskilde, Denmark), 
respectively, on Müller-Hinton agar (Müller-Hinton plate, 5% 
blood, 20 mg beta-NAD, SSI Diagnostica, Hillerød, Denmark). 
Isolates were simultaneously tested for inducible clindamycin 
resistance. Non-sensitive streptococci were tested further with 
the respective E-tests (Biomérieux), either benzylpenicillin, 
erythromycin or clindamycin on Müller-Hinton agar. The 
breakpoints used were as defined by the EUCAST. Both fully 
and intermediary resistant isolates were defined as resistant.
E. coli, K. pneumoniae, invasive P. aeruginosa, invasive E. 
faecium and E. faecalis from humans. The DCM performed 
either disk (Oxoid, Basingstoke, UK) or tablet (Neo-Sensitabs®, 
A/S Rosco) diffusion susceptibility testing on a number of 
media. As per September 2012, all DCM except Rigshospitalet 
used breakpoints defined by EUCAST.
Data on antimicrobial resistance from private hospitals and 
clinics and from psychiatric hospitals were excluded. All 
submitting laboratories participate in national and international 
quality assurance collaborations such as the United Kingdom 
National External Quality Assessment Schemes (NEQAS).
 
9.6 Data handling
9.6.1 Animal
The results from the analysis of all animal samples – positive 
as well as negative findings - and of the bacteria isolated and 
the susceptibility testing were stored in an Oracle Database 
9i Enterprise Edition® at DTU National Food Institute. The 
susceptibility data were stored as continuous values as well as 
categorised as susceptible or resistant as defined by the relevant 
ECOFF. Each isolate was identified by the bacterial species, the 
subtype as applicable and by the date of sampling and species 
of animal. Information on the farm of origin was also recorded. 
All handling and evaluation of results were carried out using 
SAS®Software, SAS Enterprise Guide 4.3.
9.6.2 Meat
Results from the analysis of food samples were reported via 
the database administrated by the DVFA, except for the data 
on Salmonella, which were reported to and extracted from 
the laboratory database at the National Food Institute, DTU. 
For each bacterial isolate, information was available on food 
type, bacterial species, date and place of sampling, date of 
examination, country of slaughter, and an identification 
number, which makes it possible to obtain further information 
about the isolate from the relevant authorities. Furthermore, 
information about the country of origin was recorded whenever 
possible.
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9.6.3 Human  
Salmonella and Campylobacter. Data on Salmonella and 
Campylobacter infections are stored in the Danish Registry 
of Enteric Pathogens (SQL database) maintained by SSI. This 
register includes only one isolate per patient within a window 
of six months and includes data on susceptibility testing of 
gastrointestinal pathogens.
Staphylococcus aureus. For MRSA, data on the characteristics 
of the isolates and the clinical/epidemiological information were 
obtained from the Danish MRSA register at SSI (mandatory 
reportable). Patients were registered, regardless of whether it 
was colonisation or infection, the first time they were diagnosed 
with MRSA or when a new subtype was demonstrated. Based 
on the reported information,  MRSA cases were classified 
as  colonization/active  screening  (i.e. surveillance samples 
to detect nasal, throat, gut or skin colonization), imported 
infection (i.e. acquired outside Denmark), infection acquired 
in a Danish hospital, defined as diagnosed >48 hours after 
hospitalisation with no sign of infection at admittance (HA-
MRSA) or infection diagnosed outside hospitals (community 
onset).
MRSA cases with community onset were further classified 
according to risk factors during the previous 12 months as 
either healthcare associated with community onset (HACO) 
or community-acquired (CA). Healthcare associated risk 
factors included prior hospitalizations or stay in long-term care 
facilities within 12 months prior to MRSA isolation and being 
a healthcare worker. Community risk factors included known 
MRSA-positive household members or other close contacts. 
Due to the increasing numbers of cases belonging to CC398 
were treated separately as both epidemiology and exposition 
are different from other CA cases.
Streptococcus pneumoniae, Streptococcus pyogenes (group 
A streptococci), group B, C and G streptococci. Data on 
susceptibility testing of isolates were stored as MICs in a 
Microsoft® Access database placed on a SQL server at SSI. 
Analysis including selection of isolates from blood and spinal 
fluid samples and removal of duplicate isolates was performed 
in Microsoft® Access.
E. coli, K. pneumoniae, invasive P. aeruginosa, invasive 
E. faecium and invasive E. faecalis. Ten out of eleven DCM 
in Denmark provided data on resistance levels in E. coli, K. 
pneumoniae, invasive P. aeruginosa, invasive E. faecium and 
invasive E. faecalis isolates. Data were extracted from the 
following laboratory information systems:
•	 ADBakt (Autonik AB, Skoldinge, Sweden) for the DCM at 
Hvidovre, Herlev and Aalborg Hospitals.
•	 MADS (DCM Skejby Hospital, Aarhus, Denmark) for 
the DCM at Rigshospitalet and Slagelse/Region Zealand, 
Odense, Esbjerg, Vejle, Herning/Viborg, and Aarhus 
(Skejby) Hospitals.
Resistance data on the first isolate per patient per year 
were included. Generally, resistance data were excluded if 
susceptibility to a certain antimicrobial agent was tested on 
only a selected number of isolates.
9.6.4 Statistical tests
Significance tests of differences between proportions of 
resistant isolates were calculated using SAS®Software, SAS 
Enterprise Guide 4.3 or StatCalc in EpiInfo™ v. 6. Difference 
in pair-wise comparisons were tested using Chi-square, or 
Fisher’s Exact Test when the number of samples is low (<25). 
When appropriate, significance of temporal trends is tested 
using linear logistic regression using Proc LOGISTC procedure 
in SAS (Likelihood ratio test).
In the text, commented differences imply statistically significant 
differences where p<0.05.
When comparing proportions between years, the EUCAST 
epidemiological cut-off values for 2013 were also used for 
interpretation of previous years MICs.
Jeppe Boel and Line Skjøt-Rasmussen
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Table 9.2. Interpretation criteriae for MIc-testing by EUcAST epidemiological cut-off values (blue fields) and the corresponding 
EUcAST clinical breakpoints (white fields) DANMAP 2013
* EUCAST epidemiological cut-off values (ECOFFs) and EUCAST clinical breakpoints.  Changes in ECOFF values since DANMAP 2011 are 
highlighted by orange.
a) The EUCAST ECOFF (>1) was not applied for quinopristin/dalfopristin (tradename synercid) according to investigations presented in DANMAP 
2006.
b) The EUCAST ECOFF (>4) was not applied for ciprofloxacin. The aim was to look for high level ciprofloxacin-resistance as described by Werner et 
al, 2010 (Int J Antimicob Agents;35:119-125). DANMAP 2006.
c) The EUCAST ECOFF (>2) for colistin was applied for S. Typhimurium and other serotypes, except for S. Enteritidis and S. Dublin where ECOFF 
>8 was applied as recommended by Agersøe et al, 2011 (DANMAP 2011, Textbox 6).
Antimicrobial agent Salmonella E. coli E. faecium E. faecalis C. jejuni  C. coli  
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
ECOFF
μg/ml
Clinical 
breakpoint
μg/ml
Ampicillin >8* >8* >8* >8* >4* >8* >4* >8*
Apramycin >16 >16
Cefotaxime >0.5* >2* >0.25* >2*
Cefoxitin
Ceftiofur >2* >1*
Chloramphenicol >16* >8* >16* >8* >32* >32* >16* >16*
Ciprofloxacin >0.06 * >1* >0.06* >1* >16(b) >8(b) >0.5* >0.5* >0.5* >0.5*
Colistin >2*/ >8(c) >2* >2* >2*
Erythromycin >4* >4* >4* >4* >8* >8*
Florfenicol >16* >16*
Gentamicin >2* >4* >2* >4* >32*  >32* >2* >2*
Kanamycin >1,024 >1,024
Linezolid >4* >4* >4* >4*
Nalidixic acid >16* >16* >16* >16*
Neomycin >4* >8*
Penicillin >16* >16*
Quinupristin/
dalfopristin >4
(a) >4*
Salinomycin >4 >4
Spectinomycin >64 >64*
Streptomycin >16* >16* >128* >512* >4* >4*
Sulfonamide >256 >64* 
Teicoplanin >2* >2* >2* >2*
Tetracycline >8* >8* >4* >4* >1* >2* >2* >2*
Tiamulin
Tigecycline >0.25* >0.5* >0.25* >0.5*
Trimethoprim >2* >4* >2* >4*
Vancomycin >4* >4* >4* >4*
Table 9.1. Number of DANMAP samples, number of isolates and MIc-tests from healthy production animals at slaughter, Denmark    
Note: Data in this table should not be used for reporting of prevalences of the bacterial species
a) From 2011, the DANMAP samples from pigs were also part of the surveillance programme for Salmonella
E. coli E. faecalis C. jejuni  
Pigs(a) No. of samples analysed (1 per farm) 260 709 0
No. of isolates obtained 258 134 0
No. of isolates MIC-tested/reported 146 109 0
Cattle No. of samples analysed (1 per farm) 166 0 166
No. of isolates obtained 150 0 95
No. of isolates MIC-tested/reported 103 0 86
Broilers No. of samples analysed (no. of flocks) 165 165 165
No. of farms represented  150 134 61
No. of isolates MIC-tested/reported 125 114 54
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Table 9. 3. Definitions of antimicrobial classes for calculation of multi-resistance (MR) in zoonotic and indicator bacteria, DANMAP
Note: An isolate is considered fully sensitive if susceptible to all antimicrobial agents included in the panel for the selected bacterial species
a) An isolates is considered multi-resistant if  resistant to three or more of the ten antimicrobial classes
b) An isolates is considered multi-resistant if  resistant to three or more of the six antimicrobial classes
Antimicrobial
classes
Salmonella and 
E. coli(a) Campylobacter
(b) Enterococcus(a)
Tetracyclines Tetracycline Tetracycline Tetracycline
Phenicoles Chloramphenicol and/or florfenicol Chloramphenicol Chloramphenicol
Penicillins Ampicillin Ampicillin and/or penicillin 
Cephalosporins Ceftiofur and/or cefotaxime
Sulfonamides Sulphonamides  
Trimethoprim Trimethoprim  
Aminoglycosides I
 Gentamicin Gentamicin   
Gentamicin and/or 
kanamycin and/or streptomycin 
Aminoglycosides II  Streptomycin Streptomycin 
Quinolones Ciprofloxacin and/or nalidixic acid  
Ciprofloxacin  and/or nalidixic 
acid  
Ciprofloxacin  and/or nalidixic 
acid  
Polymycins Colistin 
Macrolides Erythromycin Erythromycin
Glycopeptids Vancomycin and/or teicoplanin 
Ionophores Salinomycin
Oxazolidinones Linezolid
Glycylcyclines Tigercycline 
DANMAP 2013
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List of abbreviations
DADD Defined animal daily dose
DAPD Defined animal daily dose per 1,000 animals per day
AGP Antimicrobial growth promoter
ATC Anatomical Therapeutic Chemical Classification System
ATCvet Anatomical Therapeutic Chemical Classification System for veterinary medicines
CC Clonal complex
CHR Central Husbandry Register
CI Confidence interval
CNS Central nervous system
CPR Danish Civil Registry, register for social security numbers
DAD Defined Daily Doses per 100 admissions
DBD Defined Daily Doses per 100 occupied bed-days
DCM Department of Clinical Microbiology
DDD  Defined Daily Dose
DID  Defined Daily Doses per 1,000 inhabitants per day (DDD/1000 inhabitant days)
DTU  Technical University of Denmark
DVFA Danish Veterinary and Food Administration
EARS-Net The European Antimicrobial Resistance Surveillance Network
ECDC European Centre for Disease Prevention and Control
EFSA European Food Safety Authority 
ESBL Extended spectrum beta-lactamase 
GI Gastrointestinal
GP General practitioner
HLGR High-level gentamicin resistance 
MIC Minimum inhibitory concentration 
MRSA Methicillin-resistant Staphylococcus aureus 
N Number of samples
n  Number of isolates tested for antimicrobial susceptibility
OIE World Organisation for Animal Health
RFCA Regional Veterinary and Food Control Authorities
SSI Statens Serum Institut
VetStat Danish Register of Veterinary Medicines
VRE Vancomycin resistant enterococci
WHO  World Health Organization
DANMAP 2013  
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Glossary
Anatomical Therapeutic Chemical (ATC) classification. 
International classification system for drug consumption 
studies. The ATC code identifies the therapeutic ingredient(s) 
of each drug for human use according to the organ or system on 
which it acts and its chemical, pharmacological and therapeutic 
properties. Antibacterials for systemic use are known as ATC 
group J01. The ATC classification is maintained by the WHO 
Collaborating Centre for Drug Statistics and Methodology 
(Oslo, Norway) (www.whocc.no/atcddd/indexdatabase/).
The ATC classification for veterinary medicinal products,
ATCvet, is based on the same main principles as the ATC 
classification system for medicines for human use and is also 
maintained by the WHO Collaborating Centre for Drug
Statistics and Methodology (www.whocc.no/atcvet/database/).
Antibacterial agents. Synthetic (chemotherapeutics) or natural 
(antibiotics) substances that destroy bacteria or suppress 
bacterial growth or reproduction [Source: Dorland’s Illustrated 
Medical Dictionary]. Antimycobacterial agents are not 
included. In the section of human consumption, ‘antibacterial 
agents’ are referred to as ‘antimicrobial agents’ (see below).
Antimicrobial agents. The term ‘antimicrobial agents’ covers 
antibacterial, antiviral, coccidiostatic and antimycotic agents. 
In the section on veterinary consumption, the broad term
‘antimicrobial agents’ is usually used because coccidiostats 
are included. Antiviral substances are not used in veterinary 
medicine, and antimycotics are only registered for topical 
veterinary use and used mainly in companion animals. 
Antimycobacterial agents are not included. The term
’antibacterial agents’ is only used in the veterinary section 
for precision, to distinguish from use of coccidiostats as feed 
additives (poultry only). In the section of human consumption, 
the term ‘antimicrobial agents’ refers to all antibacterial agents 
for systemic use (J01 in the ATC system).
Broiler. A type of chicken raised specifically for meat 
production. In Denmark, the average weight after slaughter is 
1.97 kg.
Central Husbandry Register (CHR). This is a register of all 
Danish farms defined as geographical sites housing production 
animals. It contains information concerning ownership, farm 
size, animal species, age groups, number of animals and 
production type. Each farm has a unique farm identity number 
(CHR-number).
Defined animal daily dose (DADD). DADD is the average 
maintenance dose per day for a drug used for its main indication 
in the appropriate animal species. DADD has been specifically 
defined for use in DANMAP and does not always completely 
match the “prescribed daily dose” or the recommended dosage 
in the Summaries of Product Characteristics (SPC). In contrast 
to the ADD previously used in DANMAP, the DADD not has 
been defined for each antimicrobial agent, administration 
route and animal species but at product level. In DANMAP 
2012, the DADD replaces the ADD (as defined in VetStat), 
which has been used since DANMAP 2003. For more details, 
see Chapter 9, Materials and Methods. The DADDs used in 
DANMAP 2013 are presented the web annex.
DADD per 1,000 animals per day (DAPD). Trends in 
veterinary consumption, both within and across species, are 
presented in DAPD, allowing for comparison between sectors 
and adjusting for changes in live biomass. The estimated live 
biomass is expressed as the number of standard animals with 
an estimated average weight and lifetime. This may also be 
referred to as the ‘standard-animals-at-risk’ and takes into 
account species differences in body-mass and lifespan. DAPD 
is a statistical measure, providing an estimate of the proportion 
of animals (in thousands) treated daily with a particular 
antimicrobial agent. For example, 10 DAPDs indicate that an 
estimated 1% of the population, on average, receives a certain 
treatment on a given day (Section 4.3 and Chapter 9, Materials 
and Methods).
Defined Daily Dose (DDD). This is the assumed average 
maintenance dose per day for a drug used for its main indication 
in adults. It should be emphasised that the Defined Daily Dose 
is a unit of measurement and does not necessarily reflect the 
recommended or prescribed daily dose. DDDs provide a fixed 
unit of measurement independent of price and formulation, 
enabling the assessment of trends in drug consumption and to 
perform comparisons between population groups. The DDDs 
are defined and revised yearly by the WHO Collaborating 
Centre for Drug Statistics and Methodology (www.whocc.no/
atcddd/indexdatabase).
DDD per 1,000 inhabitants per day (DID). Consumption 
in both primary healthcare, hospital care and the overall total 
consumption is presented in DID, allowing for comparison 
between sectors and for illustration of the consumption in 
hospital care without taking account of hospital activity 
(discharges). Data presented in DID provide a rough estimate 
of the proportion of the population within a defined area treated 
daily with certain drugs. For example, 10 DIDs indicates that
1% of the population on average gets a certain treatment daily. 
In figure presented as DDD/1,000 inhabitant-days.
ESBL. In the DANMAP report, ESBL describes the clinically 
important acquired beta-lactamases with activity against 
extended-spectrum cephalosporins; including the classical 
class A ESBLs (CTX-M, SHV, TEM), the plasmid-mediated 
AmpC and OXA-ESBLs [Giske et al. 2009. J. Antimicrob. 
Chemother. 63: 1-4].
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Finishers. Pigs from 30-100 kg live weight from after the 
weaner stage to time of slaughter.
Fully sensitive. An isolate will be referred to as fully sensitive if 
susceptible to all antimicrobial agents included in the test panel 
for the specific bacteria.
Intramammaria. Antimicrobial agents for local application in 
the mammary gland (udder) to treat mastitis.
Layer. A hen raised to produce eggs for consumption.
Minimum inhibitory concentration (MIC). This is the 
lowest concentration of antimicrobial agent in a given culture 
medium, e.g. broth or agar, below which growth of the bacteria 
is not inhibited.
Multi-resistant. A Salmonella, Campylobacter, Enterococcus or E. 
coli isolate is assumed multi-resistant if it is resistant to three or 
more of the antimicrobial classes. The number of antimicrobial 
classes and antimicrobial agent included therein depend on the test 
panel for each bacterium (See Table 9.3, Materials and Methods).
Pet animals. Dogs, cats, birds, mice, guinea pigs and more exotic 
species kept at home for pleasure, rather than one kept for work or 
food. Horses are not included as pet animals. The live biomasses 
of Danish pets used for estimating veterinary consumption only 
include dogs and cat.
Piglet. The newborn pig is called a piglet from birth unjtill they 
are permanently separated from the sow at 3-4 weeks of age. The 
weight of the piglet at weaning is approximately 7 kg.
Poultry. The major production species are fowl - Gallus gallus 
(broilers, layers, including breeding and rearing) and turkey. 
Regarding antimicrobial consumption, ‘poultry’ also includes 
domesticated ducks, geese, game birds and pigeons.
Sow. Any breeding female pig on the farm.
Weaner. Any pig of 7–30 kg live weight after it has been weaned.
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